Severe Neonatal-Onset Encephalopathy With Microcephaly

Genetic MONDO:0010397 Pathograph 51 Show in embeddings browser Neurodevelopmental Disorder X-linked Disorder

Severe neonatal-onset encephalopathy with microcephaly is the most severe end of the MECP2 loss-of-function spectrum and the most common phenotype in affected males. In a non-mosaic 46,XY male there is no second X chromosome and therefore no mosaic rescue by X-chromosome inactivation, so every neuron lacks functional MeCP2. The result is not the classic Rett course: instead of an apparently normal first six to eighteen months followed by regression, these infants are encephalopathic from birth, with generalized hypotonia, abnormal tone and involuntary movements, microcephaly, intractable seizures, central hypoventilation and irregular breathing, failure to thrive and failure to attain motor milestones, following a relentless course that clinically resembles a metabolic-degenerative disease and often ends in death before age two from central respiratory failure. Autopsy and biopsy studies show a small brain with disproportionate frontal and temporal reduction, drastically diminished dendritic trees on Golgi-stained cortical layer III and V pyramidal neurons, greatly reduced synaptophysin in cerebellum and spinal cord, and type II muscle fiber hypotrophy indicating chronic central hypoxia. This entity is mechanistically distinct from both classic Rett syndrome (heterozygous females, mosaic MeCP2 loss) and MECP2 duplication syndrome (increased rather than reduced MECP2 dosage); the same gene produces a categorically different and far more severe disease when hemizygosity removes the mosaic buffer.

Ask OpenScientist

Ask a research question about Severe Neonatal-Onset Encephalopathy With Microcephaly. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🔗

Mappings

MONDO

MONDO:0010397 severe neonatal-onset encephalopathy with microcephaly

MONDO:0010397 carries "severe neonatal encephalopathy due to MECP2 mutations" and "severe congenital encephalopathy due to MECP2 mutation" as EXACT synonyms and an explicit RO:0004003 relation to HGNC:6990 MECP2, matching this entry's genetic section, and cross-references OMIM:300673 and Orphanet:209370.

📘

Definitions

GeneReviews clinical characterization of the male severe neonatal-onset phenotype

GeneReviews defines the male end of the MECP2 spectrum and identifies severe neonatal-onset encephalopathy as the most common phenotype in affected males, characterized by a relentless course resembling a metabolic-degenerative disease, abnormal tone, involuntary movements, severe seizures and breathing abnormalities, with death often before age two years. Molecular confirmation in a male proband requires suggestive findings plus a hemizygous MECP2 pathogenic variant.

CASE_DEFINITION Disease-level clinical framing and molecular diagnostic requirement for the male severe neonatal-onset phenotype within the MECP2 disorders chapter.

Show evidence (2 references)

PMID:20301670 SUPPORT Human Clinical

"Males: Severe neonatal-onset encephalopathy, the most common phenotype in affected males, is characterized by a relentless clinical course that follows a metabolic-degenerative type of pattern, abnormal tone, involuntary movements, severe seizures, and breathing abnormalities. Death often occurs..."

The GeneReviews clinical-characteristics section states the defining clinical gestalt, its rank within the male MECP2 spectrum, and the typical outcome.

PMID:20301670 SUPPORT Human Clinical

"The diagnosis of a MECP2 disorder is established by molecular genetic testing in a female proband with suggestive findings and a heterozygous MECP2 pathogenic variant, and in a male proband with suggestive findings and a hemizygous MECP2 pathogenic variant."

Establishes the molecular diagnostic requirement, and in particular that the male form is defined by hemizygosity rather than heterozygosity.

Salient clinical diagnostic criteria for non-mosaic 46,XY MECP2 null males

Case-series-derived recognition criteria. A non-mosaic 46,XY male with a MECP2 null variant presents with a phenotype explicitly distinct from Rett syndrome; the practical trigger for MECP2 testing is a boy with progressive encephalopathy plus one or more of respiratory insufficiency, abnormal movements or tone, and intractable seizures.

CASE_DEFINITION Bedside recognition rule intended to prompt MECP2 testing in males, derived from aggregated case series rather than from a consensus guideline panel.

Show evidence (3 references)

PMID:18477000 SUPPORT Human Clinical

"Non-mosaic males with a 46,XY karyotype and a MECP2 null mutation display a phenotype of severe neonatal-onset encephalopathy that is distinctly different from Rett syndrome (RTT)."

States the entity definition in terms of karyotype, mosaic status and variant class, and asserts its distinctness from Rett syndrome.

PMID:18477000 SUPPORT Human Clinical

"we are reporting novel findings in a sporadic case, compare them to 16 previously reported cases and establish salient criteria for clinical diagnosis"

Identifies the paper as the source of aggregated clinical diagnostic criteria across the then-known case set.

PMID:16832102 SUPPORT Human Clinical

"MECP2 mutations should be assessed in boys with progressive encephalopathy and one or more of respiratory insufficiency, abnormal movements or tone, and intractable seizures."

Provides the operational testing trigger, which is the practical form the case definition takes in clinical use.

👪

Inheritance

X-linked inheritance HP:0001417

MECP2 lies at Xq28 and MECP2 disorders are inherited in an X-linked manner. More than 99% of MECP2 disorders overall are simplex, arising de novo or from parental germline mosaicism; in the specific setting of an affected male, a pathogenic variant may also be inherited from a heterozygous mother whose favorably skewed X-chromosome inactivation leaves her with minimal to no clinical findings, which is why an apparently unaffected mother is not evidence against pathogenicity.

X-linked inheritance

Show evidence (5 references)

PMID:20301670 SUPPORT Human Clinical

"MECP2 disorders are inherited in an X-linked manner."

GeneReviews states the mode of inheritance directly, without committing to a dominant or recessive qualifier.

PMID:20301670 SUPPORT Human Clinical

"Rarely, a MECP2 variant may be inherited from a heterozygous mother in whom favorable skewing of X-chromosome inactivation results in minimal to no clinical findings."

Documents the transmitting-carrier scenario that makes the pedigree look recessive and that underlies the OMIM and MONDO X-linked recessive label.

PMID:20301670 SUPPORT Human Clinical

"More than 99% are simplex cases (i.e., a single occurrence in a family), resulting from a de novo pathogenic variant or possibly from inheritance of the pathogenic variant from a parent who has germline mosaicism."

Quantifies the predominance of simplex occurrence across MECP2 disorders.

+ 2 more references

◈

Mechanistic Hypotheses

Hemizygous Uniform MeCP2 Deficiency Model (loss of mosaic rescue)

hemizygous_uniform_mecp2_deficiency_model CANONICAL

Evidence balance 4 support

The canonical model holds that the severity difference between this entity and classic Rett syndrome is not a difference in the MECP2 lesion but a difference in cellular mosaicism. In a heterozygous female, random X-chromosome inactivation leaves roughly half of neurons expressing a wild-type MECP2 allele, and that wild-type population both supports and partly buffers the mutant population; the resulting phenotype permits normal development for six to eighteen months before regression. A non-mosaic 46,XY male has no second X, so every neuron and every glial cell is MeCP2-deficient from the outset. Uniform deficiency removes the reading of methylated DNA and the chromatin and co-repressor recruitment that MeCP2 provides, dysregulating activity-dependent neuronal gene expression; dendritic arborization and synaptogenesis fail cell-autonomously in neurons and are additionally impaired non-cell-autonomously by MeCP2-null astrocytes secreting inadequate soluble support; the resulting circuit failure is congenital rather than post-developmental and presents as neonatal encephalopathy with brainstem respiratory and autonomic instability and intractable epilepsy. The corollary, argued explicitly in the neuropathology literature, is that the hemizygous null male, and not the heterozygous Rett female, is the true human counterpart of the widely used Mecp2-null male mouse.

The mosaic-rescue arm of this model is supported by convergent human genetics rather than by a direct experiment in humans. Males who instead present with a recognizable Rett phenotype are almost always somatic mosaics or have 47,XXY Klinefelter syndrome, meaning they have recovered a wild-type-expressing cell population. Within the non-mosaic male group, residual severity gradation tracks the degree of biochemical impairment of MeCP2 (methyl-CpG-binding-domain DNA binding and chromocenter clustering), which is measurable in males precisely because X-inactivation does not confound genotype-phenotype comparison. Two elements of the chain are extrapolated from Rett syndrome and Mecp2-null systems rather than measured in this entity, namely the activity-dependent transcriptional dysregulation step and the astrocytic non-cell-autonomous contribution.

Show evidence (4 references)

PMID:18477000 SUPPORT Human Clinical

"Males with congenital encephalopathy, not females with RTT, represent the true human counterpart for the commonly studied Mecp2-/y mouse model and provide unique insight into the mechanisms of MeCP2 deficiency."

States the model's central translational corollary and its rationale.

PMID:27929079 SUPPORT In Vitro

"In heterozygous females the variable phenotypic severity is modulated by non-random X-inactivation, thus making genotype-phenotype comparisons unreliable."

Establishes the mosaicism confound in females that the hemizygous male state removes, which is the logical basis of the model.

PMID:34271245 SUPPORT Human Clinical

"The typical RS phenotype is not expected in males, except in those with Klinefelter syndrome or somatic mosaicism for MECP2."

The key convergent human-genetic prediction of the model, namely that restoring a wild-type-expressing cell population in a male shifts the phenotype toward Rett.

+ 1 more reference

Discussions and Knowledge Gaps

Postnatal head-growth deceleration is documented in this entity, but so are a small brain with frontotemporal predominance and bilateral perisylvian polymicrogyria. Is there therefore also a prenatal component to the microcephaly, and does the balance of prenatal and postnatal contribution differ by variant?

KNOWLEDGE GAP OPEN microcephaly_primary_versus_acquired

Attached to

pathophysiology#Reduced Brain Growth With Frontotemporal Predominance pathophysiology#Cortical Malformation With Perisylvian Polymicrogyria

This is not a question of whether the microcephaly is acquired: it demonstrably can be, since head growth decelerated from six months of age in a longitudinally followed R294X male and microcephaly was explicitly described as progressive in the T158M brothers. The open question is whether an additional prenatal component exists on top of that, and it matters because the two possibilities imply different therapeutic windows. The autopsy record points toward a prenatal contribution that growth curves cannot capture: bilateral perisylvian polymicrogyria can only arise during prenatal cortical development, and the brain was small with disproportionate frontotemporal reduction. If complete MeCP2 deficiency has a prenatal developmental role that mosaic deficiency in Rett females masks, then postnatal MeCP2 restoration could not fully rescue the male phenotype however early it were given. No published series reports birth head circumference for these boys, so the prenatal and postnatal contributions have never been separated. The entry therefore binds the neutral HP:0000252 parent term with a PROGRESSIVE clinical course rather than committing to HP:0011451 primary microcephaly or HP:0005484 secondary microcephaly.

Proposed experiments

Retrospective birth-head-circumference series across reported MECP2 males

exp_male_mecp2_birth_head_circumference_series

Assemble birth and serial head circumference z-scores for every reported non-mosaic 46,XY MECP2 male, together with prenatal ultrasound biometry where available, and test whether head size is already reduced at birth in addition to decelerating postnatally, stratifying by variant class and by presence of cortical malformation on imaging or autopsy.

Prenatal cortical development in a hemizygous null model and human tissue

exp_prenatal_mecp2_null_cortical_development

Characterise cortical progenitor proliferation, neuronal migration and gyral patterning prenatally in hemizygous Mecp2-null mice and in MECP2-null human cortical organoids, to establish whether complete MeCP2 loss perturbs cortical development before birth in a way that heterozygous mosaic loss does not.

Show evidence (4 references)

PMID:17236109 SUPPORT Human Clinical

"The head growth decelerated from the age of 6 months and the feeding problems increased requiring gastrostomy."

Establishes the postnatal, acquired arm of the microcephaly with an explicit age of deceleration, which is the half of the question that is settled.

PMID:11930274 SUPPORT Human Clinical

"Post mortem examination revealed bilateral polymicrogyria in the perisylvian region."

A malformation that must arise prenatally, which is the strongest argument that an additional developmental component exists alongside the postnatal deceleration.

PMID:18477000 SUPPORT Human Clinical

"At autopsy, the brain was small with disproportionate reduction of the frontal and temporal lobes."

Documents the small brain at autopsy without establishing whether it was already small at birth, which is precisely the missing measurement.

+ 1 more reference

The hemizygous Mecp2-null male mouse is asymptomatic until five to six weeks of age, whereas the affected human male is encephalopathic from birth. Does this onset mismatch mean the model fails to capture the congenital arm of the human disease, even though it is otherwise the correct genotypic counterpart?

HUMAN MODEL MISMATCH OPEN mecp2_null_mouse_onset_mismatch

Attached to

pathophysiology#Uniform Neuronal and Glial MeCP2 Deficiency pathophysiology#Failure of Dendritic Arborization and Synaptogenesis

This is the inverse of the usual model-fidelity problem, and it cuts both ways. The human neuropathology literature argues that the hemizygous null male, and not the heterozygous Rett female, is the true counterpart of the Mecp2-null male mouse, so the model's genotype is right, and the hemizygous male mouse does deliver the quantitative dendritic and spine phenotype. But the model's phenotype is right in kind and wrong in timing. It is normal until five weeks, and its authors interpret that delay as showing that MeCP2 is required for the stability of brain function rather than for brain development per se. The human male has no such asymptomatic interval, and in at least one case has a prenatally acquired cortical malformation. Either the mouse postnatal-maintenance interpretation understates a developmental role that only becomes visible under complete deficiency in a longer-gestation species, or the human congenital presentation reflects a species-specific prenatal requirement the mouse does not share. The model's own authors additionally caution that MeCP2 effects are context-dependent and cannot be generalized across mutation types and cell populations. Resolving this determines whether preclinical rescue timing in the mouse can be extrapolated to a human therapeutic window at all.

Proposed experiments

Prenatal and neonatal phenotyping of the hemizygous Mecp2-null mouse

exp_mecp2_null_prenatal_phenotyping

Phenotype hemizygous Mecp2-null mice prenatally and in the first postnatal week with quantitative dendritic morphometry, synaptophysin quantification, brain volumetry and plethysmographic respiratory monitoring, to test whether subclinical abnormalities matching the human neonatal findings precede the six-week symptomatic onset.

Comparative developmental timing in MECP2-null human organoids versus mouse

exp_human_organoid_versus_mouse_timing

Compare the developmental stage at which dendritic and synaptic deficits first appear in MECP2-null human cortical organoids against the corresponding stage in hemizygous Mecp2-null mouse cortex, to test whether the human requirement is earlier relative to corticogenesis.

Show evidence (4 references)

PMID:18477000 SUPPORT Human Clinical

Establishes the genotypic correctness of the model that makes the timing mismatch interesting rather than dismissible.

PMID:11242117 SUPPORT Model Organism

"The overlapping delay before symptom onset in humans and mice, despite their profoundly different rates of development, raises the possibility that stability of brain function, not brain development per se, is compromised by the absence of MeCP2."

The model authors' own maintenance-not-development interpretation, which the congenital human male presentation challenges.

PMID:11242118 SUPPORT Model Organism

"Mecp2-null mice were normal until 5 weeks of age, when they began to develop disease, leading to death between 6 and 12 weeks."

Quantifies the asymptomatic interval that the human male lacks.

+ 1 more reference

Trofinetide and the AAV-MECP2 gene therapy programmes were developed and licensed in females with Rett syndrome. Is any of this therapeutic pipeline applicable to hemizygous males with neonatal-onset encephalopathy, and what would it take to find out?

KNOWLEDGE GAP OPEN male_exclusion_from_mecp2_therapeutic_development

Attached to

pathophysiology#Uniform Neuronal and Glial MeCP2 Deficiency

The question is worth asking at all because MeCP2 deficiency is not fixed damage. Reactivation of endogenous Mecp2 in young and adult mice reverses aspects of RTT-like pathology, which is the premise on which the whole gene-replacement programme rests and the reason a therapeutic window is a meaningful notion here rather than a hypothetical one. Yet this entity has no disease-specific therapeutic evidence at all, and the gap is structural rather than merely unstudied. The two lead AAV gene-therapy programmes enrol females by protocol: NGN-401 (NCT05898620) studies females with typical Rett syndrome, and TSHA-102/REVEAL (NCT06152237) studies pediatric females. Trofinetide is likewise approved for Rett syndrome. So the pipeline that this disorder's mechanism most directly motivates is one from which affected males are excluded by eligibility criteria, not merely under-represented. Two further considerations make simple extrapolation unsafe. MECP2-directed therapy is dosage-critical in both directions, since too little MeCP2 causes this disease and too much causes MECP2 duplication syndrome; and the male target population is uniformly null rather than mosaic, so the dose window that is safe and effective in a mosaic heterozygous female need not transfer. Meanwhile the practical barriers are severe: diagnosis is made years after presentation, long after the neonatal window in which intervention would matter most, and clinicians hold documented biases and misconceptions, chiefly the historical belief that MECP2 loss of function is lethal in males, that delay recognition. Investigators in the field have stated explicitly that equal access to emerging therapies for males is critical, and male-specific anticipatory guidance is acknowledged to be lacking.

Proposed experiments

Prospective male-specific MECP2 natural history cohort

exp_male_mecp2_natural_history_cohort

Establish a prospective natural history cohort restricted to males with pathogenic MECP2 variants, stratified by mosaic status and karyotype, with standardised respiratory, cardiac (including QTc and Holter), seizure, growth and developmental endpoints, to generate the survival and outcome measures that any trial in this population would need.

Dose-window determination for MECP2 replacement in the uniformly null state

exp_hemizygous_null_gene_replacement_dose_window

Determine, in hemizygous Mecp2-null mice and MECP2-null human neurons, the MeCP2 re-expression dose window that rescues dendritic and respiratory phenotypes without producing duplication-syndrome-like overexpression toxicity, and test whether that window differs from the window established in mosaic heterozygous female models.

Show evidence (7 references)

PMID:20298210 SUPPORT Model Organism

"Recent evidence suggests that reactivation of endogenous Mecp2 in young and adult mice can reverse aspects of RTT-like pathology."

The mechanistic premise of the gap. Because MeCP2 deficiency is reversible in the model rather than representing fixed damage, the therapeutic-window question is substantive; tagged MODEL_ORGANISM because the result is a mouse result.

clinicaltrials:NCT05898620 SUPPORT Human Clinical

"This study will evaluate the efficacy and safety profiles of the investigational gene therapy, NGN-401, in females with typical Rett syndrome."

Documents that the leading MECP2 gene-replacement trial restricts enrolment to females, making the exclusion concrete rather than inferred.

clinicaltrials:NCT06152237 SUPPORT Human Clinical

"The REVEAL Pediatric Study is a multi-center, Phase 1/2 open-label, dose-escalation and dose-expansion study of TSHA-102, an investigational gene therapy, in pediatric females with Rett Syndrome."

A second independent AAV-MECP2 programme likewise restricted to females, establishing that the exclusion is a pattern across the pipeline.

+ 4 more references

How often is death in this entity cardiac (conduction failure) rather than respiratory, and should every affected male therefore have systematic cardiac conduction monitoring rather than QTc assessment alone?

KNOWLEDGE GAP OPEN mechanism_of_sudden_death

Attached to

pathophysiology#Cardiac Autonomic Conduction Instability pathophysiology#Brainstem Respiratory Network Failure

Two mechanisms of death are documented and they imply different surveillance. The autopsy-confirmed literature attributes death to central respiratory failure, which is consistent with the brainstem respiratory node. But a familial pair of affected brothers died suddenly at 17 and 30 months with sick sinus syndrome and severe bradycardia, a pattern that QTc assessment alone would not detect and that a pacemaker could in principle address. Because case numbers are tiny and post-mortem cardiac evaluation is not routine, the relative contribution of the two mechanisms is unknown, and the surveillance recommendation across MECP2 disorders, periodic QTc, may be calibrated to the female Rett phenotype rather than to this one.

Proposed experiments

Systematic cardiac rhythm monitoring in males with pathogenic MECP2 variants

exp_systematic_cardiac_monitoring_male_mecp2

Apply prospective ambulatory rhythm monitoring (Holter or implantable loop recorder) in addition to serial ECG and QTc measurement across an international cohort of males with pathogenic MECP2 variants, and record mode of death with structured cardiac and respiratory adjudication, to establish the relative contribution of conduction failure and central respiratory failure.

Show evidence (3 references)

PMID:29631775 SUPPORT Human Clinical

"However, an increasing number of male patients with MECP2 mutations have been reported, including patients who suddenly died of unknown causes."

States that sudden death of unknown cause is a recognised but unexplained outcome in affected males, which is the gap.

PMID:29631775 SUPPORT Human Clinical

"This familial case might help to clarify the causes of sudden death in cases of MECP2 mutations."

The authors position their conduction findings as a partial answer to that gap.

PMID:18477000 SUPPORT Human Clinical

"He failed to thrive and to reach any motor milestones and died at 15 months from central respiratory failure without a diagnosis."

The competing respiratory mechanism of death, against which the cardiac contribution must be weighed.

⚙

Pathophysiology

Hemizygous MECP2 Loss-of-Function Variant

A pathogenic MECP2 variant on the single X chromosome of a 46,XY male. Reported variant classes include nonsense and frameshift changes truncating the transcription-repression domain, splice-disrupting deletions, small insertions causing frameshift, and methyl-CpG-binding-domain missense substitutions such as T158M. Variants may be de novo, which is the majority situation, or inherited from a heterozygous mother with favorably skewed X-chromosome inactivation.

MECP2 hgnc:6990

epigenetic regulation of gene expression GO:0040029 ↕ DYSREGULATED

Downstream

Absence of Mosaic Rescue by X-Chromosome Inactivation A single X chromosome means the variant is present in every cell with no wild-type allele available for mosaic compensation.

Impaired MeCP2 Methyl-CpG Binding and Chromocenter Clustering Variants at or near the methyl-CpG-binding domain degrade MeCP2 DNA binding and chromatin clustering to a degree that scales with clinical severity.

Show evidence (4 references)

PMID:18477000 SUPPORT Human Clinical

"Post-mortem MECP2 mutation analysis on DNA and RNA from fibroblasts revealed a novel de novo 9-nucleotide deletion including the intron 3/exon 4 splice junction."

Documents a splice-disrupting de novo null variant as the causal lesion in an autopsy-confirmed case.

PMID:37537631 SUPPORT Human Clinical

"Here we report a rare case in a 10-month-old boy with a hemizygous insertion mutation in MECP2 as NM_001110792, c.799_c.800insAGGAAGC, which results in a frameshift mutation"

Documents a hemizygous frameshift insertion in an affected male, establishing hemizygosity of the causal allele.

PMID:17236109 SUPPORT Human Clinical

"We report on three patients with MeCP2 mutation and male Rett phenotypes."

Identifies the T158M and R294X case series that contributes the recurrent missense and nonsense variant classes seen in affected males.

+ 1 more reference

Absence of Mosaic Rescue by X-Chromosome Inactivation

The mechanistic pivot of this entity. A heterozygous female inactivates one X per cell, so roughly half of her neurons express wild-type MeCP2 and buffer the mutant population, and her phenotype accordingly permits an initial period of normal development. A non-mosaic hemizygous male has no such population. The clinical proof of this node is inverted rather than direct. Males who do have a wild-type-expressing cell population, because of post-zygotic somatic mosaicism or a supernumerary X in 47,XXY Klinefelter syndrome, present instead with a recognizable Rett phenotype and survive.

neuron CL:0000540

MECP2 hgnc:6990

dosage compensation by inactivation of X chromosome GO:0009048 ∅ ABSENT

Downstream

Uniform Neuronal and Glial MeCP2 Deficiency With no wild-type allele in any cell, MeCP2 deficiency is complete and uniform across the nervous system rather than mosaic.

Show evidence (6 references)

PMID:34271245 SUPPORT Human Clinical

"The typical RS phenotype is not expected in males, except in those with Klinefelter syndrome or somatic mosaicism for MECP2."

The inverted proof, in which recovering a wild-type-expressing cell population in a male converts the phenotype from neonatal encephalopathy toward Rett syndrome.

PMID:11738861 SUPPORT Human Clinical

"Males who have MECP2 mutations and Klinefelter syndrome or who are mosaic for the mutation are more likely to present with a RTT-like phenotype."

Independent confirmation that restoring a wild-type-expressing cell population shifts the male phenotype toward Rett syndrome.

PMID:39476560 SUPPORT Human Clinical

"Eleven (18.6%) were mosaic, 10 with somatic mosaicism and one with Klinefelter syndrome (47XXY)."

Quantifies how often surviving ascertained males owe their phenotype to a mosaic or 47,XXY rescue mechanism.

+ 3 more references

Impaired MeCP2 Methyl-CpG Binding and Chromocenter Clustering

MeCP2 binds chromocentric DNA through its methyl-CpG-binding domain. Variants at the MBD-DNA interface impair the MeCP2-DNA interaction, while more distal MBD variants impair chromatin clustering, and binding and mobility dynamics degrade in a graded fashion depending on amino-acid properties and MBD tertiary structure. In hemizygous males, where X-inactivation does not confound the comparison, the degree of functional impairment correlates directly with clinical severity across a range that runs from neonatal encephalopathy at the severe extreme to mild psychiatric abnormalities at the mild extreme. This node therefore explains the residual severity gradient within the male spectrum, given the shared absence of mosaic rescue.

MECP2 hgnc:6990

chromatin organization GO:0006325 ↕ DYSREGULATED

methyl-CpG binding GO:0008327 ↓ DECREASED

Downstream

Uniform Neuronal and Glial MeCP2 Deficiency Loss of methylated-DNA reading and chromatin clustering is the biochemical content of functional MeCP2 deficiency.

Preferential De-Repression of Long Neuronal Genes Loss of methyl-CpG reading removes repression preferentially from long genes, which is the characteristic transcriptional signature of MeCP2 loss.

Variant-Dependent Severity Within the Male MECP2 Spectrum The graded biochemical impairment maps onto the graded clinical severity seen across hemizygous males.

Show evidence (3 references)

PMID:27929079 SUPPORT In Vitro

"MeCP2 binds to chromocentric DNA through its methyl CpG-binding domain (MBD) to regulate gene expression."

Establishes the normal molecular function that the variants degrade.

PMID:27929079 SUPPORT In Vitro

"We observed impaired interaction of MeCP2-DNA for mutations around the MBD-DNA binding interface, and defective chromatin clustering for distal MBD mutations."

Provides the two distinct biochemical failure modes measured for MBD variants.

PMID:10508514 SUPPORT Human Clinical

"MeCP2 selectively binds CpG dinucleotides in the mammalian genome and mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A"

Establishes the co-repressor recruitment arm of MeCP2 function that binding loss removes.

Variant-Dependent Severity Within the Male MECP2 Spectrum

Given hemizygosity, the residual determinant of which male MECP2 phenotype results is the functional severity of the variant. Three phenotypes are seen in males with a single copy of MECP2 carrying a pathogenic variant, namely severe neonatal encephalopathy at the severe end, X-linked intellectual deficiency 13 in the middle, and pyramidal signs with parkinsonism and macroorchidism (PPM-X) at the mild end. Clinical severity across this range correlates directly with the measured functional impairment of MeCP2. Within the severe end, specific recurrent alleles may define recognizable sub-entities: two brothers with T158M followed a near identical lethal course, and the reporting authors proposed that T158M males might constitute a clinical-genetic entity within the male congenital encephalopathies, whereas an R294X boy had a more protracted course with survival past four years.

MECP2 hgnc:6990

Downstream

Uniform Neuronal and Glial MeCP2 Deficiency The most functionally damaging (null-equivalent) variants produce the deepest MeCP2 deficiency and the neonatal-onset phenotype curated in this entry.

Show evidence (4 references)

PMID:34271245 SUPPORT Human Clinical

"Three MECP2-associated phenotypes were seen in male carriers of a single copy of the gene: severe neonatal encephalopathy (n = 5); X-linked intellectual deficiency 13 (n = 2); and pyramidal signs, parkinsonism, and macroorchidism (PPM-X) (n = 1)."

Enumerates the three male phenotypes and places this entity at the severe end.

PMID:27929079 SUPPORT In Vitro

"Interestingly, a wide range of phenotypic/clinical severity, ranging from neonatal encephalopathy to mild psychiatric abnormalities were observed and all are consistent with our functional/molecular results."

Maps the observed male severity range directly onto the biochemical assay result, with neonatal encephalopathy at the severe extreme.

PMID:17236109 SUPPORT Human Clinical

"The phenotypes show a strong resemblance, and might in fact represent a clinical-genetic entity of the T158M mutation within the complex of congenital encephalopathies in males with MeCP2 mutations."

Proposes allele-specific sub-entities within the severe male phenotype, the finest grain of the variant-dependent severity claim.

+ 1 more reference

Uniform Neuronal and Glial MeCP2 Deficiency

Every neuron and every glial cell lacks functional MeCP2. Note the two different kinds of warrant behind that statement. The HUMAN claim is genetic rather than histological: MECP2 is X-linked, so a non-mosaic 46,XY male carries the variant in every cell with no wild-type allele anywhere, and uniform deficiency follows by deduction from hemizygosity. No human study has demonstrated MeCP2 protein loss in glia specifically; that demonstration comes from the Rett MOUSE model, in which MeCP2 is absent from astrocytes as well as neurons. The consequence asserted here, that the deficiency affects both compartments simultaneously and so removes the possibility of MeCP2-competent astrocytes supporting MeCP2-deficient neurons, is therefore a human-genetic inference supported by a model-organism observation, and is flagged as such rather than presented as human autopsy data.

neuron CL:0000540 astrocyte CL:0000127

MECP2 hgnc:6990

epigenetic regulation of gene expression GO:0040029 ↕ DYSREGULATED

brain UBERON:0000955

Downstream

Dysregulated Activity-Dependent Neuronal Gene Expression Loss of MeCP2 in all neurons removes its context-dependent transcriptional regulation of neuronal gene programs.

Non-Cell-Autonomous Astrocytic Failure to Support Dendritic Morphology MeCP2-deficient astrocytes fail to provide the soluble support neurons require for normal dendritic morphology.

Show evidence (4 references)

PMID:34502518 SUPPORT Human Clinical

"Methyl CpG binding protein 2 (MECP2) is located at Xq28 and is a multifunctional gene with ubiquitous expression."

The human anchor for this node. X-linkage plus ubiquitous expression is what makes a hemizygous male uniformly deficient in every expressing cell type, neuronal and glial alike; the claim is genetic rather than immunohistochemical.

PMID:18477000 SUPPORT Human Clinical

"Non-mosaic males with a 46,XY karyotype and a MECP2 null mutation display a phenotype of severe neonatal-onset encephalopathy that is distinctly different from Rett syndrome (RTT)."

Establishes the non-mosaic 46,XY human state that makes the deficiency uniform, completing the human-genetic warrant without invoking glial histology.

PMID:19234456 SUPPORT Model Organism

"We found that the loss of MeCP2 occurs not only in neurons but also in glial cells of RTT brains."

The glial arm of the node. Tagged MODEL_ORGANISM, not HUMAN_CLINICAL: the "RTT brains" here are mouse brains, the paper carries no Humans MeSH term, and the corresponding full-text passage refers to astrocytes of RTT mouse brains. This is the model-organism demonstration that MeCP2 loss extends to glia, extrapolated to the human hemizygous state via the genetic argument above.

+ 1 more reference

Preferential De-Repression of Long Neuronal Genes

The best-characterized transcriptional signature of MeCP2 loss, and the step that explains why neuronal connectivity programs specifically are hit rather than gene expression being perturbed at random. Profiling discrete neuronal subtypes rather than brain homogenates (which had shown only subtle changes because of a dilution problem) reveals that the genes up-regulated on loss of MeCP2 are biased toward longer genes, while down-regulated genes show no such bias, implying that MeCP2 selectively represses long genes. Because cell-adhesion and cell-cell-signalling genes governing neuronal connectivity and communication are themselves enriched among long genes, their de-repression is the proposed route from a generic chromatin defect to specifically miswired circuits. In a hemizygous male this de-repression is unbuffered, since no neuron retains a wild-type allele. Evidence is model-organism (Mecp2 knock-out mouse neuronal subtypes); no equivalent cell-type-resolved transcriptomic dataset exists for an affected human male.

neuron CL:0000540

MECP2 hgnc:6990

negative regulation of transcription by RNA polymerase II GO:0000122 ↓ DECREASED regulation of gene expression GO:0010468 ↕ DYSREGULATED

Downstream

Dysregulated Activity-Dependent Neuronal Gene Expression Long-gene de-repression is a principal component of the broader activity-dependent transcriptional dysregulation that follows MeCP2 loss.

Failure of Dendritic Arborization and Synaptogenesis De-repression of long cell-adhesion and cell-cell-signalling genes governing neuronal connectivity provides a direct route to failed dendritic and synaptic development.

Show evidence (3 references)

PMID:25232122 SUPPORT Model Organism

"Importantly, genes upregulated following loss of MeCP2 are biased toward longer genes but this is not true for downregulated genes, suggesting MeCP2 may selectively repress long genes."

The primary claim of the node, including the asymmetry (up-regulated but not down-regulated genes) that makes selective repression of long genes the parsimonious interpretation.

PMID:25232122 SUPPORT Model Organism

"The results reveal misregulation of genes involved in neuronal connectivity and communication."

Identifies the functional class of genes affected, which is what links this molecular node to the downstream connectivity failure.

PMID:25232122 SUPPORT Model Organism

"Because genes involved in neuronal connectivity and communication, such as cell adhesion and cell-cell signaling genes, are enriched among longer genes, their misregulation following loss of MeCP2 suggests a possible etiology for altered circuit function in Rett syndrome."

States the causal bridge from long-gene bias to altered circuit function, which is the reason this node sits upstream of the dendritic and synaptic failure node.

Dysregulated Activity-Dependent Neuronal Gene Expression

MeCP2 regulates the expression of a wide range of neuronal genes and can act as both a repressor and an activator. Its complete absence changes the expression levels of thousands of genes, disrupting the activity-dependent transcriptional programs that drive neuronal maturation.

neuron CL:0000540

regulation of gene expression GO:0010468 ↕ DYSREGULATED

Downstream

Failure of Dendritic Arborization and Synaptogenesis Loss of the transcriptional programs for neuronal maturation prevents normal dendritic and synaptic development.

Show evidence (2 references)

PMID:18511691 SUPPORT Model Organism

"MeCP2 dysfunction induced changes in the expression levels of thousands of genes"

Establishes the breadth of transcriptional dysregulation downstream of MeCP2 dysfunction.

PMID:18511691 SUPPORT Model Organism

"These studies suggest that MeCP2 regulates the expression of a wide range of genes in the hypothalamus and that it can function as both an activator and a repressor of transcription."

Establishes the bidirectional (activator and repressor) character of MeCP2 transcriptional regulation that is lost.

Non-Cell-Autonomous Astrocytic Failure to Support Dendritic Morphology

MeCP2-null astrocytes, and their conditioned medium alone, fail to support normal dendritic morphology in either wild-type or mutant hippocampal neurons, implicating aberrant secretion of soluble factors. In a hemizygous male, where astrocytes are also uniformly MeCP2-deficient, this non-cell-autonomous insult is unmitigated and compounds the cell-autonomous neuronal defect.

astrocyte CL:0000127 hippocampal neuron CL:0002608

dendrite morphogenesis GO:0048813 ↓ DECREASED

Downstream

Failure of Dendritic Arborization and Synaptogenesis Loss of astrocytic soluble support converges with the neuronal transcriptional defect on failed dendritic development.

Show evidence (2 references)

PMID:19234456 SUPPORT In Vitro

"Using an in vitro co-culture system, we found that mutant astrocytes from a RTT mouse model, and their conditioned medium, failed to support normal dendritic morphology of either wild-type or mutant hippocampal neurons."

Directly demonstrates the non-cell-autonomous astrocytic contribution to the dendritic phenotype, and shows a soluble factor suffices.

PMID:19234456 SUPPORT In Vitro

"Our studies suggest that astrocytes in the RTT brain carrying MeCP2 mutations have a non-cell autonomous effect on neuronal properties, probably as a result of aberrant secretion of soluble factor(s)."

Names the proposed mechanism, aberrant secretion of soluble factors.

Failure of Dendritic Arborization and Synaptogenesis

The pivotal cellular lesion, documented directly in human autopsy material from an affected male rather than inferred. Golgi staining of pyramidal neurons from cortical layers III and V of the frontal and temporal lobes shows drastically diminished dendritic trees, and synaptophysin staining of synaptic vesicles is greatly reduced in cerebellar and spinal cord sections, indicating that the failure is not confined to cortex. The hemizygous mutant male mouse supplies the quantitative counterpart and shows the deficit is compartment-specific, with spine density reduced by 47.4% in the apical tuft and 54.5% in secondary apical dendrites of layer 5 motor cortical neurons while primary apical and proximal basal dendrites are spared.

pyramidal neuron CL:0000598 neuron CL:0000540

dendrite morphogenesis GO:0048813 ↓ DECREASED synapse organization GO:0050808 ↓ DECREASED

cerebral cortex UBERON:0000956 cerebellum UBERON:0002037 spinal cord UBERON:0002240

Downstream

Reduced Brain Growth With Frontotemporal Predominance Failed dendritic and synaptic elaboration reduces neuropil volume and therefore brain growth.

Cortical Malformation With Perisylvian Polymicrogyria In at least some affected males the developmental disturbance extends to overt cortical malformation.

Brainstem Respiratory Network Failure Loss of synaptic organization in brainstem and spinal respiratory circuitry destabilizes ventilatory control.

Cortical Network Hyperexcitability Failed synaptic and dendritic maturation yields an epileptogenic network.

Impaired Motor Control Circuitry Failed maturation of motor circuits prevents normal tone and voluntary movement.

Cardiac Autonomic Conduction Instability Failure of autonomic circuit maturation destabilizes cardiac rate and conduction.

Sleep Disturbance Failed maturation of sleep-regulating circuitry produces sleep disturbance.

Bruxism Network dysfunction contributes to stereotyped oromotor manifestations including bruxism.

Show evidence (5 references)

PMID:18477000 SUPPORT Human Clinical

"Analysis of Golgi-stained pyramidal neurons from cortical layers III and V of the frontal and temporal lobes revealed drastically diminished dendritic trees."

Direct human neuropathological demonstration of the dendritic failure in an affected male.

PMID:18477000 SUPPORT Human Clinical

"Synaptophysin staining of synaptic vesicles was greatly reduced in cerebellar and spinal cord sections."

Direct human demonstration of reduced synaptic vesicle content beyond cortex, including spinal cord.

PMID:22412847 SUPPORT Model Organism

"Spine density was reduced by 47.4% in the apical tuft and 54.5% in secondary apical dendrites, but remained unaffected in primary apical and proximal basal dendrites."

Quantifies the spine deficit in hemizygous mutant male mice, the genotype that matches this entity, and shows it is compartment-specific rather than global.

+ 2 more references

Reduced Brain Growth With Frontotemporal Predominance

At autopsy the brain of an affected male is small with disproportionate reduction of the frontal and temporal lobes, matching the regions where the dendritic deficit was measured. In the Mecp2-null mouse, brain weight and neuronal cell size are substantially reduced without obvious structural defects or signs of neurodegeneration, indicating that reduced brain volume reflects failed neuronal growth rather than loss of previously formed neurons.

brain development GO:0007420 ↓ DECREASED

brain UBERON:0000955 frontal cortex UBERON:0001870 temporal lobe UBERON:0001871

Downstream

Microcephaly A small brain with reduced neuropil produces a small head circumference.

Severe Global Developmental Delay Global failure of brain growth underlies global failure of developmental attainment.

Show evidence (2 references)

PMID:18477000 SUPPORT Human Clinical

"At autopsy, the brain was small with disproportionate reduction of the frontal and temporal lobes."

Direct human autopsy documentation of reduced brain size with regional predominance.

PMID:11242118 SUPPORT Model Organism

"Mutant brains showed substantial reduction in both weight and neuronal cell size, but no obvious structural defects or signs of neurodegeneration."

Establishes in the corresponding null model that reduced brain size reflects failed neuronal growth rather than neurodegeneration.

Cortical Malformation With Perisylvian Polymicrogyria

In at least one autopsied affected male the developmental disturbance produced overt cortical malformation, namely bilateral polymicrogyria in the perisylvian region, visibly more severe than previously described in females with Rett syndrome or in another male with a MECP2 mutation. This places part of the pathogenesis prenatally, during cortical development, and motivated the recommendation that MECP2 be screened in bilateral perisylvian polymicrogyria syndromes.

cerebral cortex development GO:0021987 ⚠ ABNORMAL

cerebral cortex UBERON:0000956

Downstream

Polymicrogyria The malformation is directly observable as bilateral perisylvian polymicrogyria.

Cortical Network Hyperexcitability Polymicrogyric cortex is intrinsically epileptogenic.

Oropharyngeal Dyskinesia and Feeding Difficulties Perisylvian cortical malformation impairs oromotor and pharyngeal control.

Show evidence (2 references)

PMID:11930274 SUPPORT Human Clinical

"Post mortem examination revealed bilateral polymicrogyria in the perisylvian region."

Direct human neuropathological documentation of cortical malformation in an affected male.

PMID:11930274 SUPPORT Human Clinical

"This malformation was visibly more severe than previously described in females with RS and another male with an MECP2 mutation."

Grades the malformation as more severe in the hemizygous male than in Rett females, consistent with the loss-of-mosaic-rescue model.

Brainstem Respiratory Network Failure

Failure of synaptic organization in brainstem and spinal respiratory circuitry destabilizes ventilatory control, producing hypoventilation and irregular breathing from the neonatal period, apnea, and ultimately central respiratory failure. This is the proximate cause of death in autopsied cases.

neuron CL:0000540

regulation of respiratory gaseous exchange GO:0043576 ↕ DYSREGULATED

brainstem UBERON:0002298

Downstream

Central Hypoventilation and Irregular Breathing Loss of stable respiratory rhythm generation manifests as hypoventilation and irregular breathing.

Central Apnea Respiratory network instability produces central apneic events.

Respiratory Insufficiency Progressive ventilatory failure is the dominant organ-level complication.

Death in Infancy From Central Respiratory Failure Progressive brainstem respiratory network failure culminates in fatal central respiratory failure, the usual mode of death.

Show evidence (3 references)

PMID:18477000 SUPPORT Human Clinical

"The proband suffered from general hypotonia and hypoxia caused by hypoventilation and irregular breathing."

Establishes that the hypoxia is centrally driven, caused by hypoventilation and irregular breathing rather than by lung disease.

PMID:18477000 SUPPORT Human Clinical

"He failed to thrive and to reach any motor milestones and died at 15 months from central respiratory failure without a diagnosis."

Identifies central respiratory failure as the cause of death.

PMID:16832102 SUPPORT Human Clinical

"Common features include failure to thrive, respiratory insufficiency, microcephaly, and abnormal motor control."

Confirms respiratory insufficiency as a common feature across the reported male case set rather than a single-case finding.

Central Hypoventilation and Irregular Breathing

Sustained inadequate ventilation with an irregular breathing pattern, present from the neonatal period and driven centrally rather than by intrinsic lung disease.

regulation of respiratory gaseous exchange GO:0043576 ↓ DECREASED

Downstream

Chronic Central Hypoxia Chronic hypoventilation produces chronic tissue hypoxia.

Hypoventilation The clinical manifestation is measurable hypoventilation.

Show evidence (2 references)

PMID:18477000 SUPPORT Human Clinical

"The proband suffered from general hypotonia and hypoxia caused by hypoventilation and irregular breathing."

States the hypoventilation-plus-irregular-breathing pattern and its hypoxic consequence.

PMID:17236109 SUPPORT Human Clinical

"He had prolonged periods with tremor and epileptic myoclonus, shifting tonus, and dystonic extension of the trunk and legs, bruxism, and irregular breathing."

Independent case documentation of irregular breathing alongside the movement phenotype in an affected male.

Chronic Central Hypoxia

Chronic hypoxia of central (ventilatory) origin, evidenced not by blood gases alone but by its structural footprint in skeletal muscle. On muscle biopsy the type II fibers are reduced in diameter, which the reporting authors interpret as indicating central hypoxia. This gives the entity an objective, biopsy-level marker of the systemic consequence of its brainstem lesion.

cellular response to hypoxia GO:0071456 ↑ INCREASED

skeletal muscle tissue UBERON:0001134

Downstream

Type 2 Muscle Fiber Atrophy Chronic central hypoxia is reflected in reduced type II muscle fiber diameter.

Failure to Thrive Chronic hypoxia and increased work of breathing contribute to growth failure.

Show evidence (1 reference)

PMID:18477000 SUPPORT Human Clinical

"In a muscle biopsy, type II fibers were reduced in diameter, indicating central hypoxia."

Provides the muscle-biopsy evidence and the authors' interpretation of it as central hypoxia.

Death in Infancy From Central Respiratory Failure

The terminal node. Death often occurs before age two years, most commonly from central respiratory failure; reported ages at death across individual cases include 13 months, 15 months, 17 months, 1 year 8 months, 30 months and 3 years 1 month. This is modeled as a pathophysiology node rather than as a phenotypes entry because HP:0001522 (Death in infancy) sits in the HPO mortality branch outside HP:0000118 phenotypic abnormality and is therefore not bindable in phenotype_term. The competing cardiac mode of death is captured separately by the Sudden Death phenotype and the mechanism_of_sudden_death discussion.

Show evidence (4 references)

PMID:20301670 SUPPORT Human Clinical

"Death often occurs before age two years."

GeneReviews states the typical outcome for the male severe neonatal-onset phenotype.

PMID:18477000 SUPPORT Human Clinical

"He failed to thrive and to reach any motor milestones and died at 15 months from central respiratory failure without a diagnosis."

Provides the case-level mode and timing of death.

PMID:17236109 SUPPORT Human Clinical

"They died at the ages of 1 year and 8 months, and 3 years and 1 month."

Documents ages at death in an affected brother pair.

+ 1 more reference

Cortical Network Hyperexcitability

Failed synaptic and dendritic maturation, compounded where present by polymicrogyric cortex, produces an epileptogenic network. Clinically this is expressed as severe, often intractable seizures with accompanying electroencephalographic abnormality, and in reported males as prolonged periods of epileptic myoclonus.

neuron CL:0000540

chemical synaptic transmission GO:0007268 ↕ DYSREGULATED

cerebral cortex UBERON:0000956

Downstream

Seizures Network hyperexcitability manifests as severe and often intractable seizures.

EEG Abnormality Network hyperexcitability is detectable electrographically.

Myoclonus Epileptic myoclonus is a documented expression of the hyperexcitable network in affected males.

Show evidence (3 references)

PMID:18477000 SUPPORT Human Clinical

"He developed abnormal movements, seizures and electroencephalogram abnormalities."

Documents seizures together with electrographic abnormality in an autopsy-confirmed case.

PMID:16832102 SUPPORT Human Clinical

"MECP2 mutations should be assessed in boys with progressive encephalopathy and one or more of respiratory insufficiency, abnormal movements or tone, and intractable seizures."

Identifies intractability as a characteristic feature of the epilepsy in this male phenotype.

PMID:17236109 SUPPORT Human Clinical

"He had prolonged periods with tremor and epileptic myoclonus, shifting tonus, and dystonic extension of the trunk and legs, bruxism, and irregular breathing."

Documents epileptic myoclonus as an expression of network hyperexcitability in an affected male.

Impaired Motor Control Circuitry

Failed maturation of motor and extrapyramidal circuitry yields generalized hypotonia that later shifts to abnormal and fluctuating tone, with involuntary movements including tremor and dystonic extension of the trunk and legs, and, in reported cases, ocular and oropharyngeal dyskinesia. No motor milestones are attained.

neuron CL:0000540

regulation of muscle contraction GO:0006937 ↕ DYSREGULATED

Downstream

Generalized Hypotonia Failure of motor circuit maturation presents first as generalized hypotonia.

Abnormal Muscle Tone Tone is abnormal and fluctuating beyond simple hypotonia as the course progresses.

Involuntary Movements Extrapyramidal circuit failure produces involuntary movements.

Dystonia Dystonic extension of the trunk and legs is reported in affected males.

Tremor Prolonged periods of tremor are reported in affected males.

Abnormal Eye Movements Ocular dyskinesia has been reported as part of the movement phenotype.

Inability to Walk No motor milestones are attained, so ambulation is never achieved.

Show evidence (3 references)

PMID:20301670 SUPPORT Human Clinical

Establishes abnormal tone and involuntary movements as defining features of the motor phenotype.

PMID:17236109 SUPPORT Human Clinical

"He had prolonged periods with tremor and epileptic myoclonus, shifting tonus, and dystonic extension of the trunk and legs, bruxism, and irregular breathing."

Enumerates the specific movement-disorder elements (tremor, shifting tone, dystonic extension) attributed to this node.

PMID:37537631 SUPPORT Human Clinical

"The patient presented with severe encephalopathy in the neonatal period, accompanied by severe development backwardness, hypotonia, and ocular and oropharyngeal dyskinesia."

Documents hypotonia plus ocular and oropharyngeal dyskinesia in an affected hemizygous male.

Cardiac Autonomic Conduction Instability

A clinically consequential and under-recognized arm. In a familial pair of affected brothers, severe bradycardia preceded sudden death from sick sinus syndrome at 17 and 30 months. Across MECP2 disorders, QTc prolongation is a recognized surveillance target and QT-prolonging drugs are agents to avoid, so cardiac conduction instability is an actionable node rather than an incidental observation.

regulation of heart rate GO:0002027 ↕ DYSREGULATED

sinoatrial node UBERON:0002351 heart UBERON:0000948

Downstream

Bradycardia Sinoatrial node dysfunction presents as severe bradycardia.

Sick Sinus Syndrome Progressive sinoatrial dysfunction reaches the threshold of sick sinus syndrome.

Prolonged QT Interval Repolarization abnormality is a recognized surveillance target across MECP2 disorders.

Sudden Death Conduction failure is a documented mechanism of sudden death in affected males.

Show evidence (3 references)

PMID:29631775 SUPPORT Human Clinical

"He developed severe apnea, epilepsy, and psychomotor developmental delay and died suddenly of sick sinus syndrome at 17 months of age."

Documents sudden death from sick sinus syndrome in an affected male with neonatal encephalopathy.

PMID:29631775 SUPPORT Human Clinical

"His older brother followed a similar clinical course and died at 30 months of age. The brother had also experienced severe bradycardia."

Shows the conduction phenotype recurring within a family rather than being a one-off, strengthening its attribution to the MECP2 lesion.

PMID:20301670 SUPPORT Human Clinical

"regular assessment of QTc for evidence of prolongation"

Establishes QTc prolongation as a recognized surveillance target in MECP2 disorders, making the cardiac node actionable.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Cardiovascular 2

Bradycardia OCCASIONAL Bradycardia HP:0001662

Severity: SEVERE

Show evidence (2 references)

PMID:29631775 SUPPORT Human Clinical

"Severe bradycardia had been noticed since 16 months of age."

Documents severe bradycardia preceding sudden death in the index case.

PMID:29631775 SUPPORT Human Clinical

"His older brother followed a similar clinical course and died at 30 months of age. The brother had also experienced severe bradycardia."

Documents recurrence of severe bradycardia in the affected brother.

Prolonged QT Interval Prolonged QT interval HP:0001657

Show evidence (1 reference)

PMID:20301670 PARTIAL Human Clinical

"regular assessment of QTc for evidence of prolongation"

Marked PARTIAL because GeneReviews recommends surveillance for QTc prolongation across MECP2 disorders rather than reporting its frequency in this male phenotype.

Digestive 1

Oropharyngeal Dyskinesia and Feeding Difficulties FREQUENT Feeding difficulties HP:0011968

Course: PROGRESSIVE Severity: SEVERE

Show evidence (3 references)

PMID:17236109 SUPPORT Human Clinical

"Two brothers with T158M mutations and normal karyotype had a severe early onset encephalopathy, progressive microcephaly, severe feeding problems, breathing and sleep disturbances."

Documents severe feeding problems as a characteristic feature in an affected brother pair, which is the basis for the FREQUENT band and the SEVERE qualifier.

PMID:17236109 SUPPORT Human Clinical

"The head growth decelerated from the age of 6 months and the feeding problems increased requiring gastrostomy."

Documents the progressive course of the feeding difficulty and its escalation to gastrostomy dependence.

PMID:37537631 PARTIAL Human Clinical

"The patient presented with severe encephalopathy in the neonatal period, accompanied by severe development backwardness, hypotonia, and ocular and oropharyngeal dyskinesia."

Marked PARTIAL because the source reports oropharyngeal dyskinesia, the oromotor mechanism, rather than feeding difficulty as such.

Eye 1

Abnormal Eye Movements OCCASIONAL Abnormality of eye movement HP:0000496

Show evidence (1 reference)

PMID:37537631 SUPPORT Human Clinical

"The patient presented with severe encephalopathy in the neonatal period, accompanied by severe development backwardness, hypotonia, and ocular and oropharyngeal dyskinesia."

Documents ocular dyskinesia in an affected male, the basis for the eye-movement abnormality annotation.

Head and Neck 1

Microcephaly FREQUENT Microcephaly HP:0000252

Course: PROGRESSIVE

Show evidence (2 references)

PMID:16832102 SUPPORT Human Clinical

"Common features include failure to thrive, respiratory insufficiency, microcephaly, and abnormal motor control."

Case-series statement that microcephaly is a common feature, which is the basis for the FREQUENT band.

PMID:17236109 SUPPORT Human Clinical

"Two brothers with T158M mutations and normal karyotype had a severe early onset encephalopathy, progressive microcephaly, severe feeding problems, breathing and sleep disturbances."

Independent documentation of microcephaly in affected males, and specifically of its progressive character.

Context-specific annotations (1)

Progressive/acquired pattern documented longitudinally, with head-growth deceleration from six months of age.

Show evidence (1 reference)

PMID:17236109 SUPPORT Human Clinical

"The head growth decelerated from the age of 6 months and the feeding problems increased requiring gastrostomy."

Documents postnatal head-growth deceleration with an explicit age of onset, establishing that at least part of the microcephaly is acquired.

Musculoskeletal 1

Generalized Hypotonia FREQUENT Generalized hypotonia HP:0001290

Show evidence (2 references)

PMID:18477000 SUPPORT Human Clinical

"The proband suffered from general hypotonia and hypoxia caused by hypoventilation and irregular breathing."

Documents generalized hypotonia in an autopsy-confirmed case.

PMID:37537631 SUPPORT Human Clinical

"The patient presented with severe encephalopathy in the neonatal period, accompanied by severe development backwardness, hypotonia, and ocular and oropharyngeal dyskinesia."

Independent case documentation of hypotonia in an affected hemizygous male.

Nervous System 9

Involuntary Movements FREQUENT Involuntary movements HP:0004305

Show evidence (2 references)

PMID:20301670 SUPPORT Human Clinical

GeneReviews lists involuntary movements among the characterizing features.

PMID:18477000 SUPPORT Human Clinical

"He developed abnormal movements, seizures and electroencephalogram abnormalities."

Case-level documentation of abnormal movements.

Dystonia OCCASIONAL Dystonia HP:0001332

Show evidence (1 reference)

PMID:17236109 SUPPORT Human Clinical

"He had prolonged periods with tremor and epileptic myoclonus, shifting tonus, and dystonic extension of the trunk and legs, bruxism, and irregular breathing."

Documents dystonic extension of the trunk and legs in an affected male.

Tremor OCCASIONAL Tremor HP:0001337

Show evidence (1 reference)

PMID:17236109 SUPPORT Human Clinical

"He had prolonged periods with tremor and epileptic myoclonus, shifting tonus, and dystonic extension of the trunk and legs, bruxism, and irregular breathing."

Documents prolonged tremor in an affected male.

Myoclonus OCCASIONAL Myoclonus HP:0001336

Show evidence (1 reference)

PMID:17236109 SUPPORT Human Clinical

"He had prolonged periods with tremor and epileptic myoclonus, shifting tonus, and dystonic extension of the trunk and legs, bruxism, and irregular breathing."

Documents epileptic myoclonus in an affected male.

Seizures FREQUENT Seizure HP:0001250

Severity: SEVERE

Show evidence (2 references)

PMID:20301670 SUPPORT Human Clinical

GeneReviews lists severe seizures among the characterizing features, supporting both the phenotype and its SEVERE qualifier.

PMID:16832102 SUPPORT Human Clinical

"MECP2 mutations should be assessed in boys with progressive encephalopathy and one or more of respiratory insufficiency, abnormal movements or tone, and intractable seizures."

Documents intractability of the seizures in the male phenotype.

EEG Abnormality EEG abnormality HP:0002353

Show evidence (1 reference)

PMID:18477000 SUPPORT Human Clinical

"He developed abnormal movements, seizures and electroencephalogram abnormalities."

Direct case documentation of electroencephalogram abnormalities.

Severe Global Developmental Delay FREQUENT Severe global developmental delay HP:0011344

Show evidence (3 references)

PMID:18477000 SUPPORT Human Clinical

"He failed to thrive and to reach any motor milestones and died at 15 months from central respiratory failure without a diagnosis."

Documents complete failure of motor milestone attainment.

PMID:37537631 SUPPORT Human Clinical

"The patient presented with severe encephalopathy in the neonatal period, accompanied by severe development backwardness, hypotonia, and ocular and oropharyngeal dyskinesia."

Independent documentation of severe developmental impairment.

PMID:17236109 SUPPORT Human Clinical

"He had a rapid deterioration period at 2 years and lost sitting and hand grasping functions."

Documents the less common protracted variant of the course, in which limited milestones are attained and then lost.

Polymicrogyria OCCASIONAL Polymicrogyria HP:0002126

Show evidence (2 references)

PMID:11930274 SUPPORT Human Clinical

"Post mortem examination revealed bilateral polymicrogyria in the perisylvian region."

Direct neuropathological documentation of polymicrogyria in an affected male.

PMID:11930274 SUPPORT Human Clinical

"We conclude that MECP2 screening should be considered in males with severe neonatal encephalopathy and in males and females with a bilateral polymicrogyria syndrome."

The authors' own recommendation, which treats the polymicrogyria association as strong enough to change testing practice.

Sleep Disturbance OCCASIONAL Sleep disturbance HP:0002360

Show evidence (1 reference)

PMID:17236109 SUPPORT Human Clinical

"Two brothers with T158M mutations and normal karyotype had a severe early onset encephalopathy, progressive microcephaly, severe feeding problems, breathing and sleep disturbances."

Documents sleep disturbance in an affected brother pair.

Respiratory 1

Respiratory Insufficiency FREQUENT Respiratory insufficiency HP:0002093

Course: PROGRESSIVE

Show evidence (2 references)

PMID:16832102 SUPPORT Human Clinical

"Common features include failure to thrive, respiratory insufficiency, microcephaly, and abnormal motor control."

Case-series statement that respiratory insufficiency is a common feature, which is the basis for the FREQUENT band.

PMID:18477000 SUPPORT Human Clinical

"He failed to thrive and to reach any motor milestones and died at 15 months from central respiratory failure without a diagnosis."

Documents progression of respiratory insufficiency to fatal central respiratory failure.

Constitutional 1

Sudden Death Sudden death HP:0001699

Show evidence (1 reference)

PMID:29631775 SUPPORT Human Clinical

"This familial case might help to clarify the causes of sudden death in cases of MECP2 mutations."

The authors frame their case as informing the mechanism of sudden death in MECP2 mutation carriers.

Growth 1

Failure to Thrive FREQUENT Failure to thrive HP:0001508

Show evidence (2 references)

PMID:16832102 SUPPORT Human Clinical

"Common features include failure to thrive, respiratory insufficiency, microcephaly, and abnormal motor control."

Case-series statement that failure to thrive is a common feature.

PMID:18477000 SUPPORT Human Clinical

"He failed to thrive and to reach any motor milestones and died at 15 months from central respiratory failure without a diagnosis."

Case-level documentation of failure to thrive.

Other 8

Congenital Encephalopathy OBLIGATE Congenital encephalopathy HP:0007239

Temporal: CHRONIC Course: PROGRESSIVE

Show evidence (3 references)

PMID:20301670 SUPPORT Human Clinical

GeneReviews names the encephalopathy as the phenotype itself and the most common male presentation, which is why it is marked obligate and diagnostic.

PMID:11930274 SUPPORT Human Clinical

"He presented with severe neonatal encephalopathy and died at the age of 13 months."

Independent case documentation of the presenting encephalopathy.

PMID:17236109 SUPPORT Human Clinical

"Two brothers with T158M mutations and normal karyotype had a severe early onset encephalopathy, progressive microcephaly, severe feeding problems, breathing and sleep disturbances."

Second independent case pair documenting the early-onset encephalopathy with its characteristic accompanying features.

Context-specific annotations (1)

Onset: NEONATAL

Show evidence (1 reference)

PMID:18477000 SUPPORT Human Clinical

"Non-mosaic males with a 46,XY karyotype and a MECP2 null mutation display a phenotype of severe neonatal-onset encephalopathy that is distinctly different from Rett syndrome (RTT)."

Fixes the neonatal onset as part of the entity definition.

Abnormal Muscle Tone FREQUENT Abnormal muscle tone HP:0003808

Show evidence (2 references)

PMID:20301670 SUPPORT Human Clinical

GeneReviews lists abnormal tone among the four characterizing features.

PMID:16832102 SUPPORT Human Clinical

"MECP2 mutations should be assessed in boys with progressive encephalopathy and one or more of respiratory insufficiency, abnormal movements or tone, and intractable seizures."

Confirms abnormal tone as a recognized feature across the reported case set.

Hypoventilation Hypoventilation HP:0002791

Show evidence (2 references)

PMID:18477000 SUPPORT Human Clinical

"The proband suffered from general hypotonia and hypoxia caused by hypoventilation and irregular breathing."

Documents hypoventilation and irregular breathing as the mechanism of the hypoxia.

PMID:17236109 PARTIAL Human Clinical

"He had prolonged periods with tremor and epileptic myoclonus, shifting tonus, and dystonic extension of the trunk and legs, bruxism, and irregular breathing."

Marked PARTIAL because the source documents irregular breathing rather than measured hypoventilation.

Central Apnea Central apnea HP:0002871

Severity: SEVERE

Show evidence (1 reference)

PMID:29631775 SUPPORT Human Clinical

"He developed severe apnea, epilepsy, and psychomotor developmental delay and died suddenly of sick sinus syndrome at 17 months of age."

Documents severe apnea in an affected male with neonatal encephalopathy.

Inability to Walk Inability to walk HP:0002540

Show evidence (1 reference)

PMID:18477000 PARTIAL Human Clinical

"He failed to thrive and to reach any motor milestones and died at 15 months from central respiratory failure without a diagnosis."

Marked PARTIAL because the source states that no motor milestones were reached, from which inability to walk follows, rather than reporting ambulation status.

Bruxism OCCASIONAL Bruxism HP:0003763

Show evidence (1 reference)

PMID:17236109 SUPPORT Human Clinical

"He had prolonged periods with tremor and epileptic myoclonus, shifting tonus, and dystonic extension of the trunk and legs, bruxism, and irregular breathing."

Documents bruxism in an affected male.

Sick Sinus Syndrome OCCASIONAL Sick sinus syndrome HP:0011704

Show evidence (1 reference)

PMID:29631775 SUPPORT Human Clinical

"He developed severe apnea, epilepsy, and psychomotor developmental delay and died suddenly of sick sinus syndrome at 17 months of age."

Directly documents sick sinus syndrome as the cause of sudden death.

Type 2 Muscle Fiber Atrophy Type 2 muscle fiber atrophy HP:0003554

Show evidence (1 reference)

PMID:18477000 SUPPORT Human Clinical

"In a muscle biopsy, type II fibers were reduced in diameter, indicating central hypoxia."

Direct biopsy documentation of reduced type II fiber diameter and its interpretation.

🧬

Genetic Associations

MECP2 (Causative)

Gene: MECP2 hgnc:6990 relationship_type: CAUSATIVE variant_origin: DE_NOVO

X-linked inheritance

Show evidence (9 references)

PMID:34502518 SUPPORT Human Clinical

"In boys, however, mutations in MECP2 can generate a wide spectrum of clinical presentations that range from mild intellectual impairment to severe neonatal encephalopathy and premature death."

Establishes MECP2 as the causative gene for the male spectrum whose severe end this entry curates.

PMID:34502518 SUPPORT Human Clinical

"Loss-of-function mutations in MECP2 are associated with Rett syndrome (RTT), which is a well-characterized disorder that affects mainly females."

Establishes the loss-of-function direction of effect, distinguishing this entity from MECP2 duplication syndrome.

PMID:34271245 SUPPORT Human Clinical

"In males, the MECP2 pathogenic variants can be associated with different phenotypes, including neonatal severe encephalopathy, intellectual deficiency, or late-onset parkinsonism and spasticity."

Systematic review conclusion establishing the three male MECP2 phenotypes.

+ 6 more references

💊

Medical Actions

Multidisciplinary Symptomatic and Supportive Care

Action: Supportive Care NCIT:C15747

There is no disease-modifying therapy. Treatment is mainly symptomatic and focuses on optimizing the individual's abilities through a multidisciplinary approach that also includes psychosocial support for family members.

Show evidence (1 reference)

PMID:20301670 SUPPORT Human Clinical

"Treatment is mainly symptomatic and focuses on optimizing the individual's abilities using a multidisciplinary approach that should also include psychosocial support for family members."

GeneReviews management statement establishing symptomatic multidisciplinary care as the standard of care.

Seizure Management

Action: anticonvulsant therapy Ontology label: Anticonvulsant Therapy NCIT:C64172

Agent: anticonvulsant agent NCIT:C264

Antiseizure treatment per standard care. Seizures in this phenotype are frequently intractable, so epilepsy-specialist involvement is expected.

Mechanism Target:

INHIBITS Cortical Network Hyperexcitability — Antiseizure drugs suppress the epileptogenic network output rather than the upstream MeCP2 deficiency.

Show evidence (1 reference)

PMID:20301670 PARTIAL Human Clinical

"Treatment of seizures, constipation, gastroesophageal reflux, scoliosis, prolonged QTc, and spasticity per standard care."

Marked PARTIAL because GeneReviews prescribes standard-care seizure treatment without naming a mechanism-specific agent for this phenotype.

Target Phenotypes: Seizure HP:0001250

Show evidence (2 references)

PMID:20301670 SUPPORT Human Clinical

"Treatment of seizures, constipation, gastroesophageal reflux, scoliosis, prolonged QTc, and spasticity per standard care."

GeneReviews directs standard-care treatment of seizures among other manifestations.

PMID:16832102 PARTIAL Human Clinical

"MECP2 mutations should be assessed in boys with progressive encephalopathy and one or more of respiratory insufficiency, abnormal movements or tone, and intractable seizures."

Marked PARTIAL because it establishes the intractability that shapes seizure management rather than an intervention result.

Cardiac Conduction Surveillance and Avoidance of QT-Prolonging Drugs

Action: serial electrocardiography with QTc assessment Ontology label: Electrocardiography NCIT:C38053

Regular assessment of QTc for evidence of prolongation, with avoidance of drugs known to prolong the QT interval. This is the one actionable, potentially death-preventing intervention specific to the cardiac node, and it is reinforced by the documented sudden deaths from sick sinus syndrome and severe bradycardia in affected brothers.

Mechanism Target:

MODULATES Cardiac Autonomic Conduction Instability — Surveillance detects, and drug avoidance refrains from aggravating, the conduction instability node; neither corrects the underlying autonomic circuit failure.

Show evidence (1 reference)

PMID:20301670 SUPPORT Human Clinical

"Agents/circumstances to avoid: Drugs known to prolong the QT interval."

The explicit avoidance recommendation that operates on the conduction node.

Target Phenotypes: Prolonged QT interval HP:0001657 Sudden death HP:0001699

Show evidence (2 references)

PMID:20301670 SUPPORT Human Clinical

"regular assessment of QTc for evidence of prolongation"

GeneReviews surveillance recommendation for QTc.

PMID:29631775 SUPPORT Human Clinical

"This familial case might help to clarify the causes of sudden death in cases of MECP2 mutations."

Provides the clinical motivation for cardiac surveillance in affected males.

Melatonin for Sleep Disturbance

Action: Pharmacotherapy NCIT:C15986

Agent: melatonin CHEBI:16796

Melatonin can ameliorate sleep disturbances in MECP2 disorders, and sleep disturbance is documented in affected males.

Target Phenotypes: Sleep disturbance HP:0002360

Show evidence (2 references)

PMID:20301670 PARTIAL Human Clinical

"Risperidone may help in treating agitation; melatonin can ameliorate sleep disturbances."

Marked PARTIAL because GeneReviews recommends melatonin across MECP2 disorders, where the supporting experience is predominantly in females with Rett syndrome rather than in males with the neonatal-onset phenotype.

PMID:17236109 PARTIAL Human Clinical

"Two brothers with T158M mutations and normal karyotype had a severe early onset encephalopathy, progressive microcephaly, severe feeding problems, breathing and sleep disturbances."

Marked PARTIAL because it establishes the sleep disturbance that motivates the treatment in affected males rather than reporting a treatment outcome.

Nutritional Support and Gastrostomy Feeding

Action: Nutritional Support NCIT:C15433

Caloric support and management of feeding difficulty, escalating to gastrostomy when oral feeding fails. This is not optional supportive detail but a documented requirement, given the near-universal failure to thrive, severe feeding problems from birth and the aspiration risk from oropharyngeal dyskinesia.

Target Phenotypes: Failure to thrive HP:0001508 Feeding difficulties HP:0011968

Show evidence (2 references)

PMID:17236109 SUPPORT Human Clinical

"The head growth decelerated from the age of 6 months and the feeding problems increased requiring gastrostomy."

Documents escalation of feeding support to gastrostomy in an affected male.

PMID:16832102 PARTIAL Human Clinical

"Common features include failure to thrive, respiratory insufficiency, microcephaly, and abnormal motor control."

Marked PARTIAL because it establishes the failure to thrive that nutritional support addresses rather than reporting an intervention outcome.

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Counseling covers the X-linked mode, the greater than 99% simplex rate across MECP2 disorders, the possibility of parental germline mosaicism, and the possibility of a minimally affected transmitting mother with favorably skewed X-chromosome inactivation. Because of possible parental germline mosaicism, prenatal diagnosis is appropriate to offer regardless of whether a parental variant was found.

Show evidence (2 references)

PMID:20301670 SUPPORT Human Clinical

"Because of the possibility of parental germline mosaicism, it is appropriate to offer prenatal diagnosis to couples who have had a child with a MECP2 disorder regardless of whether the MECP2 pathogenic variant has been detected in a parent."

The specific counseling recommendation that follows from germline mosaicism risk.

PMID:20301670 SUPPORT Human Clinical

"When the pathogenic MECP2 variant has been identified in the family, heterozygote testing for at-risk female relatives, prenatal testing for pregnancies at increased risk, and preimplantation genetic testing are possible."

Enumerates the reproductive options that constitute the counseling intervention.

🔬

Biochemical Markers

MeCP2 protein (Absent or severely dysfunctional in all cells)

Context: Because the male is hemizygous and non-mosaic, there is no wild-type MeCP2 in any neuron or glial cell. This is the biochemical difference from the heterozygous Rett female, in whom roughly half of cells retain wild-type MeCP2. No validated circulating or CSF biomarker exists for this entity.

🔀

Differential Diagnoses

Conditions with similar clinical presentations that must be differentiated from Severe Neonatal-Onset Encephalopathy With Microcephaly:

Classic Rett syndrome MONDO:0010726

Overlapping Features The most important contrast, and the reason this entry exists as a separate entity. Classic Rett syndrome is caused by the same MECP2 loss-of-function variant classes, but in a heterozygous female whose random X-chromosome inactivation leaves half of her neurons expressing wild-type MeCP2. That mosaic buffer produces a completely different natural history, with apparently normal development for six to eighteen months, then regression with loss of acquired purposeful hand use and spoken language, hand stereotypies, gait abnormality, acquired head-growth deceleration, and survival into adulthood. The male entity has no normal interval to regress from, typically never attains motor milestones, and usually dies before age two. A male who nonetheless presents with a recognizable Rett phenotype is almost always a somatic mosaic or has 47,XXY Klinefelter syndrome, which is the exception that proves the mosaic-rescue rule.

Distinguishing Features

Heterozygous female with mosaic MeCP2 loss, versus non-mosaic hemizygous 46,XY male with uniform MeCP2 loss
Apparently normal development for 6 to 18 months followed by regression, versus encephalopathy present from birth with no normal interval
Loss of previously acquired hand use and spoken language, versus typically never attaining any motor milestone
Hand stereotypies (hand wringing) are cardinal in Rett and are not features of the male neonatal-onset phenotype
Survival into adulthood is usual in Rett, whereas death often occurs before age two years here
A male with a classic Rett phenotype is almost always a somatic mosaic or 47,XXY, and therefore not this entity
Trofinetide is FDA-approved for Rett syndrome, whereas there is no approved or trial-tested therapy for the male neonatal-onset phenotype

Show evidence (4 references)

PMID:18477000 SUPPORT Human Clinical

"Non-mosaic males with a 46,XY karyotype and a MECP2 null mutation display a phenotype of severe neonatal-onset encephalopathy that is distinctly different from Rett syndrome (RTT)."

States the distinctness of the two entities in the terms that define the differential.

PMID:10508514 SUPPORT Human Clinical

"Patients with classic RTT appear to develop normally until 6-18 months of age, then gradually lose speech and purposeful hand use"

The Rett side of the key discriminator, a normal interval followed by regression.

PMID:34271245 SUPPORT Human Clinical

"The typical RS phenotype is not expected in males, except in those with Klinefelter syndrome or somatic mosaicism for MECP2."

Establishes that a Rett phenotype in a male points to mosaicism or 47,XXY rather than to this entity.

+ 1 more reference

MECP2 duplication syndrome MONDO:0010283

Overlapping Features The same gene with the opposite direction of dosage effect. MECP2 duplication syndrome arises from Xq28 copy-number gain rather than sequence loss of function, and it is males who are predominantly affected, usually inheriting the duplication from an apparently asymptomatic carrier mother. Both entities therefore present as severe X-linked neurodevelopmental disease in a male, which is exactly why they are confused, and the discriminator is the assay rather than the phenotype. Sequencing alone cannot separate them, so copy-number analysis is required. The distinction is not academic, because therapeutic logic is inverted, with MECP2 knockdown strategies rational in duplication syndrome and MECP2 replacement rational here, and copy-number-gain findings such as recurrent respiratory infection susceptibility must not be imported into this entry.

Distinguishing Features

Xq28 copy-number gain (duplication or triplication) versus sequence loss-of-function variant
Increased MeCP2 dosage versus absent or severely dysfunctional MeCP2
Usually inherited from an apparently asymptomatic carrier mother versus mostly de novo
Requires copy-number analysis (array CGH, MLPA) to detect; sequencing alone will miss it and will also fail to exclude it
Survival is typically into later childhood and adulthood with progressive spasticity and recurrent respiratory infection, rather than death before age two
Therapeutic direction is inverted, with MeCP2 reduction the rational strategy in duplication syndrome and MeCP2 restoration the rational strategy here

Show evidence (4 references)

PMID:34502518 SUPPORT Human Clinical

"Conversely, the entire duplication of the MECP2 gene is related to MECP2 duplication syndrome (MDS). Unlike in RTT, in MDS, males are predominantly affected."

States the copy-number-gain aetiology and the male predominance that make this the most confusable entity.

PMID:34502518 SUPPORT Human Clinical

"Usually, the duplication is inherited from an apparently asymptomatic carrier mother."

The inheritance discriminator. Note that a minimally affected carrier mother is also possible in this entity, so inheritance alone is insufficient.

PMID:34502518 SUPPORT Human Clinical

"Loss-of-function mutations in MECP2 are associated with Rett syndrome (RTT), which is a well-characterized disorder that affects mainly females."

Establishes the loss-of-function direction that separates this entry from duplication syndrome.

+ 1 more reference

Milder male MECP2 phenotypes (PPM-X and X-linked syndromic intellectual disability 13) MONDO:0010235

Overlapping Features The other two phenotypes produced by a single pathogenic copy of MECP2 in a male, and the correct intra-gene differential. Pyramidal signs with parkinsonism and macroorchidism (PPM-X) and X-linked intellectual deficiency 13 arise from the same hemizygous state and the same gene, so they cannot be separated from this entity by genotype class alone, and are separated instead by the functional severity of the variant. In the published record they are also more common than the severe neonatal phenotype, with 24 and 47 reported individuals respectively against 27. Recognising this gradient matters because a boy with a MECP2 variant and intellectual disability or late-onset parkinsonism and spasticity has a different prognosis and is not a mild case of this entity.

Distinguishing Features

Later onset with intellectual disability, or adult-onset pyramidal signs, parkinsonism and macroorchidism, rather than encephalopathy from birth
Survival into adulthood rather than death before age two
Associated with less functionally damaging MECP2 variants; clinical severity across the male spectrum correlates with the measured functional impairment of MeCP2
More numerous in the published literature (47 XLMR13 and 24 PPM-X versus 27 severe neonatal encephalopathy)

Show evidence (3 references)

PMID:34271245 SUPPORT Human Clinical

Enumerates the three male phenotypes that must be distinguished from one another.

PMID:34271245 SUPPORT Human Clinical

"We were able to collect information on 27 published patients with severe neonatal encephalopathy, 47 individuals with isolated or familial mental retardation X-linked 13 (XLMR13), as well as 24 individuals with isolated or familial Pyramidal signs, parkinsonism, and macroorchidism (PPM-X)."

Gives the relative published frequencies underlying the differential.

PMID:27929079 SUPPORT In Vitro

"Overall, clinical severity showed a direct correlation with the functional impairment of MeCP2."

Provides the mechanistic basis for the gradient that separates this entity from the milder male phenotypes.

Neonatal hypoxic-ischemic encephalopathy and perinatal asphyxia Not Yet Curated MONDO:0006663

Overlapping Features The most consequential misdiagnosis in practice, because it is common, it is the default explanation for a hypotonic encephalopathic neonate with seizures, and it stops the diagnostic workup. Documented clinician biases and misconceptions, principally the historical belief that MECP2 loss of function is incompatible with life in males, push the diagnosis toward an acquired perinatal cause; the autopsy-confirmed index case in the literature died at 15 months without a diagnosis at all. Two features should redirect the workup. Hypoxia in this entity is centrally driven, caused by hypoventilation and irregular breathing rather than by a peripartum event, and the course is relentlessly progressive rather than static.

Distinguishing Features

Hypoxia is centrally driven by hypoventilation and irregular breathing, rather than resulting from a peripartum hypoxic-ischemic event
Relentlessly progressive course resembling a metabolic-degenerative disease, rather than a static encephalopathy after a discrete insult
No sentinel perinatal event, and neuroimaging does not show a watershed or basal-ganglia-thalamic hypoxic-ischemic pattern
Requires a hemizygous MECP2 pathogenic variant for diagnosis, which is only found if genomic testing is actually sent
Type II muscle fiber hypotrophy on biopsy reflects chronic central hypoxia rather than an acute perinatal insult

Show evidence (4 references)

PMID:40515634 SUPPORT Human Clinical

"Qualitative findings demonstrate that medical biases and widespread misconceptions contribute to delays in accurate clinical diagnosis, which negatively impacts child health and family functioning."

Documents that the misdiagnosis problem is real and measurable rather than hypothetical.

PMID:18477000 SUPPORT Human Clinical

"The proband suffered from general hypotonia and hypoxia caused by hypoventilation and irregular breathing."

The central (ventilatory) origin of the hypoxia is the key discriminator from a peripartum hypoxic-ischemic insult.

PMID:18477000 SUPPORT Human Clinical

"He failed to thrive and to reach any motor milestones and died at 15 months from central respiratory failure without a diagnosis."

Shows the real-world consequence of the misdiagnosis, namely death without a diagnosis.

+ 1 more reference

CDKL5 deficiency disorder MONDO:0100039

Overlapping Features The leading genetic alternative when the presenting problem is an intractable neonatal or early-infantile epilepsy in an encephalopathic infant. CDKL5 deficiency disorder was historically classified as the early-onset seizure variant of Rett syndrome and is still routinely on the same gene panel, so a boy with early refractory seizures and profound developmental impairment will often be tested for both. It is separated by gene rather than by phenotype at the bedside, which is why the practical recommendation is a panel or exome that includes MECP2 rather than a clinical distinction.

Distinguishing Features

Caused by CDKL5 rather than MECP2
Epilepsy dominates the presentation from the first weeks, whereas here seizures are one of several features of a broader congenital encephalopathy
Does not produce the central hypoventilation and irregular breathing pattern that is the hallmark respiratory lesion here
Survival beyond early childhood is usual

Show evidence (1 reference)

PMID:16832102 PARTIAL Human Clinical

"MECP2 mutations should be assessed in boys with progressive encephalopathy and one or more of respiratory insufficiency, abnormal movements or tone, and intractable seizures."

Marked PARTIAL because it supports the shared clinical presentation, intractable seizures in a progressive encephalopathy, that puts these two genes on the same panel, rather than characterising CDKL5 disease itself.

Bilateral perisylvian polymicrogyria Not Yet Curated MONDO:0020340

Overlapping Features A phenocopy relationship established by autopsy rather than by inference. An affected male with a MECP2 variant was found post-mortem to have bilateral perisylvian polymicrogyria more severe than any previously reported in Rett females, and the authors concluded he could be regarded as having a severe form of congenital perisylvian syndrome. The practical consequence is bidirectional. A bilateral perisylvian polymicrogyria syndrome should prompt MECP2 screening, and conversely a MECP2-confirmed male may carry a cortical malformation that its own genetic differential would otherwise claim.

Distinguishing Features

Usually caused by other genetic or acquired causes of cortical malformation rather than by MECP2, so MECP2 must be added to the differential rather than assumed
The MECP2-related malformation is more severe than that described in Rett females
Accompanied here by the congenital encephalopathy, central hypoventilation and early death that define this entity, rather than by isolated pseudobulbar palsy and epilepsy

Show evidence (2 references)

PMID:11930274 SUPPORT Human Clinical

"As bilateral polymicrogyria was described in congenital perisylvian syndrome, the presented patient could be regarded as having suffered from a severe form of this syndrome."

The authors' own framing of the overlap between this entity and congenital perisylvian syndrome.

PMID:11930274 SUPPORT Human Clinical

"We conclude that MECP2 screening should be considered in males with severe neonatal encephalopathy and in males and females with a bilateral polymicrogyria syndrome."

Establishes the bidirectional testing recommendation that makes this a real differential rather than a curiosity.

🔬

Clinical Trials

NCT04502199 NOT_APPLICABLE UNKNOWN

Observational study of dysautonomic signs in boys with MECP2 mutations, explicitly motivated by the fact that males with MECP2 mutations are less studied than females and have more varied phenotypes. Notable as one of the very few male-specific MECP2 studies, and directly relevant to the autonomic and cardiac conduction node.

Target Phenotypes: Bradycardia HP:0001662 Prolonged QT interval HP:0001657

Show evidence (1 reference)

clinicaltrials:NCT04502199 SUPPORT Human Clinical

"We want to search dysautonomic signs among boys with a MECP2 mutations because they are less studied than the girls and they have more varied phenotypes."

Trial record documents a male-specific MECP2 dysautonomia study and states the rationale of male under-study.

{ }

Source YAML

click to show

name: Severe Neonatal-Onset Encephalopathy With Microcephaly
creation_date: '2026-08-01T00:00:00Z'
category: Genetic
synonyms:
- severe neonatal encephalopathy due to MECP2 mutations
- severe congenital encephalopathy due to MECP2 mutation
- encephalopathy, neonatal severe, X-linked recessive
- MECP2-related severe neonatal encephalopathy in males
description: >-
  Severe neonatal-onset encephalopathy with microcephaly is the most severe end of
  the MECP2 loss-of-function spectrum and the most common phenotype in affected
  males. In a non-mosaic 46,XY male there is no second X chromosome and therefore
  no mosaic rescue by X-chromosome inactivation, so every neuron lacks functional
  MeCP2. The result is not the classic Rett course: instead of an apparently normal
  first six to eighteen months followed by regression, these infants are
  encephalopathic from birth, with generalized hypotonia, abnormal tone and
  involuntary movements, microcephaly, intractable seizures, central hypoventilation
  and irregular breathing, failure to thrive and failure to attain motor milestones,
  following a relentless course that clinically resembles a metabolic-degenerative
  disease and often ends in death before age two from central respiratory failure.
  Autopsy and biopsy studies show a small brain with disproportionate frontal and
  temporal reduction, drastically diminished dendritic trees on Golgi-stained
  cortical layer III and V pyramidal neurons, greatly reduced synaptophysin in
  cerebellum and spinal cord, and type II muscle fiber hypotrophy indicating chronic
  central hypoxia. This entity is mechanistically distinct from both classic Rett
  syndrome (heterozygous females, mosaic MeCP2 loss) and MECP2 duplication syndrome
  (increased rather than reduced MECP2 dosage); the same gene produces a
  categorically different and far more severe disease when hemizygosity removes the
  mosaic buffer.
disease_term:
  preferred_term: severe neonatal-onset encephalopathy with microcephaly
  term:
    id: MONDO:0010397
    label: severe neonatal-onset encephalopathy with microcephaly
parents:
- Neurodevelopmental Disorder
- X-linked Disorder
notes: >-
  Nosology and boundary notes. (1) MONDO, OMIM (300673) and NCIT (C132293) label the
  inheritance of this entity "X-linked recessive", which reflects the pedigree pattern
  in which a carrier mother with favorably skewed X-chromosome inactivation is
  minimally or not affected while her hemizygous son dies of congenital
  encephalopathy. That labelling describes the observed transmission pattern; it is
  not a claim that MECP2 loss of function is recessive at the allele level, since the
  same variant classes cause X-linked dominant Rett syndrome in heterozygous females.
  GeneReviews states the mode simply as X-linked, which is the term bound here.
  (2) The three MECP2-related entities in this knowledge base are deliberately kept
  separate rather than merged. Rett_Syndrome covers the heterozygous female with
  mosaic loss and a regression course; MECP2_Duplication_Syndrome covers Xq28
  copy-number gain with the opposite direction of dosage effect; and this entry covers
  the hemizygous male with uniform loss and a congenital course. Shared MeCP2
  molecular biology is duplicated in each entry with its own evidence rather than
  inherited, per project convention, and the cross-entry contrast is curated in
  differential_diagnoses. (3) Orphanet cross-reference ORPHA:209370 is recorded in
  external_assertions but is NOT cited as evidence, because the pinned Orphadata bulk
  snapshot in data/orphadata/MANIFEST.yaml no longer matches upstream (checksum
  mismatch on refresh), so no references_cache/ORPHA_209370.md record could be built
  by the sanctioned tooling for this entry. It should be added when the Orphadata pin
  is next refreshed. (4) Early death is modeled as the terminal pathophysiology node
  "Death in Infancy From Central Respiratory Failure" rather than as a phenotypes
  entry, because HP:0001522 (Death in infancy) sits in the HPO mortality branch
  outside HP:0000118 phenotypic abnormality and is therefore not bindable in
  phenotype_term. This follows the convention already used by
  Isolated_Sulfite_Oxidase_Deficiency and
  Microcephalic_Osteodysplastic_Primordial_Dwarfism_Type_I.
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0010397
      label: severe neonatal-onset encephalopathy with microcephaly
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0010397 carries "severe neonatal encephalopathy due to MECP2 mutations"
      and "severe congenital encephalopathy due to MECP2 mutation" as EXACT synonyms
      and an explicit RO:0004003 relation to HGNC:6990 MECP2, matching this entry's
      genetic section, and cross-references OMIM:300673 and Orphanet:209370.
external_assertions:
- name: MONDO:0010397 disease record and cross-references
  source: MONDO
  assertion_type: ontology_disease_record
  external_id: MONDO:0010397
  url: https://monarchinitiative.org/MONDO:0010397
  description: >-
    MONDO:0010397 anchors this entry. Its OBO record names MECP2 as the causal gene
    (RO:0004003 HGNC:6990), classifies the entity under monogenic epilepsy, neonatal
    epilepsy syndrome and Mendelian encephalopathy, and lists cross-references to
    OMIM:300673, Orphanet:209370, NCIT:C132293, DOID:0111932, MEDGEN:409616,
    MESH:C566878, GARD:0017103 and UMLS:C1968556.
  notes: >-
    Recorded as an external assertion rather than as an evidence-bearing claim because
    the ontology record itself is not a citable publication with a quotable snippet.
    The gene, OMIM identifier and synonym list were used for the
    named-entity-confusion preflight on the deep-research reports consumed by this
    entry.
definitions:
- name: GeneReviews clinical characterization of the male severe neonatal-onset phenotype
  definition_type: CASE_DEFINITION
  derivation_basis: ESTABLISHED_CRITERIA
  description: >-
    GeneReviews defines the male end of the MECP2 spectrum and identifies severe
    neonatal-onset encephalopathy as the most common phenotype in affected males,
    characterized by a relentless course resembling a metabolic-degenerative disease,
    abnormal tone, involuntary movements, severe seizures and breathing abnormalities,
    with death often before age two years. Molecular confirmation in a male proband
    requires suggestive findings plus a hemizygous MECP2 pathogenic variant.
  scope: >-
    Disease-level clinical framing and molecular diagnostic requirement for the male
    severe neonatal-onset phenotype within the MECP2 disorders chapter.
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males: Severe neonatal-onset encephalopathy, the most common phenotype in affected males, is characterized by a relentless clinical course that follows a metabolic-degenerative type of pattern, abnormal tone, involuntary movements, severe seizures, and breathing abnormalities. Death often occurs before age two years."
    explanation: >-
      The GeneReviews clinical-characteristics section states the defining clinical
      gestalt, its rank within the male MECP2 spectrum, and the typical outcome.
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of a MECP2 disorder is established by molecular genetic testing in a female proband with suggestive findings and a heterozygous MECP2 pathogenic variant, and in a male proband with suggestive findings and a hemizygous MECP2 pathogenic variant."
    explanation: >-
      Establishes the molecular diagnostic requirement, and in particular that the
      male form is defined by hemizygosity rather than heterozygosity.
- name: Salient clinical diagnostic criteria for non-mosaic 46,XY MECP2 null males
  definition_type: CASE_DEFINITION
  derivation_basis: ESTABLISHED_CRITERIA
  description: >-
    Case-series-derived recognition criteria. A non-mosaic 46,XY male with a MECP2
    null variant presents with a phenotype explicitly distinct from Rett syndrome;
    the practical trigger for MECP2 testing is a boy with progressive encephalopathy
    plus one or more of respiratory insufficiency, abnormal movements or tone, and
    intractable seizures.
  scope: >-
    Bedside recognition rule intended to prompt MECP2 testing in males, derived from
    aggregated case series rather than from a consensus guideline panel.
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Non-mosaic males with a 46,XY karyotype and a MECP2 null mutation display a phenotype of severe neonatal-onset encephalopathy that is distinctly different from Rett syndrome (RTT)."
    explanation: >-
      States the entity definition in terms of karyotype, mosaic status and variant
      class, and asserts its distinctness from Rett syndrome.
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we are reporting novel findings in a sporadic case, compare them to 16 previously reported cases and establish salient criteria for clinical diagnosis"
    explanation: >-
      Identifies the paper as the source of aggregated clinical diagnostic criteria
      across the then-known case set.
  - reference: PMID:16832102
    reference_title: Early progressive encephalopathy in boys and MECP2 mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MECP2 mutations should be assessed in boys with progressive encephalopathy and one or more of respiratory insufficiency, abnormal movements or tone, and intractable seizures."
    explanation: >-
      Provides the operational testing trigger, which is the practical form the case
      definition takes in clinical use.
inheritance:
- name: X-linked inheritance
  inheritance_term:
    preferred_term: X-linked inheritance
    term:
      id: HP:0001417
      label: X-linked inheritance
  description: >-
    MECP2 lies at Xq28 and MECP2 disorders are inherited in an X-linked manner. More
    than 99% of MECP2 disorders overall are simplex, arising de novo or from parental
    germline mosaicism; in the specific setting of an affected male, a pathogenic
    variant may also be inherited from a heterozygous mother whose favorably skewed
    X-chromosome inactivation leaves her with minimal to no clinical findings, which
    is why an apparently unaffected mother is not evidence against pathogenicity.
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MECP2 disorders are inherited in an X-linked manner."
    explanation: >-
      GeneReviews states the mode of inheritance directly, without committing to a
      dominant or recessive qualifier.
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Rarely, a MECP2 variant may be inherited from a heterozygous mother in whom favorable skewing of X-chromosome inactivation results in minimal to no clinical findings."
    explanation: >-
      Documents the transmitting-carrier scenario that makes the pedigree look
      recessive and that underlies the OMIM and MONDO X-linked recessive label.
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "More than 99% are simplex cases (i.e., a single occurrence in a family), resulting from a de novo pathogenic variant or possibly from inheritance of the pathogenic variant from a parent who has germline mosaicism."
    explanation: >-
      Quantifies the predominance of simplex occurrence across MECP2 disorders.
  - reference: PMID:11738861
    reference_title: Rethinking the fate of males with mutations in the gene that causes Rett syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Rett syndrome (RTT) is usually described as an X-linked dominant disorder that is lethal prenatally to males."
    explanation: >-
      States the historical inheritance framing that this entity refutes, which is why
      the neutral X-linked term is bound rather than a dominant or recessive qualifier.
  - reference: PMID:10577905
    reference_title: "Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An 806delG deletion causing a V288X stop in the transcription-repression domain was identified in a woman with motor-coordination problems, mild learning disability, and skewed X inactivation; in her sister and daughter, who were affected with classic RTT; and in her hemizygous son, who died from congenital encephalopathy."
    explanation: >-
      The classic pedigree that establishes the pattern. One MECP2 allele produces a
      minimally affected skewed-XCI carrier mother, classic Rett in heterozygous
      relatives, and lethal congenital encephalopathy in the hemizygous male.
prevalence:
- population: Published male cases hemizygous for a pathogenic MECP2 variant
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    A 2021 systematic review of the entire published literature (1999-2020) on males
    hemizygous for a pathogenic MECP2 variant identified only 27 published patients
    with severe neonatal encephalopathy, alongside larger numbers with the milder male
    MECP2 phenotypes. No population prevalence or incidence estimate specific to this
    entity exists; the Rett syndrome figure of roughly 1 in 10,000 females must not be
    transferred to it.
  evidence:
  - reference: PMID:34271245
    reference_title: "MECP2-related conditions in males: A systematic literature review and 8 additional cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We were able to collect information on 27 published patients with severe neonatal encephalopathy, 47 individuals with isolated or familial mental retardation X-linked 13 (XLMR13), as well as 24 individuals with isolated or familial Pyramidal signs, parkinsonism, and macroorchidism (PPM-X)."
    explanation: >-
      Gives the literature case count for this specific phenotype and situates it as
      the smallest of the three male MECP2 phenotypes in the published record.
  - reference: PMID:34271245
    reference_title: "MECP2-related conditions in males: A systematic literature review and 8 additional cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The literature search yielded a total of 3,185 publications, of which 58 were included in our systematic review."
    explanation: >-
      Establishes that the 27-patient count is the yield of a systematic search rather
      than a convenience sample.
- population: Males with pathogenic MECP2 variants in US natural history study and parent group
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Contemporary ascertainment of the whole male MECP2 spectrum (not only the severe
    neonatal-onset phenotype) reached 85 males, of whom 27 were deceased. Historical
    counts systematically underestimate occurrence for two documented reasons: the
    entity was presumed lethal in males and therefore not sought, and its congenital
    encephalopathy is clinically non-specific, so sporadic cases went unascertained.
  evidence:
  - reference: PMID:39476560
    reference_title: "MECP2 Variants in Males: More Common than Previously Appreciated."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Together with males reported previously from the US Natural History Study, the total group represents 85 males, of whom 27 are deceased."
    explanation: >-
      Provides the current aggregate ascertainment for males with MECP2 variants and
      the deceased fraction.
  - reference: PMID:40515634
    reference_title: Medical Biases and Misconceptions Impact Diagnoses in Males With Loss of Function MECP2 Variants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These variants were historically believed to be incompatible with life in males; however, recent advances in genetic testing have revealed significant clinical heterogeneity."
    explanation: >-
      Explains why historical case counts underestimate occurrence, since the entity
      was presumed lethal and therefore not sought.
  - reference: PMID:11738861
    reference_title: Rethinking the fate of males with mutations in the gene that causes Rett syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is likely that sporadic cases are not ascertained because of the relative non-specific congenital onset encephalopathy."
    explanation: >-
      Identifies clinical non-specificity as the second, independent reason
      ascertainment has historically been incomplete.
progression:
- phase: Onset
  age_range: Neonatal period
  notes: >-
    Impairment is present from birth rather than after an apparently normal interval.
    There is no Rett-like period of normal early development to regress from.
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Non-mosaic males with a 46,XY karyotype and a MECP2 null mutation display a phenotype of severe neonatal-onset encephalopathy that is distinctly different from Rett syndrome (RTT)."
    explanation: >-
      Fixes onset in the neonatal period and contrasts it with the Rett course.
- phase: Relentless progressive course
  age_range: Infancy
  notes: >-
    The clinical course is relentless and clinically resembles a metabolic-degenerative
    disease, with accruing tone abnormality, involuntary movements, severe seizures and
    breathing abnormality, and failure to attain motor milestones.
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males: Severe neonatal-onset encephalopathy, the most common phenotype in affected males, is characterized by a relentless clinical course that follows a metabolic-degenerative type of pattern, abnormal tone, involuntary movements, severe seizures, and breathing abnormalities. Death often occurs before age two years."
    explanation: >-
      Describes the progressive character of the course between onset and death.
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He failed to thrive and to reach any motor milestones and died at 15 months from central respiratory failure without a diagnosis."
    explanation: >-
      Documents complete failure of motor milestone attainment during the progressive
      phase, in contrast to the acquire-then-lose pattern of Rett syndrome.
- phase: Death
  age_range: Usually before 2 years
  notes: >-
    Death often occurs before age two years, typically from central respiratory
    failure. Reported ages at death in individual cases include 13 months, 15 months,
    17 months, 1 year 8 months, 30 months and 3 years 1 month, so a minority survive
    into the third year.
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Death often occurs before age two years."
    explanation: >-
      States the typical outcome window. Marked PARTIAL because no survival curve or
      median survival specific to this entity has been published.
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "They died at the ages of 1 year and 8 months, and 3 years and 1 month."
    explanation: >-
      Gives ages at death for an affected brother pair, documenting the upper end of
      the survival range.
  - reference: PMID:11930274
    reference_title: "MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He presented with severe neonatal encephalopathy and died at the age of 13 months."
    explanation: >-
      Independent primary human case documenting the lower end of the reported age-at-death
      range, replacing a weaker literature-summary sentence from a mouse paper.
mechanistic_hypotheses:
- hypothesis_group_id: hemizygous_uniform_mecp2_deficiency_model
  hypothesis_label: Hemizygous Uniform MeCP2 Deficiency Model (loss of mosaic rescue)
  status: CANONICAL
  description: >-
    The canonical model holds that the severity difference between this entity and
    classic Rett syndrome is not a difference in the MECP2 lesion but a difference in
    cellular mosaicism. In a heterozygous female, random X-chromosome inactivation
    leaves roughly half of neurons expressing a wild-type MECP2 allele, and that
    wild-type population both supports and partly buffers the mutant population; the
    resulting phenotype permits normal development for six to eighteen months before
    regression. A non-mosaic 46,XY male has no second X, so every neuron and every
    glial cell is MeCP2-deficient from the outset. Uniform deficiency removes the
    reading of methylated DNA and the chromatin and co-repressor recruitment that
    MeCP2 provides, dysregulating activity-dependent neuronal gene expression;
    dendritic arborization and synaptogenesis fail cell-autonomously in neurons and
    are additionally impaired non-cell-autonomously by MeCP2-null astrocytes secreting
    inadequate soluble support; the resulting circuit failure is congenital rather than
    post-developmental and presents as neonatal encephalopathy with brainstem
    respiratory and autonomic instability and intractable epilepsy. The corollary,
    argued explicitly in the neuropathology literature, is that the hemizygous null
    male, and not the heterozygous Rett female, is the true human counterpart of the
    widely used Mecp2-null male mouse.
  notes: >-
    The mosaic-rescue arm of this model is supported by convergent human genetics rather
    than by a direct experiment in humans. Males who instead present with a recognizable
    Rett phenotype are almost always somatic mosaics or have 47,XXY Klinefelter
    syndrome, meaning they have recovered a wild-type-expressing cell population. Within
    the non-mosaic male group, residual severity gradation tracks the degree of
    biochemical impairment of MeCP2 (methyl-CpG-binding-domain DNA binding and
    chromocenter clustering), which is measurable in males precisely because
    X-inactivation does not confound genotype-phenotype comparison. Two elements of the
    chain are extrapolated from Rett syndrome and Mecp2-null systems rather than
    measured in this entity, namely the activity-dependent transcriptional dysregulation
    step and the astrocytic non-cell-autonomous contribution.
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males with congenital encephalopathy, not females with RTT, represent the true human counterpart for the commonly studied Mecp2-/y mouse model and provide unique insight into the mechanisms of MeCP2 deficiency."
    explanation: >-
      States the model's central translational corollary and its rationale.
  - reference: PMID:27929079
    reference_title: "From Function to Phenotype: Impaired DNA Binding and Clustering Correlates with Clinical Severity in Males with Missense Mutations in MECP2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In heterozygous females the variable phenotypic severity is modulated by non-random X-inactivation, thus making genotype-phenotype comparisons unreliable."
    explanation: >-
      Establishes the mosaicism confound in females that the hemizygous male state
      removes, which is the logical basis of the model.
  - reference: PMID:34271245
    reference_title: "MECP2-related conditions in males: A systematic literature review and 8 additional cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The typical RS phenotype is not expected in males, except in those with Klinefelter syndrome or somatic mosaicism for MECP2."
    explanation: >-
      The key convergent human-genetic prediction of the model, namely that restoring a
      wild-type-expressing cell population in a male shifts the phenotype toward Rett.
  - reference: PMID:11738861
    reference_title: Rethinking the fate of males with mutations in the gene that causes Rett syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males who have MECP2 mutations and Klinefelter syndrome or who are mosaic for the mutation are more likely to present with a RTT-like phenotype."
    explanation: >-
      Independent statement of the same mosaic-rescue prediction, made two decades
      earlier and from a different case set.
pathophysiology:
- name: Hemizygous MECP2 Loss-of-Function Variant
  biological_scale: MOLECULAR
  description: >-
    A pathogenic MECP2 variant on the single X chromosome of a 46,XY male. Reported
    variant classes include nonsense and frameshift changes truncating the
    transcription-repression domain, splice-disrupting deletions, small insertions
    causing frameshift, and methyl-CpG-binding-domain missense substitutions such as
    T158M. Variants may be de novo, which is the majority situation, or inherited from
    a heterozygous mother with favorably skewed X-chromosome inactivation.
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  biological_processes:
  - preferred_term: epigenetic regulation of gene expression
    term:
      id: GO:0040029
      label: epigenetic regulation of gene expression
    modifier: DYSREGULATED
  downstream:
  - target: Absence of Mosaic Rescue by X-Chromosome Inactivation
    description: >-
      A single X chromosome means the variant is present in every cell with no
      wild-type allele available for mosaic compensation.
  - target: Impaired MeCP2 Methyl-CpG Binding and Chromocenter Clustering
    description: >-
      Variants at or near the methyl-CpG-binding domain degrade MeCP2 DNA binding and
      chromatin clustering to a degree that scales with clinical severity.
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Post-mortem MECP2 mutation analysis on DNA and RNA from fibroblasts revealed a novel de novo 9-nucleotide deletion including the intron 3/exon 4 splice junction."
    explanation: >-
      Documents a splice-disrupting de novo null variant as the causal lesion in an
      autopsy-confirmed case.
  - reference: PMID:37537631
    reference_title: "An insertion mutation of the MECP2 gene in severe neonatal encephalopathy and ocular and oropharyngeal dyskinesia: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here we report a rare case in a 10-month-old boy with a hemizygous insertion mutation in MECP2 as NM_001110792, c.799_c.800insAGGAAGC, which results in a frameshift mutation"
    explanation: >-
      Documents a hemizygous frameshift insertion in an affected male, establishing
      hemizygosity of the causal allele.
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report on three patients with MeCP2 mutation and male Rett phenotypes."
    explanation: >-
      Identifies the T158M and R294X case series that contributes the recurrent
      missense and nonsense variant classes seen in affected males.
  - reference: PMID:34502518
    reference_title: MECP2-Related Disorders in Males.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Methyl CpG binding protein 2 (MECP2) is located at Xq28 and is a multifunctional gene with ubiquitous expression."
    explanation: >-
      Establishes the X-chromosomal location that makes males hemizygous for this gene.
- name: Absence of Mosaic Rescue by X-Chromosome Inactivation
  biological_scale: CELLULAR
  description: >-
    The mechanistic pivot of this entity. A heterozygous female inactivates one X per
    cell, so roughly half of her neurons express wild-type MeCP2 and buffer the mutant
    population, and her phenotype accordingly permits an initial period of normal
    development. A non-mosaic hemizygous male has no such population. The clinical
    proof of this node is inverted rather than direct. Males who do have a
    wild-type-expressing cell population, because of post-zygotic somatic mosaicism or
    a supernumerary X in 47,XXY Klinefelter syndrome, present instead with a
    recognizable Rett phenotype and survive.
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: dosage compensation by inactivation of X chromosome
    term:
      id: GO:0009048
      label: dosage compensation by inactivation of X chromosome
    modifier: ABSENT
  downstream:
  - target: Uniform Neuronal and Glial MeCP2 Deficiency
    description: >-
      With no wild-type allele in any cell, MeCP2 deficiency is complete and uniform
      across the nervous system rather than mosaic.
  evidence:
  - reference: PMID:34271245
    reference_title: "MECP2-related conditions in males: A systematic literature review and 8 additional cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The typical RS phenotype is not expected in males, except in those with Klinefelter syndrome or somatic mosaicism for MECP2."
    explanation: >-
      The inverted proof, in which recovering a wild-type-expressing cell population in
      a male converts the phenotype from neonatal encephalopathy toward Rett syndrome.
  - reference: PMID:11738861
    reference_title: Rethinking the fate of males with mutations in the gene that causes Rett syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males who have MECP2 mutations and Klinefelter syndrome or who are mosaic for the mutation are more likely to present with a RTT-like phenotype."
    explanation: >-
      Independent confirmation that restoring a wild-type-expressing cell population
      shifts the male phenotype toward Rett syndrome.
  - reference: PMID:39476560
    reference_title: "MECP2 Variants in Males: More Common than Previously Appreciated."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eleven (18.6%) were mosaic, 10 with somatic mosaicism and one with Klinefelter syndrome (47XXY)."
    explanation: >-
      Quantifies how often surviving ascertained males owe their phenotype to a
      mosaic or 47,XXY rescue mechanism.
  - reference: PMID:27929079
    reference_title: "From Function to Phenotype: Impaired DNA Binding and Clustering Correlates with Clinical Severity in Males with Missense Mutations in MECP2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In heterozygous females the variable phenotypic severity is modulated by non-random X-inactivation, thus making genotype-phenotype comparisons unreliable."
    explanation: >-
      Establishes that X-inactivation is the modulator of severity in females and is
      absent as a variable in hemizygous males.
  - reference: PMID:30405208
    reference_title: Genomic mosaicism in the pathogenesis and inheritance of a Rett syndrome cohort.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Somatic MECP2 mosaicism was confirmed in 5/471 (1.1%) patients, including 3/18 males (16.7%) and 2/453 females (0.4%)."
    explanation: >-
      Systematic cohort screening showing somatic mosaicism is roughly forty-fold more
      frequent among ascertained male than female patients, which is what this node
      predicts: a surviving, clinically ascertained male is disproportionately likely to
      be one who recovered a wild-type-expressing cell population.
  - reference: PMID:30405208
    reference_title: Genomic mosaicism in the pathogenesis and inheritance of a Rett syndrome cohort.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our findings indicate that somatic MECP2 mosaicism contributes directly to the pathogenicity of Rett syndrome, especially in male patients."
    explanation: >-
      The authors' own conclusion that mosaic status is a male-specific determinant of
      phenotype, which is the claim this node makes.
- name: Impaired MeCP2 Methyl-CpG Binding and Chromocenter Clustering
  biological_scale: MOLECULAR
  description: >-
    MeCP2 binds chromocentric DNA through its methyl-CpG-binding domain. Variants at
    the MBD-DNA interface impair the MeCP2-DNA interaction, while more distal MBD
    variants impair chromatin clustering, and binding and mobility dynamics degrade in
    a graded fashion depending on amino-acid properties and MBD tertiary structure. In
    hemizygous males, where X-inactivation does not confound the comparison, the degree
    of functional impairment correlates directly with clinical severity across a range
    that runs from neonatal encephalopathy at the severe extreme to mild psychiatric
    abnormalities at the mild extreme. This node therefore explains the residual
    severity gradient within the male spectrum, given the shared absence of mosaic
    rescue.
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  molecular_functions:
  - preferred_term: methyl-CpG binding
    term:
      id: GO:0008327
      label: methyl-CpG binding
    modifier: DECREASED
  biological_processes:
  - preferred_term: chromatin organization
    term:
      id: GO:0006325
      label: chromatin organization
    modifier: DYSREGULATED
  downstream:
  - target: Uniform Neuronal and Glial MeCP2 Deficiency
    description: >-
      Loss of methylated-DNA reading and chromatin clustering is the biochemical
      content of functional MeCP2 deficiency.
  - target: Preferential De-Repression of Long Neuronal Genes
    description: >-
      Loss of methyl-CpG reading removes repression preferentially from long genes,
      which is the characteristic transcriptional signature of MeCP2 loss.
  - target: Variant-Dependent Severity Within the Male MECP2 Spectrum
    description: >-
      The graded biochemical impairment maps onto the graded clinical severity seen
      across hemizygous males.
  evidence:
  - reference: PMID:27929079
    reference_title: "From Function to Phenotype: Impaired DNA Binding and Clustering Correlates with Clinical Severity in Males with Missense Mutations in MECP2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "MeCP2 binds to chromocentric DNA through its methyl CpG-binding domain (MBD) to regulate gene expression."
    explanation: >-
      Establishes the normal molecular function that the variants degrade.
  - reference: PMID:27929079
    reference_title: "From Function to Phenotype: Impaired DNA Binding and Clustering Correlates with Clinical Severity in Males with Missense Mutations in MECP2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We observed impaired interaction of MeCP2-DNA for mutations around the MBD-DNA binding interface, and defective chromatin clustering for distal MBD mutations."
    explanation: >-
      Provides the two distinct biochemical failure modes measured for MBD variants.
  - reference: PMID:10508514
    reference_title: "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MeCP2 selectively binds CpG dinucleotides in the mammalian genome and mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A"
    explanation: >-
      Establishes the co-repressor recruitment arm of MeCP2 function that binding loss
      removes.
- name: Variant-Dependent Severity Within the Male MECP2 Spectrum
  biological_scale: ORGANISM
  description: >-
    Given hemizygosity, the residual determinant of which male MECP2 phenotype results
    is the functional severity of the variant. Three phenotypes are seen in males with
    a single copy of MECP2 carrying a pathogenic variant, namely severe neonatal
    encephalopathy at the severe end, X-linked intellectual deficiency 13 in the
    middle, and pyramidal signs with parkinsonism and macroorchidism (PPM-X) at the
    mild end. Clinical severity across this range correlates directly with the measured
    functional impairment of MeCP2. Within the severe end, specific recurrent alleles
    may define recognizable sub-entities: two brothers with T158M followed a near
    identical lethal course, and the reporting authors proposed that T158M males might
    constitute a clinical-genetic entity within the male congenital encephalopathies,
    whereas an R294X boy had a more protracted course with survival past four years.
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  downstream:
  - target: Uniform Neuronal and Glial MeCP2 Deficiency
    description: >-
      The most functionally damaging (null-equivalent) variants produce the deepest
      MeCP2 deficiency and the neonatal-onset phenotype curated in this entry.
  evidence:
  - reference: PMID:34271245
    reference_title: "MECP2-related conditions in males: A systematic literature review and 8 additional cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three MECP2-associated phenotypes were seen in male carriers of a single copy of the gene: severe neonatal encephalopathy (n = 5); X-linked intellectual deficiency 13 (n = 2); and pyramidal signs, parkinsonism, and macroorchidism (PPM-X) (n = 1)."
    explanation: >-
      Enumerates the three male phenotypes and places this entity at the severe end.
  - reference: PMID:27929079
    reference_title: "From Function to Phenotype: Impaired DNA Binding and Clustering Correlates with Clinical Severity in Males with Missense Mutations in MECP2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Interestingly, a wide range of phenotypic/clinical severity, ranging from neonatal encephalopathy to mild psychiatric abnormalities were observed and all are consistent with our functional/molecular results."
    explanation: >-
      Maps the observed male severity range directly onto the biochemical assay result,
      with neonatal encephalopathy at the severe extreme.
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The phenotypes show a strong resemblance, and might in fact represent a clinical-genetic entity of the T158M mutation within the complex of congenital encephalopathies in males with MeCP2 mutations."
    explanation: >-
      Proposes allele-specific sub-entities within the severe male phenotype, the
      finest grain of the variant-dependent severity claim.
  - reference: PMID:34502518
    reference_title: MECP2-Related Disorders in Males.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In boys, however, mutations in MECP2 can generate a wide spectrum of clinical presentations that range from mild intellectual impairment to severe neonatal encephalopathy and premature death."
    explanation: >-
      Independent statement of the male severity spectrum and its severe endpoint.
- name: Uniform Neuronal and Glial MeCP2 Deficiency
  biological_scale: CELLULAR
  description: >-
    Every neuron and every glial cell lacks functional MeCP2. Note the two different
    kinds of warrant behind that statement. The HUMAN claim is genetic rather than
    histological: MECP2 is X-linked, so a non-mosaic 46,XY male carries the variant in
    every cell with no wild-type allele anywhere, and uniform deficiency follows by
    deduction from hemizygosity. No human study has demonstrated MeCP2 protein loss in
    glia specifically; that demonstration comes from the Rett MOUSE model, in which MeCP2
    is absent from astrocytes as well as neurons. The consequence asserted here, that the
    deficiency affects both compartments simultaneously and so removes the possibility of
    MeCP2-competent astrocytes supporting MeCP2-deficient neurons, is therefore a
    human-genetic inference supported by a model-organism observation, and is flagged as
    such rather than presented as human autopsy data.
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  biological_processes:
  - preferred_term: epigenetic regulation of gene expression
    term:
      id: GO:0040029
      label: epigenetic regulation of gene expression
    modifier: DYSREGULATED
  downstream:
  - target: Dysregulated Activity-Dependent Neuronal Gene Expression
    description: >-
      Loss of MeCP2 in all neurons removes its context-dependent transcriptional
      regulation of neuronal gene programs.
  - target: Non-Cell-Autonomous Astrocytic Failure to Support Dendritic Morphology
    description: >-
      MeCP2-deficient astrocytes fail to provide the soluble support neurons require
      for normal dendritic morphology.
  evidence:
  - reference: PMID:34502518
    reference_title: MECP2-Related Disorders in Males.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Methyl CpG binding protein 2 (MECP2) is located at Xq28 and is a multifunctional gene with ubiquitous expression."
    explanation: >-
      The human anchor for this node. X-linkage plus ubiquitous expression is what makes
      a hemizygous male uniformly deficient in every expressing cell type, neuronal and
      glial alike; the claim is genetic rather than immunohistochemical.
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Non-mosaic males with a 46,XY karyotype and a MECP2 null mutation display a phenotype of severe neonatal-onset encephalopathy that is distinctly different from Rett syndrome (RTT)."
    explanation: >-
      Establishes the non-mosaic 46,XY human state that makes the deficiency uniform,
      completing the human-genetic warrant without invoking glial histology.
  - reference: PMID:19234456
    reference_title: Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We found that the loss of MeCP2 occurs not only in neurons but also in glial cells of RTT brains."
    explanation: >-
      The glial arm of the node. Tagged MODEL_ORGANISM, not HUMAN_CLINICAL: the "RTT
      brains" here are mouse brains, the paper carries no Humans MeSH term, and the
      corresponding full-text passage refers to astrocytes of RTT mouse brains. This is
      the model-organism demonstration that MeCP2 loss extends to glia, extrapolated to
      the human hemizygous state via the genetic argument above.
  - reference: PMID:11242118
    reference_title: Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Brain-specific deletion of Mecp2 at embryonic day (E) 12 resulted in a phenotype identical to that of the null mutation, indicating that the phenotype is caused by Mecp2 deficiency in the CNS rather than in peripheral tissues."
    explanation: >-
      Localizes the pathogenic consequence of complete Mecp2 deficiency to the CNS.
- name: Preferential De-Repression of Long Neuronal Genes
  biological_scale: MOLECULAR
  description: >-
    The best-characterized transcriptional signature of MeCP2 loss, and the step that
    explains why neuronal connectivity programs specifically are hit rather than gene
    expression being perturbed at random. Profiling discrete neuronal subtypes rather
    than brain homogenates (which had shown only subtle changes because of a dilution
    problem) reveals that the genes up-regulated on loss of MeCP2 are biased toward
    longer genes, while down-regulated genes show no such bias, implying that MeCP2
    selectively represses long genes. Because cell-adhesion and cell-cell-signalling
    genes governing neuronal connectivity and communication are themselves enriched among
    long genes, their de-repression is the proposed route from a generic chromatin defect
    to specifically miswired circuits. In a hemizygous male this de-repression is
    unbuffered, since no neuron retains a wild-type allele. Evidence is model-organism
    (Mecp2 knock-out mouse neuronal subtypes); no equivalent cell-type-resolved
    transcriptomic dataset exists for an affected human male.
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: negative regulation of transcription by RNA polymerase II
    term:
      id: GO:0000122
      label: negative regulation of transcription by RNA polymerase II
    modifier: DECREASED
  - preferred_term: regulation of gene expression
    term:
      id: GO:0010468
      label: regulation of gene expression
    modifier: DYSREGULATED
  downstream:
  - target: Dysregulated Activity-Dependent Neuronal Gene Expression
    description: >-
      Long-gene de-repression is a principal component of the broader activity-dependent
      transcriptional dysregulation that follows MeCP2 loss.
  - target: Failure of Dendritic Arborization and Synaptogenesis
    description: >-
      De-repression of long cell-adhesion and cell-cell-signalling genes governing
      neuronal connectivity provides a direct route to failed dendritic and synaptic
      development.
  evidence:
  - reference: PMID:25232122
    reference_title: Cell-type-specific repression by methyl-CpG-binding protein 2 is biased toward long genes.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Importantly, genes upregulated following loss of MeCP2 are biased toward longer genes but this is not true for downregulated genes, suggesting MeCP2 may selectively repress long genes."
    explanation: >-
      The primary claim of the node, including the asymmetry (up-regulated but not
      down-regulated genes) that makes selective repression of long genes the
      parsimonious interpretation.
  - reference: PMID:25232122
    reference_title: Cell-type-specific repression by methyl-CpG-binding protein 2 is biased toward long genes.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The results reveal misregulation of genes involved in neuronal connectivity and communication."
    explanation: >-
      Identifies the functional class of genes affected, which is what links this
      molecular node to the downstream connectivity failure.
  - reference: PMID:25232122
    reference_title: Cell-type-specific repression by methyl-CpG-binding protein 2 is biased toward long genes.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Because genes involved in neuronal connectivity and communication, such as cell adhesion and cell-cell signaling genes, are enriched among longer genes, their misregulation following loss of MeCP2 suggests a possible etiology for altered circuit function in Rett syndrome."
    explanation: >-
      States the causal bridge from long-gene bias to altered circuit function, which is
      the reason this node sits upstream of the dendritic and synaptic failure node.
- name: Dysregulated Activity-Dependent Neuronal Gene Expression
  biological_scale: MOLECULAR
  description: >-
    MeCP2 regulates the expression of a wide range of neuronal genes and can act as
    both a repressor and an activator. Its complete absence changes the expression
    levels of thousands of genes, disrupting the activity-dependent transcriptional
    programs that drive neuronal maturation.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: regulation of gene expression
    term:
      id: GO:0010468
      label: regulation of gene expression
    modifier: DYSREGULATED
  downstream:
  - target: Failure of Dendritic Arborization and Synaptogenesis
    description: >-
      Loss of the transcriptional programs for neuronal maturation prevents normal
      dendritic and synaptic development.
  evidence:
  - reference: PMID:18511691
    reference_title: "MeCP2, a key contributor to neurological disease, activates and represses transcription."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "MeCP2 dysfunction induced changes in the expression levels of thousands of genes"
    explanation: >-
      Establishes the breadth of transcriptional dysregulation downstream of MeCP2
      dysfunction.
  - reference: PMID:18511691
    reference_title: "MeCP2, a key contributor to neurological disease, activates and represses transcription."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These studies suggest that MeCP2 regulates the expression of a wide range of genes in the hypothalamus and that it can function as both an activator and a repressor of transcription."
    explanation: >-
      Establishes the bidirectional (activator and repressor) character of MeCP2
      transcriptional regulation that is lost.
- name: Non-Cell-Autonomous Astrocytic Failure to Support Dendritic Morphology
  biological_scale: CELLULAR
  description: >-
    MeCP2-null astrocytes, and their conditioned medium alone, fail to support normal
    dendritic morphology in either wild-type or mutant hippocampal neurons, implicating
    aberrant secretion of soluble factors. In a hemizygous male, where astrocytes are
    also uniformly MeCP2-deficient, this non-cell-autonomous insult is unmitigated and
    compounds the cell-autonomous neuronal defect.
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  - preferred_term: hippocampal neuron
    term:
      id: CL:0002608
      label: hippocampal neuron
  biological_processes:
  - preferred_term: dendrite morphogenesis
    term:
      id: GO:0048813
      label: dendrite morphogenesis
    modifier: DECREASED
  downstream:
  - target: Failure of Dendritic Arborization and Synaptogenesis
    description: >-
      Loss of astrocytic soluble support converges with the neuronal transcriptional
      defect on failed dendritic development.
  evidence:
  - reference: PMID:19234456
    reference_title: Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Using an in vitro co-culture system, we found that mutant astrocytes from a RTT mouse model, and their conditioned medium, failed to support normal dendritic morphology of either wild-type or mutant hippocampal neurons."
    explanation: >-
      Directly demonstrates the non-cell-autonomous astrocytic contribution to the
      dendritic phenotype, and shows a soluble factor suffices.
  - reference: PMID:19234456
    reference_title: Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Our studies suggest that astrocytes in the RTT brain carrying MeCP2 mutations have a non-cell autonomous effect on neuronal properties, probably as a result of aberrant secretion of soluble factor(s)."
    explanation: >-
      Names the proposed mechanism, aberrant secretion of soluble factors.
- name: Failure of Dendritic Arborization and Synaptogenesis
  biological_scale: CELLULAR
  description: >-
    The pivotal cellular lesion, documented directly in human autopsy material from an
    affected male rather than inferred. Golgi staining of pyramidal neurons from
    cortical layers III and V of the frontal and temporal lobes shows drastically
    diminished dendritic trees, and synaptophysin staining of synaptic vesicles is
    greatly reduced in cerebellar and spinal cord sections, indicating that the failure
    is not confined to cortex. The hemizygous mutant male mouse supplies the
    quantitative counterpart and shows the deficit is compartment-specific, with spine
    density reduced by 47.4% in the apical tuft and 54.5% in secondary apical dendrites
    of layer 5 motor cortical neurons while primary apical and proximal basal dendrites
    are spared.
  cell_types:
  - preferred_term: pyramidal neuron
    term:
      id: CL:0000598
      label: pyramidal neuron
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  - preferred_term: spinal cord
    term:
      id: UBERON:0002240
      label: spinal cord
  biological_processes:
  - preferred_term: dendrite morphogenesis
    term:
      id: GO:0048813
      label: dendrite morphogenesis
    modifier: DECREASED
  - preferred_term: synapse organization
    term:
      id: GO:0050808
      label: synapse organization
    modifier: DECREASED
  downstream:
  - target: Reduced Brain Growth With Frontotemporal Predominance
    description: >-
      Failed dendritic and synaptic elaboration reduces neuropil volume and therefore
      brain growth.
  - target: Cortical Malformation With Perisylvian Polymicrogyria
    description: >-
      In at least some affected males the developmental disturbance extends to overt
      cortical malformation.
  - target: Brainstem Respiratory Network Failure
    description: >-
      Loss of synaptic organization in brainstem and spinal respiratory circuitry
      destabilizes ventilatory control.
  - target: Cortical Network Hyperexcitability
    description: >-
      Failed synaptic and dendritic maturation yields an epileptogenic network.
  - target: Impaired Motor Control Circuitry
    description: >-
      Failed maturation of motor circuits prevents normal tone and voluntary movement.
  - target: Cardiac Autonomic Conduction Instability
    description: >-
      Failure of autonomic circuit maturation destabilizes cardiac rate and conduction.
  - target: Sleep Disturbance
    description: >-
      Failed maturation of sleep-regulating circuitry produces sleep disturbance.
  - target: Bruxism
    description: >-
      Network dysfunction contributes to stereotyped oromotor manifestations including
      bruxism.
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Analysis of Golgi-stained pyramidal neurons from cortical layers III and V of the frontal and temporal lobes revealed drastically diminished dendritic trees."
    explanation: >-
      Direct human neuropathological demonstration of the dendritic failure in an
      affected male.
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Synaptophysin staining of synaptic vesicles was greatly reduced in cerebellar and spinal cord sections."
    explanation: >-
      Direct human demonstration of reduced synaptic vesicle content beyond cortex,
      including spinal cord.
  - reference: PMID:22412847
    reference_title: "MeCP2 mutation results in compartment-specific reductions in dendritic branching and spine density in layer 5 motor cortical neurons of YFP-H mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Spine density was reduced by 47.4% in the apical tuft and 54.5% in secondary apical dendrites, but remained unaffected in primary apical and proximal basal dendrites."
    explanation: >-
      Quantifies the spine deficit in hemizygous mutant male mice, the genotype that
      matches this entity, and shows it is compartment-specific rather than global.
  - reference: PMID:22412847
    reference_title: "MeCP2 mutation results in compartment-specific reductions in dendritic branching and spine density in layer 5 motor cortical neurons of YFP-H mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Total basal dendritic length was decreased by 18.6% due to both shorter dendrites and reduced branching proximal to the soma."
    explanation: >-
      Quantifies the dendritic-branching arm of the same lesion in the hemizygous male
      model.
  - reference: PMID:19234456
    reference_title: Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "mutant astrocytes from a RTT mouse model, and their conditioned medium, failed to support normal dendritic morphology"
    explanation: >-
      Provides the experimental counterpart of the human dendritic finding.
- name: Reduced Brain Growth With Frontotemporal Predominance
  biological_scale: TISSUE
  description: >-
    At autopsy the brain of an affected male is small with disproportionate reduction of
    the frontal and temporal lobes, matching the regions where the dendritic deficit was
    measured. In the Mecp2-null mouse, brain weight and neuronal cell size are
    substantially reduced without obvious structural defects or signs of
    neurodegeneration, indicating that reduced brain volume reflects failed neuronal
    growth rather than loss of previously formed neurons.
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: frontal cortex
    term:
      id: UBERON:0001870
      label: frontal cortex
  - preferred_term: temporal lobe
    term:
      id: UBERON:0001871
      label: temporal lobe
  biological_processes:
  - preferred_term: brain development
    term:
      id: GO:0007420
      label: brain development
    modifier: DECREASED
  downstream:
  - target: Microcephaly
    description: >-
      A small brain with reduced neuropil produces a small head circumference.
  - target: Severe Global Developmental Delay
    description: >-
      Global failure of brain growth underlies global failure of developmental
      attainment.
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At autopsy, the brain was small with disproportionate reduction of the frontal and temporal lobes."
    explanation: >-
      Direct human autopsy documentation of reduced brain size with regional
      predominance.
  - reference: PMID:11242118
    reference_title: Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Mutant brains showed substantial reduction in both weight and neuronal cell size, but no obvious structural defects or signs of neurodegeneration."
    explanation: >-
      Establishes in the corresponding null model that reduced brain size reflects
      failed neuronal growth rather than neurodegeneration.
- name: Cortical Malformation With Perisylvian Polymicrogyria
  biological_scale: TISSUE
  description: >-
    In at least one autopsied affected male the developmental disturbance produced overt
    cortical malformation, namely bilateral polymicrogyria in the perisylvian region,
    visibly more severe than previously described in females with Rett syndrome or in
    another male with a MECP2 mutation. This places part of the pathogenesis prenatally,
    during cortical development, and motivated the recommendation that MECP2 be screened
    in bilateral perisylvian polymicrogyria syndromes.
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  biological_processes:
  - preferred_term: cerebral cortex development
    term:
      id: GO:0021987
      label: cerebral cortex development
    modifier: ABNORMAL
  downstream:
  - target: Polymicrogyria
    description: >-
      The malformation is directly observable as bilateral perisylvian polymicrogyria.
  - target: Cortical Network Hyperexcitability
    description: >-
      Polymicrogyric cortex is intrinsically epileptogenic.
  - target: Oropharyngeal Dyskinesia and Feeding Difficulties
    description: >-
      Perisylvian cortical malformation impairs oromotor and pharyngeal control.
  evidence:
  - reference: PMID:11930274
    reference_title: "MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Post mortem examination revealed bilateral polymicrogyria in the perisylvian region."
    explanation: >-
      Direct human neuropathological documentation of cortical malformation in an
      affected male.
  - reference: PMID:11930274
    reference_title: "MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This malformation was visibly more severe than previously described in females with RS and another male with an MECP2 mutation."
    explanation: >-
      Grades the malformation as more severe in the hemizygous male than in Rett
      females, consistent with the loss-of-mosaic-rescue model.
- name: Brainstem Respiratory Network Failure
  biological_scale: TISSUE
  description: >-
    Failure of synaptic organization in brainstem and spinal respiratory circuitry
    destabilizes ventilatory control, producing hypoventilation and irregular breathing
    from the neonatal period, apnea, and ultimately central respiratory failure. This
    is the proximate cause of death in autopsied cases.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brainstem
    term:
      id: UBERON:0002298
      label: brainstem
  biological_processes:
  - preferred_term: regulation of respiratory gaseous exchange
    term:
      id: GO:0043576
      label: regulation of respiratory gaseous exchange
    modifier: DYSREGULATED
  downstream:
  - target: Central Hypoventilation and Irregular Breathing
    description: >-
      Loss of stable respiratory rhythm generation manifests as hypoventilation and
      irregular breathing.
  - target: Central Apnea
    description: >-
      Respiratory network instability produces central apneic events.
  - target: Respiratory Insufficiency
    description: >-
      Progressive ventilatory failure is the dominant organ-level complication.
  - target: Death in Infancy From Central Respiratory Failure
    description: >-
      Progressive brainstem respiratory network failure culminates in fatal central
      respiratory failure, the usual mode of death.
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The proband suffered from general hypotonia and hypoxia caused by hypoventilation and irregular breathing."
    explanation: >-
      Establishes that the hypoxia is centrally driven, caused by hypoventilation and
      irregular breathing rather than by lung disease.
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He failed to thrive and to reach any motor milestones and died at 15 months from central respiratory failure without a diagnosis."
    explanation: >-
      Identifies central respiratory failure as the cause of death.
  - reference: PMID:16832102
    reference_title: Early progressive encephalopathy in boys and MECP2 mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Common features include failure to thrive, respiratory insufficiency, microcephaly, and abnormal motor control."
    explanation: >-
      Confirms respiratory insufficiency as a common feature across the reported male
      case set rather than a single-case finding.
- name: Central Hypoventilation and Irregular Breathing
  biological_scale: ORGANISM
  description: >-
    Sustained inadequate ventilation with an irregular breathing pattern, present from
    the neonatal period and driven centrally rather than by intrinsic lung disease.
  biological_processes:
  - preferred_term: regulation of respiratory gaseous exchange
    term:
      id: GO:0043576
      label: regulation of respiratory gaseous exchange
    modifier: DECREASED
  downstream:
  - target: Chronic Central Hypoxia
    description: >-
      Chronic hypoventilation produces chronic tissue hypoxia.
  - target: Hypoventilation
    description: >-
      The clinical manifestation is measurable hypoventilation.
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The proband suffered from general hypotonia and hypoxia caused by hypoventilation and irregular breathing."
    explanation: >-
      States the hypoventilation-plus-irregular-breathing pattern and its hypoxic
      consequence.
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He had prolonged periods with tremor and epileptic myoclonus, shifting tonus, and dystonic extension of the trunk and legs, bruxism, and irregular breathing."
    explanation: >-
      Independent case documentation of irregular breathing alongside the movement
      phenotype in an affected male.
- name: Chronic Central Hypoxia
  biological_scale: ORGANISM
  description: >-
    Chronic hypoxia of central (ventilatory) origin, evidenced not by blood gases alone
    but by its structural footprint in skeletal muscle. On muscle biopsy the type II
    fibers are reduced in diameter, which the reporting authors interpret as indicating
    central hypoxia. This gives the entity an objective, biopsy-level marker of the
    systemic consequence of its brainstem lesion.
  locations:
  - preferred_term: skeletal muscle tissue
    term:
      id: UBERON:0001134
      label: skeletal muscle tissue
  biological_processes:
  - preferred_term: cellular response to hypoxia
    term:
      id: GO:0071456
      label: cellular response to hypoxia
    modifier: INCREASED
  downstream:
  - target: Type 2 Muscle Fiber Atrophy
    description: >-
      Chronic central hypoxia is reflected in reduced type II muscle fiber diameter.
  - target: Failure to Thrive
    description: >-
      Chronic hypoxia and increased work of breathing contribute to growth failure.
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In a muscle biopsy, type II fibers were reduced in diameter, indicating central hypoxia."
    explanation: >-
      Provides the muscle-biopsy evidence and the authors' interpretation of it as
      central hypoxia.
- name: Death in Infancy From Central Respiratory Failure
  biological_scale: ORGANISM
  description: >-
    The terminal node. Death often occurs before age two years, most commonly from
    central respiratory failure; reported ages at death across individual cases include
    13 months, 15 months, 17 months, 1 year 8 months, 30 months and 3 years 1 month.
    This is modeled as a pathophysiology node rather than as a phenotypes entry because
    HP:0001522 (Death in infancy) sits in the HPO mortality branch outside HP:0000118
    phenotypic abnormality and is therefore not bindable in phenotype_term. The
    competing cardiac mode of death is captured separately by the Sudden Death phenotype
    and the mechanism_of_sudden_death discussion.
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Death often occurs before age two years."
    explanation: >-
      GeneReviews states the typical outcome for the male severe neonatal-onset
      phenotype.
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He failed to thrive and to reach any motor milestones and died at 15 months from central respiratory failure without a diagnosis."
    explanation: >-
      Provides the case-level mode and timing of death.
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "They died at the ages of 1 year and 8 months, and 3 years and 1 month."
    explanation: >-
      Documents ages at death in an affected brother pair.
  - reference: PMID:11930274
    reference_title: "MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He presented with severe neonatal encephalopathy and died at the age of 13 months."
    explanation: >-
      Third independent primary human case of death in infancy, replacing a weaker
      literature-summary sentence taken from a mouse paper.
- name: Cortical Network Hyperexcitability
  biological_scale: CELLULAR
  description: >-
    Failed synaptic and dendritic maturation, compounded where present by polymicrogyric
    cortex, produces an epileptogenic network. Clinically this is expressed as severe,
    often intractable seizures with accompanying electroencephalographic abnormality,
    and in reported males as prolonged periods of epileptic myoclonus.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  biological_processes:
  - preferred_term: chemical synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
    modifier: DYSREGULATED
  downstream:
  - target: Seizures
    description: >-
      Network hyperexcitability manifests as severe and often intractable seizures.
  - target: EEG Abnormality
    description: >-
      Network hyperexcitability is detectable electrographically.
  - target: Myoclonus
    description: >-
      Epileptic myoclonus is a documented expression of the hyperexcitable network in
      affected males.
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He developed abnormal movements, seizures and electroencephalogram abnormalities."
    explanation: >-
      Documents seizures together with electrographic abnormality in an
      autopsy-confirmed case.
  - reference: PMID:16832102
    reference_title: Early progressive encephalopathy in boys and MECP2 mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MECP2 mutations should be assessed in boys with progressive encephalopathy and one or more of respiratory insufficiency, abnormal movements or tone, and intractable seizures."
    explanation: >-
      Identifies intractability as a characteristic feature of the epilepsy in this
      male phenotype.
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He had prolonged periods with tremor and epileptic myoclonus, shifting tonus, and dystonic extension of the trunk and legs, bruxism, and irregular breathing."
    explanation: >-
      Documents epileptic myoclonus as an expression of network hyperexcitability in an
      affected male.
- name: Impaired Motor Control Circuitry
  biological_scale: CELLULAR
  description: >-
    Failed maturation of motor and extrapyramidal circuitry yields generalized hypotonia
    that later shifts to abnormal and fluctuating tone, with involuntary movements
    including tremor and dystonic extension of the trunk and legs, and, in reported
    cases, ocular and oropharyngeal dyskinesia. No motor milestones are attained.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: regulation of muscle contraction
    term:
      id: GO:0006937
      label: regulation of muscle contraction
    modifier: DYSREGULATED
  downstream:
  - target: Generalized Hypotonia
    description: >-
      Failure of motor circuit maturation presents first as generalized hypotonia.
  - target: Abnormal Muscle Tone
    description: >-
      Tone is abnormal and fluctuating beyond simple hypotonia as the course progresses.
  - target: Involuntary Movements
    description: >-
      Extrapyramidal circuit failure produces involuntary movements.
  - target: Dystonia
    description: >-
      Dystonic extension of the trunk and legs is reported in affected males.
  - target: Tremor
    description: >-
      Prolonged periods of tremor are reported in affected males.
  - target: Abnormal Eye Movements
    description: >-
      Ocular dyskinesia has been reported as part of the movement phenotype.
  - target: Inability to Walk
    description: >-
      No motor milestones are attained, so ambulation is never achieved.
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males: Severe neonatal-onset encephalopathy, the most common phenotype in affected males, is characterized by a relentless clinical course that follows a metabolic-degenerative type of pattern, abnormal tone, involuntary movements, severe seizures, and breathing abnormalities. Death often occurs before age two years."
    explanation: >-
      Establishes abnormal tone and involuntary movements as defining features of the
      motor phenotype.
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He had prolonged periods with tremor and epileptic myoclonus, shifting tonus, and dystonic extension of the trunk and legs, bruxism, and irregular breathing."
    explanation: >-
      Enumerates the specific movement-disorder elements (tremor, shifting tone,
      dystonic extension) attributed to this node.
  - reference: PMID:37537631
    reference_title: "An insertion mutation of the MECP2 gene in severe neonatal encephalopathy and ocular and oropharyngeal dyskinesia: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient presented with severe encephalopathy in the neonatal period, accompanied by severe development backwardness, hypotonia, and ocular and oropharyngeal dyskinesia."
    explanation: >-
      Documents hypotonia plus ocular and oropharyngeal dyskinesia in an affected
      hemizygous male.
- name: Cardiac Autonomic Conduction Instability
  biological_scale: TISSUE
  description: >-
    A clinically consequential and under-recognized arm. In a familial pair of affected
    brothers, severe bradycardia preceded sudden death from sick sinus syndrome at 17
    and 30 months. Across MECP2 disorders, QTc prolongation is a recognized
    surveillance target and QT-prolonging drugs are agents to avoid, so cardiac
    conduction instability is an actionable node rather than an incidental observation.
  locations:
  - preferred_term: sinoatrial node
    term:
      id: UBERON:0002351
      label: sinoatrial node
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  biological_processes:
  - preferred_term: regulation of heart rate
    term:
      id: GO:0002027
      label: regulation of heart rate
    modifier: DYSREGULATED
  downstream:
  - target: Bradycardia
    description: >-
      Sinoatrial node dysfunction presents as severe bradycardia.
  - target: Sick Sinus Syndrome
    description: >-
      Progressive sinoatrial dysfunction reaches the threshold of sick sinus syndrome.
  - target: Prolonged QT Interval
    description: >-
      Repolarization abnormality is a recognized surveillance target across MECP2
      disorders.
  - target: Sudden Death
    description: >-
      Conduction failure is a documented mechanism of sudden death in affected males.
  evidence:
  - reference: PMID:29631775
    reference_title: MECP2 mutation in a boy with severe apnea and sick sinus syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He developed severe apnea, epilepsy, and psychomotor developmental delay and died suddenly of sick sinus syndrome at 17 months of age."
    explanation: >-
      Documents sudden death from sick sinus syndrome in an affected male with
      neonatal encephalopathy.
  - reference: PMID:29631775
    reference_title: MECP2 mutation in a boy with severe apnea and sick sinus syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "His older brother followed a similar clinical course and died at 30 months of age. The brother had also experienced severe bradycardia."
    explanation: >-
      Shows the conduction phenotype recurring within a family rather than being a
      one-off, strengthening its attribution to the MECP2 lesion.
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "regular assessment of QTc for evidence of prolongation"
    explanation: >-
      Establishes QTc prolongation as a recognized surveillance target in MECP2
      disorders, making the cardiac node actionable.
phenotypes:
- name: Congenital Encephalopathy
  category: Neurological
  diagnostic: true
  frequency: OBLIGATE
  description: >-
    Severe encephalopathy evident from birth, without the six-to-eighteen-month interval
    of apparently normal development that precedes regression in classic Rett syndrome.
    This is the defining feature of the entity.
  phenotype_term:
    preferred_term: Congenital encephalopathy
    term:
      id: HP:0007239
      label: Congenital encephalopathy
    temporality: CHRONIC
    clinical_course: PROGRESSIVE
  phenotype_contexts:
  - onset:
      onset_category: NEONATAL
      notes: Neonatal onset is definitional for this entity.
    evidence:
    - reference: PMID:18477000
      reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Non-mosaic males with a 46,XY karyotype and a MECP2 null mutation display a phenotype of severe neonatal-onset encephalopathy that is distinctly different from Rett syndrome (RTT)."
      explanation: >-
        Fixes the neonatal onset as part of the entity definition.
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males: Severe neonatal-onset encephalopathy, the most common phenotype in affected males, is characterized by a relentless clinical course that follows a metabolic-degenerative type of pattern, abnormal tone, involuntary movements, severe seizures, and breathing abnormalities. Death often occurs before age two years."
    explanation: >-
      GeneReviews names the encephalopathy as the phenotype itself and the most common
      male presentation, which is why it is marked obligate and diagnostic.
  - reference: PMID:11930274
    reference_title: "MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He presented with severe neonatal encephalopathy and died at the age of 13 months."
    explanation: >-
      Independent case documentation of the presenting encephalopathy.
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two brothers with T158M mutations and normal karyotype had a severe early onset encephalopathy, progressive microcephaly, severe feeding problems, breathing and sleep disturbances."
    explanation: >-
      Second independent case pair documenting the early-onset encephalopathy with its
      characteristic accompanying features.
- name: Microcephaly
  category: Neurological
  diagnostic: true
  frequency: FREQUENT
  description: >-
    Microcephaly is named in the disease label and is reported as a common feature across
    the male case series. Where head growth was followed longitudinally it was
    progressive, with deceleration documented from six months of age in one affected boy,
    so the acquired-deceleration pattern familiar from Rett syndrome does occur here. The
    neutral parent term is nonetheless bound rather than a primary or secondary subtype,
    because the autopsy record (a small brain with frontotemporal predominance, and
    bilateral perisylvian polymicrogyria in another case) indicates an additional
    prenatal developmental component that has never been separated from the postnatal
    one. See the microcephaly_primary_versus_acquired discussion.
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
    clinical_course: PROGRESSIVE
  phenotype_contexts:
  - notes: >-
      Progressive/acquired pattern documented longitudinally, with head-growth
      deceleration from six months of age.
    evidence:
    - reference: PMID:17236109
      reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The head growth decelerated from the age of 6 months and the feeding problems increased requiring gastrostomy."
      explanation: >-
        Documents postnatal head-growth deceleration with an explicit age of onset,
        establishing that at least part of the microcephaly is acquired.
  evidence:
  - reference: PMID:16832102
    reference_title: Early progressive encephalopathy in boys and MECP2 mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Common features include failure to thrive, respiratory insufficiency, microcephaly, and abnormal motor control."
    explanation: >-
      Case-series statement that microcephaly is a common feature, which is the basis
      for the FREQUENT band.
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two brothers with T158M mutations and normal karyotype had a severe early onset encephalopathy, progressive microcephaly, severe feeding problems, breathing and sleep disturbances."
    explanation: >-
      Independent documentation of microcephaly in affected males, and specifically of
      its progressive character.
- name: Generalized Hypotonia
  category: Neurological
  frequency: FREQUENT
  description: >-
    Marked generalized hypotonia from the neonatal period, contributing to poor motor
    acquisition, feeding difficulty and respiratory compromise.
  phenotype_term:
    preferred_term: Generalized hypotonia
    term:
      id: HP:0001290
      label: Generalized hypotonia
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The proband suffered from general hypotonia and hypoxia caused by hypoventilation and irregular breathing."
    explanation: >-
      Documents generalized hypotonia in an autopsy-confirmed case.
  - reference: PMID:37537631
    reference_title: "An insertion mutation of the MECP2 gene in severe neonatal encephalopathy and ocular and oropharyngeal dyskinesia: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient presented with severe encephalopathy in the neonatal period, accompanied by severe development backwardness, hypotonia, and ocular and oropharyngeal dyskinesia."
    explanation: >-
      Independent case documentation of hypotonia in an affected hemizygous male.
- name: Abnormal Muscle Tone
  category: Neurological
  frequency: FREQUENT
  description: >-
    Abnormality of tone beyond simple hypotonia is one of the four features GeneReviews
    lists as characterizing the male severe neonatal-onset phenotype, and abnormal tone
    or movement is one of the case-series triggers for MECP2 testing in a boy. In a
    longitudinally described male the tone was explicitly shifting rather than uniformly
    low.
  phenotype_term:
    preferred_term: Abnormal muscle tone
    term:
      id: HP:0003808
      label: Abnormal muscle tone
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males: Severe neonatal-onset encephalopathy, the most common phenotype in affected males, is characterized by a relentless clinical course that follows a metabolic-degenerative type of pattern, abnormal tone, involuntary movements, severe seizures, and breathing abnormalities. Death often occurs before age two years."
    explanation: >-
      GeneReviews lists abnormal tone among the four characterizing features.
  - reference: PMID:16832102
    reference_title: Early progressive encephalopathy in boys and MECP2 mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MECP2 mutations should be assessed in boys with progressive encephalopathy and one or more of respiratory insufficiency, abnormal movements or tone, and intractable seizures."
    explanation: >-
      Confirms abnormal tone as a recognized feature across the reported case set.
- name: Involuntary Movements
  category: Neurological
  frequency: FREQUENT
  description: >-
    Involuntary movements are one of the four features GeneReviews lists as
    characterizing the phenotype, and abnormal movements were documented in the
    autopsy-confirmed index case.
  phenotype_term:
    preferred_term: Involuntary movements
    term:
      id: HP:0004305
      label: Involuntary movements
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males: Severe neonatal-onset encephalopathy, the most common phenotype in affected males, is characterized by a relentless clinical course that follows a metabolic-degenerative type of pattern, abnormal tone, involuntary movements, severe seizures, and breathing abnormalities. Death often occurs before age two years."
    explanation: >-
      GeneReviews lists involuntary movements among the characterizing features.
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He developed abnormal movements, seizures and electroencephalogram abnormalities."
    explanation: >-
      Case-level documentation of abnormal movements.
- name: Dystonia
  category: Neurological
  frequency: OCCASIONAL
  description: >-
    Dystonic extension of the trunk and legs was documented in a longitudinally followed
    affected male, as part of a mixed movement disorder.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He had prolonged periods with tremor and epileptic myoclonus, shifting tonus, and dystonic extension of the trunk and legs, bruxism, and irregular breathing."
    explanation: >-
      Documents dystonic extension of the trunk and legs in an affected male.
- name: Tremor
  category: Neurological
  frequency: OCCASIONAL
  description: >-
    Prolonged periods of tremor were documented in a longitudinally followed affected
    male.
  phenotype_term:
    preferred_term: Tremor
    term:
      id: HP:0001337
      label: Tremor
  evidence:
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He had prolonged periods with tremor and epileptic myoclonus, shifting tonus, and dystonic extension of the trunk and legs, bruxism, and irregular breathing."
    explanation: >-
      Documents prolonged tremor in an affected male.
- name: Myoclonus
  category: Neurological
  frequency: OCCASIONAL
  description: >-
    Epileptic myoclonus was documented in a longitudinally followed affected male, and is
    curated downstream of cortical network hyperexcitability rather than of the motor
    circuitry node because the source describes it as epileptic.
  phenotype_term:
    preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  evidence:
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He had prolonged periods with tremor and epileptic myoclonus, shifting tonus, and dystonic extension of the trunk and legs, bruxism, and irregular breathing."
    explanation: >-
      Documents epileptic myoclonus in an affected male.
- name: Seizures
  category: Neurological
  frequency: FREQUENT
  description: >-
    Severe and often intractable seizures. GeneReviews describes severe seizures as
    characterizing the phenotype, and the case-series testing rule names intractable
    seizures specifically.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
    severity: SEVERE
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males: Severe neonatal-onset encephalopathy, the most common phenotype in affected males, is characterized by a relentless clinical course that follows a metabolic-degenerative type of pattern, abnormal tone, involuntary movements, severe seizures, and breathing abnormalities. Death often occurs before age two years."
    explanation: >-
      GeneReviews lists severe seizures among the characterizing features, supporting
      both the phenotype and its SEVERE qualifier.
  - reference: PMID:16832102
    reference_title: Early progressive encephalopathy in boys and MECP2 mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MECP2 mutations should be assessed in boys with progressive encephalopathy and one or more of respiratory insufficiency, abnormal movements or tone, and intractable seizures."
    explanation: >-
      Documents intractability of the seizures in the male phenotype.
- name: EEG Abnormality
  category: Neurological
  description: >-
    Electroencephalographic abnormalities accompany the seizures.
  phenotype_term:
    preferred_term: EEG abnormality
    term:
      id: HP:0002353
      label: EEG abnormality
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He developed abnormal movements, seizures and electroencephalogram abnormalities."
    explanation: >-
      Direct case documentation of electroencephalogram abnormalities.
- name: Respiratory Insufficiency
  category: Respiratory
  frequency: FREQUENT
  description: >-
    Respiratory insufficiency is one of the common features across the reported male
    case set and, as central respiratory failure, is the usual proximate cause of death.
  phenotype_term:
    preferred_term: Respiratory insufficiency
    term:
      id: HP:0002093
      label: Respiratory insufficiency
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:16832102
    reference_title: Early progressive encephalopathy in boys and MECP2 mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Common features include failure to thrive, respiratory insufficiency, microcephaly, and abnormal motor control."
    explanation: >-
      Case-series statement that respiratory insufficiency is a common feature, which
      is the basis for the FREQUENT band.
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He failed to thrive and to reach any motor milestones and died at 15 months from central respiratory failure without a diagnosis."
    explanation: >-
      Documents progression of respiratory insufficiency to fatal central respiratory
      failure.
- name: Hypoventilation
  category: Respiratory
  description: >-
    Centrally driven hypoventilation with an irregular breathing pattern, distinguishable
    from the hyperventilation-predominant breathing dysrhythmia of classic Rett syndrome.
  phenotype_term:
    preferred_term: Hypoventilation
    term:
      id: HP:0002791
      label: Hypoventilation
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The proband suffered from general hypotonia and hypoxia caused by hypoventilation and irregular breathing."
    explanation: >-
      Documents hypoventilation and irregular breathing as the mechanism of the
      hypoxia.
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "He had prolonged periods with tremor and epileptic myoclonus, shifting tonus, and dystonic extension of the trunk and legs, bruxism, and irregular breathing."
    explanation: >-
      Marked PARTIAL because the source documents irregular breathing rather than
      measured hypoventilation.
- name: Central Apnea
  category: Respiratory
  description: >-
    Severe apnea has been documented in affected males, in one case alongside the
    conduction disorder that caused sudden death.
  phenotype_term:
    preferred_term: Central apnea
    term:
      id: HP:0002871
      label: Central apnea
    severity: SEVERE
  evidence:
  - reference: PMID:29631775
    reference_title: MECP2 mutation in a boy with severe apnea and sick sinus syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He developed severe apnea, epilepsy, and psychomotor developmental delay and died suddenly of sick sinus syndrome at 17 months of age."
    explanation: >-
      Documents severe apnea in an affected male with neonatal encephalopathy.
- name: Failure to Thrive
  category: Growth
  frequency: FREQUENT
  description: >-
    Failure to thrive is one of the common features across the reported male case set.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:16832102
    reference_title: Early progressive encephalopathy in boys and MECP2 mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Common features include failure to thrive, respiratory insufficiency, microcephaly, and abnormal motor control."
    explanation: >-
      Case-series statement that failure to thrive is a common feature.
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He failed to thrive and to reach any motor milestones and died at 15 months from central respiratory failure without a diagnosis."
    explanation: >-
      Case-level documentation of failure to thrive.
- name: Severe Global Developmental Delay
  category: Neurological
  frequency: FREQUENT
  description: >-
    Profound developmental impairment without milestone attainment. In contrast to Rett
    syndrome there is no acquire-then-lose pattern in the most severe cases, since motor
    milestones are never reached, although a more protracted R294X male did acquire and
    then lose sitting and hand grasping.
  phenotype_term:
    preferred_term: Severe global developmental delay
    term:
      id: HP:0011344
      label: Severe global developmental delay
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He failed to thrive and to reach any motor milestones and died at 15 months from central respiratory failure without a diagnosis."
    explanation: >-
      Documents complete failure of motor milestone attainment.
  - reference: PMID:37537631
    reference_title: "An insertion mutation of the MECP2 gene in severe neonatal encephalopathy and ocular and oropharyngeal dyskinesia: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient presented with severe encephalopathy in the neonatal period, accompanied by severe development backwardness, hypotonia, and ocular and oropharyngeal dyskinesia."
    explanation: >-
      Independent documentation of severe developmental impairment.
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He had a rapid deterioration period at 2 years and lost sitting and hand grasping functions."
    explanation: >-
      Documents the less common protracted variant of the course, in which limited
      milestones are attained and then lost.
- name: Inability to Walk
  category: Neurological
  description: >-
    No motor milestones are attained, so independent ambulation is never achieved.
  phenotype_term:
    preferred_term: Inability to walk
    term:
      id: HP:0002540
      label: Inability to walk
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "He failed to thrive and to reach any motor milestones and died at 15 months from central respiratory failure without a diagnosis."
    explanation: >-
      Marked PARTIAL because the source states that no motor milestones were reached,
      from which inability to walk follows, rather than reporting ambulation status.
- name: Polymicrogyria
  category: Neurological
  frequency: OCCASIONAL
  description: >-
    Bilateral perisylvian polymicrogyria was found at post-mortem in an affected male,
    visibly more severe than in Rett females. It has not been reported in every case, so
    it is banded as occasional rather than characteristic.
  phenotype_term:
    preferred_term: Polymicrogyria
    term:
      id: HP:0002126
      label: Polymicrogyria
  evidence:
  - reference: PMID:11930274
    reference_title: "MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Post mortem examination revealed bilateral polymicrogyria in the perisylvian region."
    explanation: >-
      Direct neuropathological documentation of polymicrogyria in an affected male.
  - reference: PMID:11930274
    reference_title: "MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We conclude that MECP2 screening should be considered in males with severe neonatal encephalopathy and in males and females with a bilateral polymicrogyria syndrome."
    explanation: >-
      The authors' own recommendation, which treats the polymicrogyria association as
      strong enough to change testing practice.
- name: Abnormal Eye Movements
  category: Ophthalmological
  frequency: OCCASIONAL
  description: >-
    Ocular dyskinesia has been reported as part of the movement phenotype in an affected
    hemizygous male, alongside oropharyngeal dyskinesia. HPO has no term for ocular
    dyskinesia as such: the nearest specific candidates (HP:0010553 oculogyric crisis,
    HP:0031931 ocular flutter, HP:0010543 opsoclonus) each name a distinct eye-movement
    pattern that the source does not specify. The general parent is therefore bound with
    a precise preferred_term rather than over-committing to one of them.
  phenotype_term:
    preferred_term: Ocular dyskinesia
    term:
      id: HP:0000496
      label: Abnormality of eye movement
  evidence:
  - reference: PMID:37537631
    reference_title: "An insertion mutation of the MECP2 gene in severe neonatal encephalopathy and ocular and oropharyngeal dyskinesia: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient presented with severe encephalopathy in the neonatal period, accompanied by severe development backwardness, hypotonia, and ocular and oropharyngeal dyskinesia."
    explanation: >-
      Documents ocular dyskinesia in an affected male, the basis for the eye-movement
      abnormality annotation.
- name: Oropharyngeal Dyskinesia and Feeding Difficulties
  category: Gastrointestinal
  frequency: FREQUENT
  description: >-
    Severe feeding problems are a characteristic feature, documented as poor sucking from
    birth, then increasing to the point of requiring gastrostomy. Oropharyngeal
    dyskinesia has also been reported and provides the oromotor mechanism.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
    severity: SEVERE
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two brothers with T158M mutations and normal karyotype had a severe early onset encephalopathy, progressive microcephaly, severe feeding problems, breathing and sleep disturbances."
    explanation: >-
      Documents severe feeding problems as a characteristic feature in an affected
      brother pair, which is the basis for the FREQUENT band and the SEVERE qualifier.
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The head growth decelerated from the age of 6 months and the feeding problems increased requiring gastrostomy."
    explanation: >-
      Documents the progressive course of the feeding difficulty and its escalation to
      gastrostomy dependence.
  - reference: PMID:37537631
    reference_title: "An insertion mutation of the MECP2 gene in severe neonatal encephalopathy and ocular and oropharyngeal dyskinesia: a case report."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient presented with severe encephalopathy in the neonatal period, accompanied by severe development backwardness, hypotonia, and ocular and oropharyngeal dyskinesia."
    explanation: >-
      Marked PARTIAL because the source reports oropharyngeal dyskinesia, the oromotor
      mechanism, rather than feeding difficulty as such.
- name: Sleep Disturbance
  category: Neurological
  frequency: OCCASIONAL
  description: >-
    Sleep disturbances were documented alongside breathing disturbances in an affected
    brother pair.
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two brothers with T158M mutations and normal karyotype had a severe early onset encephalopathy, progressive microcephaly, severe feeding problems, breathing and sleep disturbances."
    explanation: >-
      Documents sleep disturbance in an affected brother pair.
- name: Bruxism
  category: Neurological
  frequency: OCCASIONAL
  description: >-
    Bruxism was documented in a longitudinally followed affected male, mirroring its
    frequent occurrence in classic Rett syndrome.
  phenotype_term:
    preferred_term: Bruxism
    term:
      id: HP:0003763
      label: Bruxism
  evidence:
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He had prolonged periods with tremor and epileptic myoclonus, shifting tonus, and dystonic extension of the trunk and legs, bruxism, and irregular breathing."
    explanation: >-
      Documents bruxism in an affected male.
- name: Bradycardia
  category: Cardiovascular
  frequency: OCCASIONAL
  description: >-
    Severe bradycardia preceded sudden death in two affected brothers, noticed one month
    before death in the index case.
  phenotype_term:
    preferred_term: Bradycardia
    term:
      id: HP:0001662
      label: Bradycardia
    severity: SEVERE
  evidence:
  - reference: PMID:29631775
    reference_title: MECP2 mutation in a boy with severe apnea and sick sinus syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Severe bradycardia had been noticed since 16 months of age."
    explanation: >-
      Documents severe bradycardia preceding sudden death in the index case.
  - reference: PMID:29631775
    reference_title: MECP2 mutation in a boy with severe apnea and sick sinus syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "His older brother followed a similar clinical course and died at 30 months of age. The brother had also experienced severe bradycardia."
    explanation: >-
      Documents recurrence of severe bradycardia in the affected brother.
- name: Sick Sinus Syndrome
  category: Cardiovascular
  frequency: OCCASIONAL
  description: >-
    Sick sinus syndrome caused sudden death in an affected male at 17 months.
  phenotype_term:
    preferred_term: Sick sinus syndrome
    term:
      id: HP:0011704
      label: Sick sinus syndrome
  evidence:
  - reference: PMID:29631775
    reference_title: MECP2 mutation in a boy with severe apnea and sick sinus syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He developed severe apnea, epilepsy, and psychomotor developmental delay and died suddenly of sick sinus syndrome at 17 months of age."
    explanation: >-
      Directly documents sick sinus syndrome as the cause of sudden death.
- name: Prolonged QT Interval
  category: Cardiovascular
  description: >-
    QTc prolongation is a recognized surveillance target across MECP2 disorders, and
    QT-prolonging drugs are listed as agents to avoid.
  phenotype_term:
    preferred_term: Prolonged QT interval
    term:
      id: HP:0001657
      label: Prolonged QT interval
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "regular assessment of QTc for evidence of prolongation"
    explanation: >-
      Marked PARTIAL because GeneReviews recommends surveillance for QTc prolongation
      across MECP2 disorders rather than reporting its frequency in this male phenotype.
- name: Sudden Death
  category: Cardiovascular
  description: >-
    Sudden death has been documented in affected males and attributed to cardiac
    conduction failure, providing a mechanism distinct from the more usual central
    respiratory failure.
  phenotype_term:
    preferred_term: Sudden death
    term:
      id: HP:0001699
      label: Sudden death
  evidence:
  - reference: PMID:29631775
    reference_title: MECP2 mutation in a boy with severe apnea and sick sinus syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This familial case might help to clarify the causes of sudden death in cases of MECP2 mutations."
    explanation: >-
      The authors frame their case as informing the mechanism of sudden death in MECP2
      mutation carriers.
- name: Type 2 Muscle Fiber Atrophy
  category: Musculoskeletal
  description: >-
    Reduced type II muscle fiber diameter on muscle biopsy, interpreted by the reporting
    authors as an indicator of chronic central hypoxia rather than a primary myopathy.
  phenotype_term:
    preferred_term: Type 2 muscle fiber atrophy
    term:
      id: HP:0003554
      label: Type 2 muscle fiber atrophy
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In a muscle biopsy, type II fibers were reduced in diameter, indicating central hypoxia."
    explanation: >-
      Direct biopsy documentation of reduced type II fiber diameter and its
      interpretation.
genetic:
- name: MECP2
  association: Causative
  gene_term:
    preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  variant_origin: DE_NOVO
  relationship_type: CAUSATIVE
  frequency: >-
    Across contemporary male ascertainment, 78.0% of MECP2 variants in males were de
    novo and 15.3% maternally inherited.
  inheritance:
  - name: X-linked inheritance
    inheritance_term:
      preferred_term: X-linked inheritance
      term:
        id: HP:0001417
        label: X-linked inheritance
    expressivity: VARIABLE
    evidence:
    - reference: PMID:20301670
      reference_title: MECP2 Disorders.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "MECP2 disorders are inherited in an X-linked manner."
      explanation: >-
        GeneReviews states the mode of inheritance for MECP2 disorders.
  notes: >-
    MECP2 lies at Xq28, so a male is hemizygous. Most severe male cases are de novo, but
    maternal transmission from a heterozygous mother with favorably skewed X-chromosome
    inactivation is well documented and an apparently unaffected mother is therefore not
    evidence against pathogenicity. Two modifiers convert the male phenotype away from
    neonatal encephalopathy toward Rett syndrome by restoring a wild-type-expressing cell
    population, namely post-zygotic somatic mosaicism and 47,XXY Klinefelter syndrome.
    Affected males in the reported series had normal karyotypes and no dysmorphic
    features, so the diagnosis cannot be reached on gestalt or cytogenetics alone.

    Two findings bear directly on recurrence-risk counselling. First, de novo MECP2
    variants show a strong paternal-origin bias, paternal in 84 of 88 sporadic cases in a
    large Chinese series, consistent with errors arising during spermatogenesis. Second,
    that bias is at least partly explained by paternal germline mosaicism, detected in 5
    of 21 fathers of variant-carrying probands, which means a father can transmit more
    than once and recurrence risk is not the near-zero figure a de novo result naively
    implies. Systematic screening also found somatic MECP2 mosaicism far more often in
    males than females (3 of 18 versus 2 of 453), which is the quantitative counterpart of
    the mosaic-rescue mechanism modelled in the pathograph. A separate signal worth noting
    at the counselling table is that single-base-pair gains or losses were in excess on
    maternally derived alleles, a category the authors link to elevated gonadal-mosaicism
    risk.
  case_fractions:
  - population: Males with pathogenic MECP2 variants ascertained through a parent group
    case_fraction_percent: 78.0
    cohort_size: 59
    notes: De novo variants as a fraction of MECP2 variants in ascertained males.
    evidence:
    - reference: PMID:39476560
      reference_title: "MECP2 Variants in Males: More Common than Previously Appreciated."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Of these variants, 46 (78.0%) were de novo, nine (15.3%) were maternally inherited, and for four (6.8%) inheritance was not known."
      explanation: >-
        Quantifies the de novo fraction in the largest contemporary male series.
    - reference: PMID:39476560
      reference_title: "MECP2 Variants in Males: More Common than Previously Appreciated."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Fifty-nine males were identified through the parent group."
      explanation: >-
        Establishes the cohort size for the de novo fraction.
  - population: Males with pathogenic MECP2 variants ascertained through a parent group
    case_fraction_percent: 18.6
    cohort_size: 59
    notes: >-
      Mosaic fraction (somatic mosaicism or 47,XXY). These are the males expected to
      present with a Rett phenotype rather than with neonatal encephalopathy, so this
      figure bounds how often the mosaic-rescue modifier operates.
    evidence:
    - reference: PMID:39476560
      reference_title: "MECP2 Variants in Males: More Common than Previously Appreciated."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Eleven (18.6%) were mosaic, 10 with somatic mosaicism and one with Klinefelter syndrome (47XXY)."
      explanation: >-
        Quantifies the mosaic and 47,XXY fraction in ascertained males.
  variants:
  - name: MECP2 truncating variants disrupting the transcription-repression domain
    clinical_significance: PATHOGENIC
    description: >-
      Nonsense and frameshift variants that truncate MeCP2 within or before the
      transcription-repression domain. The prototype is 806delG (V288X), which in a
      single family produced a minimally affected skewed-XCI carrier mother, classic
      Rett syndrome in heterozygous relatives, and lethal congenital encephalopathy in
      the hemizygous son. The recurrent nonsense allele R294X has also been reported in
      an affected male, with a more protracted course.
    evidence:
    - reference: PMID:10577905
      reference_title: "Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "An 806delG deletion causing a V288X stop in the transcription-repression domain was identified in a woman with motor-coordination problems, mild learning disability, and skewed X inactivation; in her sister and daughter, who were affected with classic RTT; and in her hemizygous son, who died from congenital encephalopathy."
      explanation: >-
        Establishes the variant, the affected protein domain, and the full
        genotype-phenotype range it produces depending on X-chromosome context.
    - reference: PMID:10577905
      reference_title: "Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Thus, some males with RTT-causing MECP2 mutations may survive to birth, and female heterozygotes with favorably skewed X-inactivation patterns may have little or no involvement."
      explanation: >-
        The authors' own conclusion that RTT-causing variants are compatible with male
        live birth, which is the foundational observation for this entity.
    - reference: PMID:11738861
      reference_title: Rethinking the fate of males with mutations in the gene that causes Rett syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "mutations in MECP2 that lead to the classical phenotype in females do not appear to result in prenatal lethality of affected hemizygous males"
      explanation: >-
        Independently refutes the prenatal-lethality assumption for the same
        Rett-causing variant classes, which is what makes this entity possible.
    - reference: PMID:37537631
      reference_title: "An insertion mutation of the MECP2 gene in severe neonatal encephalopathy and ocular and oropharyngeal dyskinesia: a case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Here we report a rare case in a 10-month-old boy with a hemizygous insertion mutation in MECP2 as NM_001110792, c.799_c.800insAGGAAGC, which results in a frameshift mutation"
      explanation: >-
        A further hemizygous frameshift variant in this class in an affected male.
  - name: MECP2 splice-disrupting deletion
    clinical_significance: PATHOGENIC
    description: >-
      A de novo 9-nucleotide deletion spanning the intron 3 to exon 4 splice junction
      creates a new splice site; the aberrantly spliced transcript loses seven
      nucleotides, causing a frameshift and premature termination codon.
    evidence:
    - reference: PMID:18477000
      reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Post-mortem MECP2 mutation analysis on DNA and RNA from fibroblasts revealed a novel de novo 9-nucleotide deletion including the intron 3/exon 4 splice junction."
      explanation: >-
        Documents the splice-disrupting deletion class in the autopsy-confirmed case.
    - reference: PMID:18477000
      reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The two nucleotides flanking the deletion form a new splice site, and the aberrantly spliced transcript lacks seven nucleotides"
      explanation: >-
        Establishes the RNA-level consequence, confirming a null mechanism.
  - name: MECP2 methyl-CpG-binding-domain missense variants
    clinical_significance: PATHOGENIC
    description: >-
      Missense substitutions in and around the methyl-CpG-binding domain, of which T158M
      is the recurrent allele reported in affected males. In hemizygous males these
      produce a graded phenotype, with the most functionally damaging variants at the
      neonatal-encephalopathy end of the spectrum, because X-inactivation does not
      confound the genotype-phenotype comparison. T158M males have been proposed to form
      a recognizable clinical-genetic sub-entity.
    evidence:
    - reference: PMID:27929079
      reference_title: "From Function to Phenotype: Impaired DNA Binding and Clustering Correlates with Clinical Severity in Males with Missense Mutations in MECP2."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Overall, clinical severity showed a direct correlation with the functional impairment of MeCP2."
      explanation: >-
        Establishes the graded genotype-phenotype relationship for MBD missense
        variants in hemizygous males.
    - reference: PMID:27929079
      reference_title: "From Function to Phenotype: Impaired DNA Binding and Clustering Correlates with Clinical Severity in Males with Missense Mutations in MECP2."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Furthermore, binding and mobility dynamics show a gradient of impairment depending on the amino acid properties and tertiary structure within the MBD."
      explanation: >-
        Provides the biochemical basis of the severity gradient.
    - reference: PMID:17236109
      reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The phenotypes show a strong resemblance, and might in fact represent a clinical-genetic entity of the T158M mutation within the complex of congenital encephalopathies in males with MeCP2 mutations."
      explanation: >-
        Documents T158M as a recurrent MBD missense allele in affected males and
        proposes it as an allele-specific sub-entity.
  evidence:
  - reference: PMID:34502518
    reference_title: MECP2-Related Disorders in Males.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In boys, however, mutations in MECP2 can generate a wide spectrum of clinical presentations that range from mild intellectual impairment to severe neonatal encephalopathy and premature death."
    explanation: >-
      Establishes MECP2 as the causative gene for the male spectrum whose severe end
      this entry curates.
  - reference: PMID:34502518
    reference_title: MECP2-Related Disorders in Males.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Loss-of-function mutations in MECP2 are associated with Rett syndrome (RTT), which is a well-characterized disorder that affects mainly females."
    explanation: >-
      Establishes the loss-of-function direction of effect, distinguishing this entity
      from MECP2 duplication syndrome.
  - reference: PMID:34271245
    reference_title: "MECP2-related conditions in males: A systematic literature review and 8 additional cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In males, the MECP2 pathogenic variants can be associated with different phenotypes, including neonatal severe encephalopathy, intellectual deficiency, or late-onset parkinsonism and spasticity."
    explanation: >-
      Systematic review conclusion establishing the three male MECP2 phenotypes.
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "None of the boys had dysmorphic features."
    explanation: >-
      Records the absence of a recognizable dysmorphic gestalt, which is why molecular
      testing rather than physical examination establishes the diagnosis.
  - reference: PMID:22182064
    reference_title: What does the nature of the MECP2 mutation tell us about parental origin and recurrence risk in Rett syndrome?
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The parental origin was paternal in 84/88"
    explanation: >-
      Quantifies the paternal-origin bias of de novo MECP2 variants, which is the
      counselling-relevant fact about where these variants arise.
  - reference: PMID:22182064
    reference_title: What does the nature of the MECP2 mutation tell us about parental origin and recurrence risk in Rett syndrome?
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The excess we found of 'single base pair gains or losses' on maternally derived MECP2 gene alleles suggests that this mutational category is associated with an elevated risk of gonadal mosaicism, which has implications for genetic counseling."
    explanation: >-
      The authors' own counselling implication, and the reason parental origin is not a
      purely academic observation.
  - reference: PMID:30405208
    reference_title: Genomic mosaicism in the pathogenesis and inheritance of a Rett syndrome cohort.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Germline MECP2 mosaicism was detected in 5/21 (23.8%) fathers."
    explanation: >-
      Establishes paternal germline mosaicism at a substantial rate, which raises
      recurrence risk above the naive de novo expectation.
  - reference: PMID:30405208
    reference_title: Genomic mosaicism in the pathogenesis and inheritance of a Rett syndrome cohort.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Somatic MECP2 mosaicism was confirmed in 5/471 (1.1%) patients, including 3/18 males (16.7%) and 2/453 females (0.4%)."
    explanation: >-
      Quantifies how much more often somatic mosaicism is found in males than females,
      the human-genetic counterpart of the mosaic-rescue node in the pathograph.
  - reference: PMID:30405208
    reference_title: Genomic mosaicism in the pathogenesis and inheritance of a Rett syndrome cohort.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The high proportion of paternal germline MECP2 mosaicism indicates an underestimated mechanism underlying the paternal origin bias of MECP2 variants."
    explanation: >-
      Links the two findings: germline mosaicism in fathers is the proposed mechanism
      behind the paternal-origin bias.
biochemical:
- name: MeCP2 protein
  presence: Absent or severely dysfunctional in all cells
  context: >-
    Because the male is hemizygous and non-mosaic, there is no wild-type MeCP2 in any
    neuron or glial cell. This is the biochemical difference from the heterozygous Rett
    female, in whom roughly half of cells retain wild-type MeCP2. No validated
    circulating or CSF biomarker exists for this entity.
treatments:
- name: Multidisciplinary Symptomatic and Supportive Care
  description: >-
    There is no disease-modifying therapy. Treatment is mainly symptomatic and focuses
    on optimizing the individual's abilities through a multidisciplinary approach that
    also includes psychosocial support for family members.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment is mainly symptomatic and focuses on optimizing the individual's abilities using a multidisciplinary approach that should also include psychosocial support for family members."
    explanation: >-
      GeneReviews management statement establishing symptomatic multidisciplinary care
      as the standard of care.
- name: Seizure Management
  description: >-
    Antiseizure treatment per standard care. Seizures in this phenotype are frequently
    intractable, so epilepsy-specialist involvement is expected.
  treatment_term:
    preferred_term: anticonvulsant therapy
    term:
      id: NCIT:C64172
      label: Anticonvulsant Therapy
    therapeutic_agent:
    - preferred_term: anticonvulsant agent
      term:
        id: NCIT:C264
        label: Anticonvulsant Agent
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  target_mechanisms:
  - target: Cortical Network Hyperexcitability
    treatment_effect: INHIBITS
    description: >-
      Antiseizure drugs suppress the epileptogenic network output rather than the
      upstream MeCP2 deficiency.
    evidence:
    - reference: PMID:20301670
      reference_title: MECP2 Disorders.
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Treatment of seizures, constipation, gastroesophageal reflux, scoliosis, prolonged QTc, and spasticity per standard care."
      explanation: >-
        Marked PARTIAL because GeneReviews prescribes standard-care seizure treatment
        without naming a mechanism-specific agent for this phenotype.
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of seizures, constipation, gastroesophageal reflux, scoliosis, prolonged QTc, and spasticity per standard care."
    explanation: >-
      GeneReviews directs standard-care treatment of seizures among other
      manifestations.
  - reference: PMID:16832102
    reference_title: Early progressive encephalopathy in boys and MECP2 mutations.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "MECP2 mutations should be assessed in boys with progressive encephalopathy and one or more of respiratory insufficiency, abnormal movements or tone, and intractable seizures."
    explanation: >-
      Marked PARTIAL because it establishes the intractability that shapes seizure
      management rather than an intervention result.
- name: Cardiac Conduction Surveillance and Avoidance of QT-Prolonging Drugs
  description: >-
    Regular assessment of QTc for evidence of prolongation, with avoidance of drugs known
    to prolong the QT interval. This is the one actionable, potentially death-preventing
    intervention specific to the cardiac node, and it is reinforced by the documented
    sudden deaths from sick sinus syndrome and severe bradycardia in affected brothers.
  treatment_term:
    preferred_term: serial electrocardiography with QTc assessment
    term:
      id: NCIT:C38053
      label: Electrocardiography
  target_phenotypes:
  - preferred_term: Prolonged QT interval
    term:
      id: HP:0001657
      label: Prolonged QT interval
  - preferred_term: Sudden death
    term:
      id: HP:0001699
      label: Sudden death
  target_mechanisms:
  - target: Cardiac Autonomic Conduction Instability
    treatment_effect: MODULATES
    description: >-
      Surveillance detects, and drug avoidance refrains from aggravating, the conduction
      instability node; neither corrects the underlying autonomic circuit failure.
    evidence:
    - reference: PMID:20301670
      reference_title: MECP2 Disorders.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Agents/circumstances to avoid: Drugs known to prolong the QT interval."
      explanation: >-
        The explicit avoidance recommendation that operates on the conduction node.
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "regular assessment of QTc for evidence of prolongation"
    explanation: >-
      GeneReviews surveillance recommendation for QTc.
  - reference: PMID:29631775
    reference_title: MECP2 mutation in a boy with severe apnea and sick sinus syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This familial case might help to clarify the causes of sudden death in cases of MECP2 mutations."
    explanation: >-
      Provides the clinical motivation for cardiac surveillance in affected males.
- name: Melatonin for Sleep Disturbance
  description: >-
    Melatonin can ameliorate sleep disturbances in MECP2 disorders, and sleep disturbance
    is documented in affected males.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: melatonin
      term:
        id: CHEBI:16796
        label: melatonin
  target_phenotypes:
  - preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Risperidone may help in treating agitation; melatonin can ameliorate sleep disturbances."
    explanation: >-
      Marked PARTIAL because GeneReviews recommends melatonin across MECP2 disorders,
      where the supporting experience is predominantly in females with Rett syndrome
      rather than in males with the neonatal-onset phenotype.
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Two brothers with T158M mutations and normal karyotype had a severe early onset encephalopathy, progressive microcephaly, severe feeding problems, breathing and sleep disturbances."
    explanation: >-
      Marked PARTIAL because it establishes the sleep disturbance that motivates the
      treatment in affected males rather than reporting a treatment outcome.
- name: Nutritional Support and Gastrostomy Feeding
  description: >-
    Caloric support and management of feeding difficulty, escalating to gastrostomy when
    oral feeding fails. This is not optional supportive detail but a documented
    requirement, given the near-universal failure to thrive, severe feeding problems from
    birth and the aspiration risk from oropharyngeal dyskinesia.
  treatment_term:
    preferred_term: Nutritional Support
    term:
      id: NCIT:C15433
      label: Nutritional Support
  target_phenotypes:
  - preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  - preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The head growth decelerated from the age of 6 months and the feeding problems increased requiring gastrostomy."
    explanation: >-
      Documents escalation of feeding support to gastrostomy in an affected male.
  - reference: PMID:16832102
    reference_title: Early progressive encephalopathy in boys and MECP2 mutations.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Common features include failure to thrive, respiratory insufficiency, microcephaly, and abnormal motor control."
    explanation: >-
      Marked PARTIAL because it establishes the failure to thrive that nutritional
      support addresses rather than reporting an intervention outcome.
- name: Genetic Counseling
  description: >-
    Counseling covers the X-linked mode, the greater than 99% simplex rate across MECP2
    disorders, the possibility of parental germline mosaicism, and the possibility of a
    minimally affected transmitting mother with favorably skewed X-chromosome
    inactivation. Because of possible parental germline mosaicism, prenatal diagnosis is
    appropriate to offer regardless of whether a parental variant was found.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Because of the possibility of parental germline mosaicism, it is appropriate to offer prenatal diagnosis to couples who have had a child with a MECP2 disorder regardless of whether the MECP2 pathogenic variant has been detected in a parent."
    explanation: >-
      The specific counseling recommendation that follows from germline mosaicism risk.
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "When the pathogenic MECP2 variant has been identified in the family, heterozygote testing for at-risk female relatives, prenatal testing for pregnancies at increased risk, and preimplantation genetic testing are possible."
    explanation: >-
      Enumerates the reproductive options that constitute the counseling intervention.
clinical_trials:
- name: NCT04502199
  phase: NOT_APPLICABLE
  status: UNKNOWN
  description: >-
    Observational study of dysautonomic signs in boys with MECP2 mutations, explicitly
    motivated by the fact that males with MECP2 mutations are less studied than females
    and have more varied phenotypes. Notable as one of the very few male-specific MECP2
    studies, and directly relevant to the autonomic and cardiac conduction node.
  target_phenotypes:
  - preferred_term: Bradycardia
    term:
      id: HP:0001662
      label: Bradycardia
  - preferred_term: Prolonged QT interval
    term:
      id: HP:0001657
      label: Prolonged QT interval
  evidence:
  - reference: clinicaltrials:NCT04502199
    reference_title: Dysautonomic Signs Among MECP2boys
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We want to search dysautonomic signs among boys with a MECP2 mutations because they are less studied than the girls and they have more varied phenotypes."
    explanation: >-
      Trial record documents a male-specific MECP2 dysautonomia study and states the
      rationale of male under-study.
animal_models:
- species: Mus musculus
  genotype: Mecp2-null hemizygous male
  category: Knockout
  description: >-
    The hemizygous Mecp2-null male mouse is argued in the human neuropathology
    literature to be the true counterpart of THIS entity rather than of Rett syndrome,
    because it reproduces the non-mosaic, uniformly MeCP2-deficient male state. Null
    mice and brain-restricted deletions develop severe neurological symptoms at about
    six weeks and die between six and twelve weeks, with brains substantially reduced in
    weight and neuronal cell size but no structural defect or neurodegeneration.
    Hemizygous mutant males also give the quantitative dendritic phenotype, with reduced
    basal dendritic length and compartment-specific spine loss in layer 5 motor cortex.
    Two important limitations qualify its use for this entity. The mouse is normal until
    five to six weeks of age, whereas the affected human male is encephalopathic from
    birth, and the mouse literature interprets its own delayed onset as evidence that
    MeCP2 maintains brain function rather than builds it, which sits awkwardly beside
    the human autopsy findings of a small brain and perisylvian polymicrogyria.
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males with congenital encephalopathy, not females with RTT, represent the true human counterpart for the commonly studied Mecp2-/y mouse model and provide unique insight into the mechanisms of MeCP2 deficiency."
    explanation: >-
      States the claim that licenses using the hemizygous null mouse as the model for
      this entity specifically.
  - reference: PMID:11242117
    reference_title: A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Both Mecp2-null mice and mice in which Mecp2 was deleted in brain showed severe neurological symptoms at approximately six weeks of age."
    explanation: >-
      Establishes the model's phenotype and its timing, which is the basis of the
      onset-mismatch limitation.
  - reference: PMID:11242118
    reference_title: Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Mecp2-null mice were normal until 5 weeks of age, when they began to develop disease, leading to death between 6 and 12 weeks."
    explanation: >-
      Documents the model's asymptomatic early period and lethality window.
  - reference: PMID:11242118
    reference_title: Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Mutant brains showed substantial reduction in both weight and neuronal cell size, but no obvious structural defects or signs of neurodegeneration."
    explanation: >-
      The model's brain-growth phenotype, which matches the human small-brain finding
      while lacking the human cortical malformation.
  - reference: PMID:22412847
    reference_title: "MeCP2 mutation results in compartment-specific reductions in dendritic branching and spine density in layer 5 motor cortical neurons of YFP-H mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "YFP(+) Layer 5 pyramidal neurons in the motor cortex of wildtype and hemizygous mutant male mice were examined for differences in dendrite morphology and spine density."
    explanation: >-
      Confirms the model is the hemizygous mutant male, the genotype that corresponds to
      this entity rather than to Rett syndrome.
  - reference: PMID:22412847
    reference_title: "MeCP2 mutation results in compartment-specific reductions in dendritic branching and spine density in layer 5 motor cortical neurons of YFP-H mice."
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "Our results support the view that the effects of MeCP2 mutation are highly context-dependent and cannot be generalized across mutation types and cell populations."
    explanation: >-
      Marked PARTIAL and recorded as a limitation: the authors caution against
      generalizing model findings across mutation types and cell populations.
  - reference: PMID:20298210
    reference_title: Reversibility of functional deficits in experimental models of Rett syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Recent evidence suggests that reactivation of endogenous Mecp2 in young and adult mice can reverse aspects of RTT-like pathology."
    explanation: >-
      The model's most consequential property for this entity: the deficit is reversible
      on restoring MeCP2, which is what makes gene replacement a rational strategy and
      the therapeutic-window question in the discussions substantive.
  - reference: PMID:20298210
    reference_title: Reversibility of functional deficits in experimental models of Rett syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Deletion of Mecp2 in mice recapitulates many of the overt neurological features seen in humans, and the delayed onset of symptoms is accompanied by deficits in neuronal morphology and synaptic physiology."
    explanation: >-
      States both the model's fidelity and, explicitly, its delayed symptom onset, which
      is the limitation examined in the mecp2_null_mouse_onset_mismatch discussion.
- species: Mus musculus
  genotype: Mecp2 mutant astrocyte-neuron coculture
  category: Knockout
  description: >-
    Astrocyte-neuron coculture from Mecp2-mutant mice provides the experimental basis for
    the non-cell-autonomous arm of the mechanism. Mutant astrocytes and their conditioned
    medium alone fail to support normal dendritic morphology in either wild-type or mutant
    hippocampal neurons, implicating aberrant secretion of soluble factors. This is
    especially relevant to a hemizygous male, in whom astrocytes are also uniformly
    MeCP2-deficient.
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  evidence:
  - reference: PMID:19234456
    reference_title: Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Using an in vitro co-culture system, we found that mutant astrocytes from a RTT mouse model, and their conditioned medium, failed to support normal dendritic morphology of either wild-type or mutant hippocampal neurons."
    explanation: >-
      The coculture result that establishes the non-cell-autonomous astrocytic
      contribution.
diagnosis:
- name: MECP2 molecular genetic testing in a male proband
  description: >-
    Diagnosis is established in a male proband with suggestive findings plus a hemizygous
    MECP2 pathogenic variant. Because the phenotype was long presumed lethal in males,
    the practical bottleneck is recognition rather than assay, and because affected boys
    have normal karyotypes and no dysmorphic features there is no gestalt to prompt it.
    Broad genomic testing that includes MECP2 should be applied to a boy with progressive
    encephalopathy plus one or more of respiratory insufficiency, abnormal movements or
    tone, and intractable seizures, and MECP2 should also be screened in bilateral
    perisylvian polymicrogyria. High-depth data are needed to detect low-level somatic
    mosaicism, and copy-number analysis is needed to distinguish loss of function from
    MECP2 duplication.
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of a MECP2 disorder is established by molecular genetic testing in a female proband with suggestive findings and a heterozygous MECP2 pathogenic variant, and in a male proband with suggestive findings and a hemizygous MECP2 pathogenic variant."
    explanation: >-
      States the diagnostic requirement for a male proband.
  - reference: PMID:16832102
    reference_title: Early progressive encephalopathy in boys and MECP2 mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MECP2 mutations should be assessed in boys with progressive encephalopathy and one or more of respiratory insufficiency, abnormal movements or tone, and intractable seizures."
    explanation: >-
      Gives the clinical trigger for testing.
  - reference: PMID:11930274
    reference_title: "MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We conclude that MECP2 screening should be considered in males with severe neonatal encephalopathy and in males and females with a bilateral polymicrogyria syndrome."
    explanation: >-
      Extends the testing indication to bilateral polymicrogyria syndromes.
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "None of the boys had dysmorphic features."
    explanation: >-
      Establishes that there is no dysmorphic gestalt to trigger testing, which is why
      the clinical rule above carries the diagnostic burden.
  - reference: PMID:40515634
    reference_title: Medical Biases and Misconceptions Impact Diagnoses in Males With Loss of Function MECP2 Variants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Multivariate analysis showed that for every year increase in year of birth, age of diagnosis (in years) decreased by 0.31."
    explanation: >-
      Quantifies the diagnostic delay and its improvement over birth cohorts, which is
      the practical failure mode this diagnostic entry addresses.
discussions:
- discussion_id: microcephaly_primary_versus_acquired
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Postnatal head-growth deceleration is documented in this entity, but so are a small
    brain with frontotemporal predominance and bilateral perisylvian polymicrogyria. Is
    there therefore also a prenatal component to the microcephaly, and does the balance
    of prenatal and postnatal contribution differ by variant?
  rationale: >-
    This is not a question of whether the microcephaly is acquired: it demonstrably can
    be, since head growth decelerated from six months of age in a longitudinally
    followed R294X male and microcephaly was explicitly described as progressive in the
    T158M brothers. The open question is whether an additional prenatal component exists
    on top of that, and it matters because the two possibilities imply different
    therapeutic windows. The autopsy record points toward a prenatal contribution that
    growth curves cannot capture: bilateral perisylvian polymicrogyria can only arise
    during prenatal cortical development, and the brain was small with disproportionate
    frontotemporal reduction. If complete MeCP2 deficiency has a prenatal developmental
    role that mosaic deficiency in Rett females masks, then postnatal MeCP2 restoration
    could not fully rescue the male phenotype however early it were given. No published
    series reports birth head circumference for these boys, so the prenatal and postnatal
    contributions have never been separated. The entry therefore binds the neutral
    HP:0000252 parent term with a PROGRESSIVE clinical course rather than committing to
    HP:0011451 primary microcephaly or HP:0005484 secondary microcephaly.
  attaches_to:
  - pathophysiology#Reduced Brain Growth With Frontotemporal Predominance
  - pathophysiology#Cortical Malformation With Perisylvian Polymicrogyria
  proposed_experiments:
  - experiment_id: exp_male_mecp2_birth_head_circumference_series
    name: Retrospective birth-head-circumference series across reported MECP2 males
    description: >-
      Assemble birth and serial head circumference z-scores for every reported
      non-mosaic 46,XY MECP2 male, together with prenatal ultrasound biometry where
      available, and test whether head size is already reduced at birth in addition to
      decelerating postnatally, stratifying by variant class and by presence of cortical
      malformation on imaging or autopsy.
  - experiment_id: exp_prenatal_mecp2_null_cortical_development
    name: Prenatal cortical development in a hemizygous null model and human tissue
    description: >-
      Characterise cortical progenitor proliferation, neuronal migration and gyral
      patterning prenatally in hemizygous Mecp2-null mice and in MECP2-null human
      cortical organoids, to establish whether complete MeCP2 loss perturbs cortical
      development before birth in a way that heterozygous mosaic loss does not.
  evidence:
  - reference: PMID:17236109
    reference_title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The head growth decelerated from the age of 6 months and the feeding problems increased requiring gastrostomy."
    explanation: >-
      Establishes the postnatal, acquired arm of the microcephaly with an explicit age
      of deceleration, which is the half of the question that is settled.
  - reference: PMID:11930274
    reference_title: "MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Post mortem examination revealed bilateral polymicrogyria in the perisylvian region."
    explanation: >-
      A malformation that must arise prenatally, which is the strongest argument that an
      additional developmental component exists alongside the postnatal deceleration.
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At autopsy, the brain was small with disproportionate reduction of the frontal and temporal lobes."
    explanation: >-
      Documents the small brain at autopsy without establishing whether it was already
      small at birth, which is precisely the missing measurement.
  - reference: PMID:16832102
    reference_title: Early progressive encephalopathy in boys and MECP2 mutations.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Common features include failure to thrive, respiratory insufficiency, microcephaly, and abnormal motor control."
    explanation: >-
      Marked PARTIAL because it illustrates the gap directly, reporting microcephaly
      across the case set without specifying congenital versus acquired timing.
- discussion_id: mecp2_null_mouse_onset_mismatch
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    The hemizygous Mecp2-null male mouse is asymptomatic until five to six weeks of age,
    whereas the affected human male is encephalopathic from birth. Does this onset
    mismatch mean the model fails to capture the congenital arm of the human disease,
    even though it is otherwise the correct genotypic counterpart?
  rationale: >-
    This is the inverse of the usual model-fidelity problem, and it cuts both ways. The
    human neuropathology literature argues that the hemizygous null male, and not the
    heterozygous Rett female, is the true counterpart of the Mecp2-null male mouse, so
    the model's genotype is right, and the hemizygous male mouse does deliver the
    quantitative dendritic and spine phenotype. But the model's phenotype is right in
    kind and wrong in timing. It is normal until five weeks, and its authors interpret
    that delay as showing that MeCP2 is required for the stability of brain function
    rather than for brain development per se. The human male has no such asymptomatic
    interval, and in at least one case has a prenatally acquired cortical malformation.
    Either the mouse postnatal-maintenance interpretation understates a developmental
    role that only becomes visible under complete deficiency in a longer-gestation
    species, or the human congenital presentation reflects a species-specific prenatal
    requirement the mouse does not share. The model's own authors additionally caution
    that MeCP2 effects are context-dependent and cannot be generalized across mutation
    types and cell populations. Resolving this determines whether preclinical rescue
    timing in the mouse can be extrapolated to a human therapeutic window at all.
  attaches_to:
  - pathophysiology#Uniform Neuronal and Glial MeCP2 Deficiency
  - pathophysiology#Failure of Dendritic Arborization and Synaptogenesis
  proposed_experiments:
  - experiment_id: exp_mecp2_null_prenatal_phenotyping
    name: Prenatal and neonatal phenotyping of the hemizygous Mecp2-null mouse
    description: >-
      Phenotype hemizygous Mecp2-null mice prenatally and in the first postnatal week
      with quantitative dendritic morphometry, synaptophysin quantification, brain
      volumetry and plethysmographic respiratory monitoring, to test whether subclinical
      abnormalities matching the human neonatal findings precede the six-week
      symptomatic onset.
  - experiment_id: exp_human_organoid_versus_mouse_timing
    name: Comparative developmental timing in MECP2-null human organoids versus mouse
    description: >-
      Compare the developmental stage at which dendritic and synaptic deficits first
      appear in MECP2-null human cortical organoids against the corresponding stage in
      hemizygous Mecp2-null mouse cortex, to test whether the human requirement is
      earlier relative to corticogenesis.
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males with congenital encephalopathy, not females with RTT, represent the true human counterpart for the commonly studied Mecp2-/y mouse model and provide unique insight into the mechanisms of MeCP2 deficiency."
    explanation: >-
      Establishes the genotypic correctness of the model that makes the timing mismatch
      interesting rather than dismissible.
  - reference: PMID:11242117
    reference_title: A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The overlapping delay before symptom onset in humans and mice, despite their profoundly different rates of development, raises the possibility that stability of brain function, not brain development per se, is compromised by the absence of MeCP2."
    explanation: >-
      The model authors' own maintenance-not-development interpretation, which the
      congenital human male presentation challenges.
  - reference: PMID:11242118
    reference_title: Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Mecp2-null mice were normal until 5 weeks of age, when they began to develop disease, leading to death between 6 and 12 weeks."
    explanation: >-
      Quantifies the asymptomatic interval that the human male lacks.
  - reference: PMID:22412847
    reference_title: "MeCP2 mutation results in compartment-specific reductions in dendritic branching and spine density in layer 5 motor cortical neurons of YFP-H mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Our results support the view that the effects of MeCP2 mutation are highly context-dependent and cannot be generalized across mutation types and cell populations."
    explanation: >-
      The model literature's own caution against generalization, which compounds the
      translational uncertainty this mismatch raises.
- discussion_id: male_exclusion_from_mecp2_therapeutic_development
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Trofinetide and the AAV-MECP2 gene therapy programmes were developed and licensed in
    females with Rett syndrome. Is any of this therapeutic pipeline applicable to
    hemizygous males with neonatal-onset encephalopathy, and what would it take to find
    out?
  rationale: >-
    The question is worth asking at all because MeCP2 deficiency is not fixed damage.
    Reactivation of endogenous Mecp2 in young and adult mice reverses aspects of RTT-like
    pathology, which is the premise on which the whole gene-replacement programme rests
    and the reason a therapeutic window is a meaningful notion here rather than a
    hypothetical one.

    Yet this entity has no disease-specific therapeutic evidence at all, and the gap is
    structural rather than merely unstudied. The two lead AAV gene-therapy programmes
    enrol females by protocol: NGN-401 (NCT05898620) studies females with typical Rett
    syndrome, and TSHA-102/REVEAL (NCT06152237) studies pediatric females. Trofinetide is
    likewise approved for Rett syndrome. So the pipeline that this disorder's mechanism
    most directly motivates is one from which affected males are excluded by eligibility
    criteria, not merely under-represented.

    Two further considerations make simple extrapolation unsafe. MECP2-directed therapy is
    dosage-critical in both directions, since too little MeCP2 causes this disease and too
    much causes MECP2 duplication syndrome; and the male target population is uniformly
    null rather than mosaic, so the dose window that is safe and effective in a mosaic
    heterozygous female need not transfer. Meanwhile the practical barriers are severe:
    diagnosis is made years after presentation, long after the neonatal window in which
    intervention would matter most, and clinicians hold documented biases and
    misconceptions, chiefly the historical belief that MECP2 loss of function is lethal in
    males, that delay recognition. Investigators in the field have stated explicitly that
    equal access to emerging therapies for males is critical, and male-specific
    anticipatory guidance is acknowledged to be lacking.
  attaches_to:
  - pathophysiology#Uniform Neuronal and Glial MeCP2 Deficiency
  proposed_experiments:
  - experiment_id: exp_male_mecp2_natural_history_cohort
    name: Prospective male-specific MECP2 natural history cohort
    description: >-
      Establish a prospective natural history cohort restricted to males with pathogenic
      MECP2 variants, stratified by mosaic status and karyotype, with standardised
      respiratory, cardiac (including QTc and Holter), seizure, growth and developmental
      endpoints, to generate the survival and outcome measures that any trial in this
      population would need.
  - experiment_id: exp_hemizygous_null_gene_replacement_dose_window
    name: Dose-window determination for MECP2 replacement in the uniformly null state
    description: >-
      Determine, in hemizygous Mecp2-null mice and MECP2-null human neurons, the
      MeCP2 re-expression dose window that rescues dendritic and respiratory phenotypes
      without producing duplication-syndrome-like overexpression toxicity, and test
      whether that window differs from the window established in mosaic heterozygous
      female models.
  evidence:
  - reference: PMID:20298210
    reference_title: Reversibility of functional deficits in experimental models of Rett syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Recent evidence suggests that reactivation of endogenous Mecp2 in young and adult mice can reverse aspects of RTT-like pathology."
    explanation: >-
      The mechanistic premise of the gap. Because MeCP2 deficiency is reversible in the
      model rather than representing fixed damage, the therapeutic-window question is
      substantive; tagged MODEL_ORGANISM because the result is a mouse result.
  - reference: clinicaltrials:NCT05898620
    reference_title: "A Baseline-Controlled, Open-Label, Multicenter, Single-Arm, Pivotal Study to Evaluate the Efficacy, Safety, and Tolerability of NGN-401 in Subjects With Rett Syndrome (Embolden)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study will evaluate the efficacy and safety profiles of the investigational gene therapy, NGN-401, in females with typical Rett syndrome."
    explanation: >-
      Documents that the leading MECP2 gene-replacement trial restricts enrolment to
      females, making the exclusion concrete rather than inferred.
  - reference: clinicaltrials:NCT06152237
    reference_title: "A Multicenter, Open Label, Randomized, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, and Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, for the Treatment of Pediatric Females With Rett Syndrome"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The REVEAL Pediatric Study is a multi-center, Phase 1/2 open-label, dose-escalation and dose-expansion study of TSHA-102, an investigational gene therapy, in pediatric females with Rett Syndrome."
    explanation: >-
      A second independent AAV-MECP2 programme likewise restricted to females,
      establishing that the exclusion is a pattern across the pipeline.
  - reference: PMID:39476560
    reference_title: "MECP2 Variants in Males: More Common than Previously Appreciated."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Equal access to such therapies for males is critical."
    explanation: >-
      Field investigators state the equity gap in therapeutic access directly.
  - reference: PMID:39476560
    reference_title: "MECP2 Variants in Males: More Common than Previously Appreciated."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These data on males with MECP2 variants are important to caregivers, physicians, and researchers to begin to characterize their historical and clinical features, improve diagnostic recognition and overall care, and accelerate access to therapeutic studies including gene replacement strategies."
    explanation: >-
      Frames the male cohort as a prerequisite for therapeutic-study access, which is
      the content of this gap.
  - reference: PMID:40515634
    reference_title: Medical Biases and Misconceptions Impact Diagnoses in Males With Loss of Function MECP2 Variants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "As genetic testing becomes more widely available, age of genetic diagnosis is decreasing, resulting in more providers and families with unexpected results and a notable lack of male-specific anticipatory guidance and clinical recommendations."
    explanation: >-
      Documents the absence of male-specific clinical recommendations that this gap
      would close.
  - reference: PMID:40515634
    reference_title: Medical Biases and Misconceptions Impact Diagnoses in Males With Loss of Function MECP2 Variants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Qualitative findings demonstrate that medical biases and widespread misconceptions contribute to delays in accurate clinical diagnosis, which negatively impacts child health and family functioning."
    explanation: >-
      Identifies clinician bias as the mechanism of the diagnostic delay that
      forecloses early intervention.
- discussion_id: mechanism_of_sudden_death
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    How often is death in this entity cardiac (conduction failure) rather than
    respiratory, and should every affected male therefore have systematic cardiac
    conduction monitoring rather than QTc assessment alone?
  rationale: >-
    Two mechanisms of death are documented and they imply different surveillance. The
    autopsy-confirmed literature attributes death to central respiratory failure, which
    is consistent with the brainstem respiratory node. But a familial pair of affected
    brothers died suddenly at 17 and 30 months with sick sinus syndrome and severe
    bradycardia, a pattern that QTc assessment alone would not detect and that a
    pacemaker could in principle address. Because case numbers are tiny and post-mortem
    cardiac evaluation is not routine, the relative contribution of the two mechanisms is
    unknown, and the surveillance recommendation across MECP2 disorders, periodic QTc,
    may be calibrated to the female Rett phenotype rather than to this one.
  attaches_to:
  - pathophysiology#Cardiac Autonomic Conduction Instability
  - pathophysiology#Brainstem Respiratory Network Failure
  proposed_experiments:
  - experiment_id: exp_systematic_cardiac_monitoring_male_mecp2
    name: Systematic cardiac rhythm monitoring in males with pathogenic MECP2 variants
    description: >-
      Apply prospective ambulatory rhythm monitoring (Holter or implantable loop
      recorder) in addition to serial ECG and QTc measurement across an international
      cohort of males with pathogenic MECP2 variants, and record mode of death with
      structured cardiac and respiratory adjudication, to establish the relative
      contribution of conduction failure and central respiratory failure.
  evidence:
  - reference: PMID:29631775
    reference_title: MECP2 mutation in a boy with severe apnea and sick sinus syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, an increasing number of male patients with MECP2 mutations have been reported, including patients who suddenly died of unknown causes."
    explanation: >-
      States that sudden death of unknown cause is a recognised but unexplained outcome
      in affected males, which is the gap.
  - reference: PMID:29631775
    reference_title: MECP2 mutation in a boy with severe apnea and sick sinus syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This familial case might help to clarify the causes of sudden death in cases of MECP2 mutations."
    explanation: >-
      The authors position their conduction findings as a partial answer to that gap.
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He failed to thrive and to reach any motor milestones and died at 15 months from central respiratory failure without a diagnosis."
    explanation: >-
      The competing respiratory mechanism of death, against which the cardiac
      contribution must be weighed.
differential_diagnoses:
- name: Classic Rett syndrome
  description: >-
    The most important contrast, and the reason this entry exists as a separate entity.
    Classic Rett syndrome is caused by the same MECP2 loss-of-function variant classes,
    but in a heterozygous female whose random X-chromosome inactivation leaves half of
    her neurons expressing wild-type MeCP2. That mosaic buffer produces a completely
    different natural history, with apparently normal development for six to eighteen
    months, then regression with loss of acquired purposeful hand use and spoken
    language, hand stereotypies, gait abnormality, acquired head-growth deceleration, and
    survival into adulthood. The male entity has no normal interval to regress from,
    typically never attains motor milestones, and usually dies before age two. A male who
    nonetheless presents with a recognizable Rett phenotype is almost always a somatic
    mosaic or has 47,XXY Klinefelter syndrome, which is the exception that proves the
    mosaic-rescue rule.
  distinguishing_features:
  - Heterozygous female with mosaic MeCP2 loss, versus non-mosaic hemizygous 46,XY male
    with uniform MeCP2 loss
  - Apparently normal development for 6 to 18 months followed by regression, versus
    encephalopathy present from birth with no normal interval
  - Loss of previously acquired hand use and spoken language, versus typically never
    attaining any motor milestone
  - Hand stereotypies (hand wringing) are cardinal in Rett and are not features of the
    male neonatal-onset phenotype
  - Survival into adulthood is usual in Rett, whereas death often occurs before age two
    years here
  - A male with a classic Rett phenotype is almost always a somatic mosaic or 47,XXY, and
    therefore not this entity
  - Trofinetide is FDA-approved for Rett syndrome, whereas there is no approved or
    trial-tested therapy for the male neonatal-onset phenotype
  disease_term:
    preferred_term: Rett syndrome
    term:
      id: MONDO:0010726
      label: Rett syndrome
  evidence:
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Non-mosaic males with a 46,XY karyotype and a MECP2 null mutation display a phenotype of severe neonatal-onset encephalopathy that is distinctly different from Rett syndrome (RTT)."
    explanation: >-
      States the distinctness of the two entities in the terms that define the
      differential.
  - reference: PMID:10508514
    reference_title: "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with classic RTT appear to develop normally until 6-18 months of age, then gradually lose speech and purposeful hand use"
    explanation: >-
      The Rett side of the key discriminator, a normal interval followed by regression.
  - reference: PMID:34271245
    reference_title: "MECP2-related conditions in males: A systematic literature review and 8 additional cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The typical RS phenotype is not expected in males, except in those with Klinefelter syndrome or somatic mosaicism for MECP2."
    explanation: >-
      Establishes that a Rett phenotype in a male points to mosaicism or 47,XXY rather
      than to this entity.
  - reference: PMID:11738861
    reference_title: Rethinking the fate of males with mutations in the gene that causes Rett syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males who have MECP2 mutations and Klinefelter syndrome or who are mosaic for the mutation are more likely to present with a RTT-like phenotype."
    explanation: >-
      Independent statement of the same rule, from a different case set two decades
      earlier.
- name: MECP2 duplication syndrome
  description: >-
    The same gene with the opposite direction of dosage effect. MECP2 duplication
    syndrome arises from Xq28 copy-number gain rather than sequence loss of function, and
    it is males who are predominantly affected, usually inheriting the duplication from
    an apparently asymptomatic carrier mother. Both entities therefore present as severe
    X-linked neurodevelopmental disease in a male, which is exactly why they are
    confused, and the discriminator is the assay rather than the phenotype. Sequencing
    alone cannot separate them, so copy-number analysis is required. The distinction is
    not academic, because therapeutic logic is inverted, with MECP2 knockdown strategies
    rational in duplication syndrome and MECP2 replacement rational here, and
    copy-number-gain findings such as recurrent respiratory infection susceptibility must
    not be imported into this entry.
  distinguishing_features:
  - Xq28 copy-number gain (duplication or triplication) versus sequence loss-of-function
    variant
  - Increased MeCP2 dosage versus absent or severely dysfunctional MeCP2
  - Usually inherited from an apparently asymptomatic carrier mother versus mostly de
    novo
  - Requires copy-number analysis (array CGH, MLPA) to detect; sequencing alone will miss
    it and will also fail to exclude it
  - Survival is typically into later childhood and adulthood with progressive spasticity
    and recurrent respiratory infection, rather than death before age two
  - Therapeutic direction is inverted, with MeCP2 reduction the rational strategy in
    duplication syndrome and MeCP2 restoration the rational strategy here
  disease_term:
    preferred_term: MECP2 duplication syndrome
    term:
      id: MONDO:0010283
      label: syndromic X-linked intellectual disability Lubs type
  evidence:
  - reference: PMID:34502518
    reference_title: MECP2-Related Disorders in Males.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Conversely, the entire duplication of the MECP2 gene is related to MECP2 duplication syndrome (MDS). Unlike in RTT, in MDS, males are predominantly affected."
    explanation: >-
      States the copy-number-gain aetiology and the male predominance that make this the
      most confusable entity.
  - reference: PMID:34502518
    reference_title: MECP2-Related Disorders in Males.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Usually, the duplication is inherited from an apparently asymptomatic carrier mother."
    explanation: >-
      The inheritance discriminator. Note that a minimally affected carrier mother is
      also possible in this entity, so inheritance alone is insufficient.
  - reference: PMID:34502518
    reference_title: MECP2-Related Disorders in Males.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Loss-of-function mutations in MECP2 are associated with Rett syndrome (RTT), which is a well-characterized disorder that affects mainly females."
    explanation: >-
      Establishes the loss-of-function direction that separates this entry from
      duplication syndrome.
  - reference: PMID:37537631
    reference_title: "An insertion mutation of the MECP2 gene in severe neonatal encephalopathy and ocular and oropharyngeal dyskinesia: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pathogenic variation of the MECP2 gene presents mostly as Rett syndrome in females and is extremely rare in males. Most male patients with MECP2 gene mutation show MECP2 duplication syndrome."
    explanation: >-
      Documents the prior probability that drives the confusion, since a male with a
      MECP2 finding is more likely to have duplication syndrome, which is why this
      entity is under-recognised.
- name: Milder male MECP2 phenotypes (PPM-X and X-linked syndromic intellectual disability 13)
  description: >-
    The other two phenotypes produced by a single pathogenic copy of MECP2 in a male, and
    the correct intra-gene differential. Pyramidal signs with parkinsonism and
    macroorchidism (PPM-X) and X-linked intellectual deficiency 13 arise from the same
    hemizygous state and the same gene, so they cannot be separated from this entity by
    genotype class alone, and are separated instead by the functional severity of the
    variant. In the published record they are also more common than the severe neonatal
    phenotype, with 24 and 47 reported individuals respectively against 27. Recognising
    this gradient matters because a boy with a MECP2 variant and intellectual disability
    or late-onset parkinsonism and spasticity has a different prognosis and is not a mild
    case of this entity.
  distinguishing_features:
  - Later onset with intellectual disability, or adult-onset pyramidal signs,
    parkinsonism and macroorchidism, rather than encephalopathy from birth
  - Survival into adulthood rather than death before age two
  - Associated with less functionally damaging MECP2 variants; clinical severity across
    the male spectrum correlates with the measured functional impairment of MeCP2
  - More numerous in the published literature (47 XLMR13 and 24 PPM-X versus 27 severe
    neonatal encephalopathy)
  disease_term:
    preferred_term: X-linked intellectual disability-psychosis-macroorchidism syndrome
    term:
      id: MONDO:0010235
      label: X-linked intellectual disability-psychosis-macroorchidism syndrome
  evidence:
  - reference: PMID:34271245
    reference_title: "MECP2-related conditions in males: A systematic literature review and 8 additional cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three MECP2-associated phenotypes were seen in male carriers of a single copy of the gene: severe neonatal encephalopathy (n = 5); X-linked intellectual deficiency 13 (n = 2); and pyramidal signs, parkinsonism, and macroorchidism (PPM-X) (n = 1)."
    explanation: >-
      Enumerates the three male phenotypes that must be distinguished from one another.
  - reference: PMID:34271245
    reference_title: "MECP2-related conditions in males: A systematic literature review and 8 additional cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We were able to collect information on 27 published patients with severe neonatal encephalopathy, 47 individuals with isolated or familial mental retardation X-linked 13 (XLMR13), as well as 24 individuals with isolated or familial Pyramidal signs, parkinsonism, and macroorchidism (PPM-X)."
    explanation: >-
      Gives the relative published frequencies underlying the differential.
  - reference: PMID:27929079
    reference_title: "From Function to Phenotype: Impaired DNA Binding and Clustering Correlates with Clinical Severity in Males with Missense Mutations in MECP2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Overall, clinical severity showed a direct correlation with the functional impairment of MeCP2."
    explanation: >-
      Provides the mechanistic basis for the gradient that separates this entity from
      the milder male phenotypes.
- name: Neonatal hypoxic-ischemic encephalopathy and perinatal asphyxia
  description: >-
    The most consequential misdiagnosis in practice, because it is common, it is the
    default explanation for a hypotonic encephalopathic neonate with seizures, and it
    stops the diagnostic workup. Documented clinician biases and misconceptions,
    principally the historical belief that MECP2 loss of function is incompatible with
    life in males, push the diagnosis toward an acquired perinatal cause; the
    autopsy-confirmed index case in the literature died at 15 months without a diagnosis
    at all. Two features should redirect the workup. Hypoxia in this entity is centrally
    driven, caused by hypoventilation and irregular breathing rather than by a peripartum
    event, and the course is relentlessly progressive rather than static.
  distinguishing_features:
  - Hypoxia is centrally driven by hypoventilation and irregular breathing, rather than
    resulting from a peripartum hypoxic-ischemic event
  - Relentlessly progressive course resembling a metabolic-degenerative disease, rather
    than a static encephalopathy after a discrete insult
  - No sentinel perinatal event, and neuroimaging does not show a watershed or
    basal-ganglia-thalamic hypoxic-ischemic pattern
  - Requires a hemizygous MECP2 pathogenic variant for diagnosis, which is only found if
    genomic testing is actually sent
  - Type II muscle fiber hypotrophy on biopsy reflects chronic central hypoxia rather
    than an acute perinatal insult
  disease_term:
    preferred_term: perinatal asphyxia
    term:
      id: MONDO:0006663
      label: perinatal asphyxia
  evidence:
  - reference: PMID:40515634
    reference_title: Medical Biases and Misconceptions Impact Diagnoses in Males With Loss of Function MECP2 Variants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Qualitative findings demonstrate that medical biases and widespread misconceptions contribute to delays in accurate clinical diagnosis, which negatively impacts child health and family functioning."
    explanation: >-
      Documents that the misdiagnosis problem is real and measurable rather than
      hypothetical.
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The proband suffered from general hypotonia and hypoxia caused by hypoventilation and irregular breathing."
    explanation: >-
      The central (ventilatory) origin of the hypoxia is the key discriminator from a
      peripartum hypoxic-ischemic insult.
  - reference: PMID:18477000
    reference_title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He failed to thrive and to reach any motor milestones and died at 15 months from central respiratory failure without a diagnosis."
    explanation: >-
      Shows the real-world consequence of the misdiagnosis, namely death without a
      diagnosis.
  - reference: PMID:11738861
    reference_title: Rethinking the fate of males with mutations in the gene that causes Rett syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is likely that sporadic cases are not ascertained because of the relative non-specific congenital onset encephalopathy."
    explanation: >-
      Names clinical non-specificity as the reason these boys are assigned to generic
      neonatal-encephalopathy categories instead of being tested.
- name: CDKL5 deficiency disorder
  description: >-
    The leading genetic alternative when the presenting problem is an intractable
    neonatal or early-infantile epilepsy in an encephalopathic infant. CDKL5 deficiency
    disorder was historically classified as the early-onset seizure variant of Rett
    syndrome and is still routinely on the same gene panel, so a boy with early
    refractory seizures and profound developmental impairment will often be tested for
    both. It is separated by gene rather than by phenotype at the bedside, which is why
    the practical recommendation is a panel or exome that includes MECP2 rather than a
    clinical distinction.
  distinguishing_features:
  - Caused by CDKL5 rather than MECP2
  - Epilepsy dominates the presentation from the first weeks, whereas here seizures are
    one of several features of a broader congenital encephalopathy
  - Does not produce the central hypoventilation and irregular breathing pattern that is
    the hallmark respiratory lesion here
  - Survival beyond early childhood is usual
  disease_term:
    preferred_term: CDKL5 disorder
    term:
      id: MONDO:0100039
      label: CDKL5 disorder
  evidence:
  - reference: PMID:16832102
    reference_title: Early progressive encephalopathy in boys and MECP2 mutations.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "MECP2 mutations should be assessed in boys with progressive encephalopathy and one or more of respiratory insufficiency, abnormal movements or tone, and intractable seizures."
    explanation: >-
      Marked PARTIAL because it supports the shared clinical presentation, intractable
      seizures in a progressive encephalopathy, that puts these two genes on the same
      panel, rather than characterising CDKL5 disease itself.
- name: Bilateral perisylvian polymicrogyria
  description: >-
    A phenocopy relationship established by autopsy rather than by inference. An affected
    male with a MECP2 variant was found post-mortem to have bilateral perisylvian
    polymicrogyria more severe than any previously reported in Rett females, and the
    authors concluded he could be regarded as having a severe form of congenital
    perisylvian syndrome. The practical consequence is bidirectional. A bilateral
    perisylvian polymicrogyria syndrome should prompt MECP2 screening, and conversely a
    MECP2-confirmed male may carry a cortical malformation that its own genetic
    differential would otherwise claim.
  distinguishing_features:
  - Usually caused by other genetic or acquired causes of cortical malformation rather
    than by MECP2, so MECP2 must be added to the differential rather than assumed
  - The MECP2-related malformation is more severe than that described in Rett females
  - Accompanied here by the congenital encephalopathy, central hypoventilation and early
    death that define this entity, rather than by isolated pseudobulbar palsy and
    epilepsy
  disease_term:
    preferred_term: bilateral perisylvian polymicrogyria
    term:
      id: MONDO:0020340
      label: bilateral perisylvian polymicrogyria
  evidence:
  - reference: PMID:11930274
    reference_title: "MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "As bilateral polymicrogyria was described in congenital perisylvian syndrome, the presented patient could be regarded as having suffered from a severe form of this syndrome."
    explanation: >-
      The authors' own framing of the overlap between this entity and congenital
      perisylvian syndrome.
  - reference: PMID:11930274
    reference_title: "MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We conclude that MECP2 screening should be considered in males with severe neonatal encephalopathy and in males and females with a bilateral polymicrogyria syndrome."
    explanation: >-
      Establishes the bidirectional testing recommendation that makes this a real
      differential rather than a curiosity.
references:
- reference: PMID:20301670
  title: MECP2 Disorders.
  tags:
  - GeneReviews
- reference: PMID:18477000
  title: "Severe congenital encephalopathy caused by MECP2 null mutations in males: central
    hypoxia and reduced neuronal dendritic structure."
- reference: PMID:16832102
  title: Early progressive encephalopathy in boys and MECP2 mutations.
- reference: PMID:11930274
  title: "MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological
    and molecular findings."
- reference: PMID:11738861
  title: Rethinking the fate of males with mutations in the gene that causes Rett syndrome.
- reference: PMID:10577905
  title: "Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations
    at CpG hotspots."
- reference: PMID:17236109
  title: Male Rett phenotypes in T158M and R294X MeCP2-mutations.
- reference: PMID:34271245
  title: "MECP2-related conditions in males: A systematic literature review and 8 additional
    cases."
- reference: PMID:34502518
  title: MECP2-Related Disorders in Males.
- reference: PMID:39476560
  title: "MECP2 Variants in Males: More Common than Previously Appreciated."
- reference: PMID:40515634
  title: Medical Biases and Misconceptions Impact Diagnoses in Males With Loss of Function
    MECP2 Variants.
- reference: PMID:27929079
  title: "From Function to Phenotype: Impaired DNA Binding and Clustering Correlates with
    Clinical Severity in Males with Missense Mutations in MECP2."
- reference: PMID:37537631
  title: "An insertion mutation of the MECP2 gene in severe neonatal encephalopathy and
    ocular and oropharyngeal dyskinesia: a case report."
- reference: PMID:29631775
  title: MECP2 mutation in a boy with severe apnea and sick sinus syndrome.
- reference: PMID:22182064
  title: What does the nature of the MECP2 mutation tell us about parental origin and
    recurrence risk in Rett syndrome?
- reference: PMID:30405208
  title: Genomic mosaicism in the pathogenesis and inheritance of a Rett syndrome cohort.
- reference: PMID:10508514
  title: Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding
    protein 2.
- reference: PMID:18511691
  title: MeCP2, a key contributor to neurological disease, activates and represses transcription.
- reference: PMID:25232122
  title: Cell-type-specific repression by methyl-CpG-binding protein 2 is biased toward
    long genes.
- reference: PMID:19234456
  title: Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology.
- reference: PMID:11242117
  title: A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome.
- reference: PMID:11242118
  title: Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like
    phenotype in mice.
- reference: PMID:22412847
  title: "MeCP2 mutation results in compartment-specific reductions in dendritic branching
    and spine density in layer 5 motor cortical neurons of YFP-H mice."
- reference: PMID:20298210
  title: Reversibility of functional deficits in experimental models of Rett syndrome.

📚

References & Deep Research

References

PMID:20301670

MECP2 Disorders.

No top-level findings curated for this source.

PMID:18477000

Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure.

No top-level findings curated for this source.

PMID:16832102

Early progressive encephalopathy in boys and MECP2 mutations.

No top-level findings curated for this source.

PMID:11930274

MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings.

No top-level findings curated for this source.

PMID:11738861

Rethinking the fate of males with mutations in the gene that causes Rett syndrome.

No top-level findings curated for this source.

PMID:10577905

Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots.

No top-level findings curated for this source.

PMID:17236109

Male Rett phenotypes in T158M and R294X MeCP2-mutations.

No top-level findings curated for this source.

PMID:34271245

MECP2-related conditions in males: A systematic literature review and 8 additional cases.

No top-level findings curated for this source.

PMID:34502518

MECP2-Related Disorders in Males.

No top-level findings curated for this source.

PMID:39476560

MECP2 Variants in Males: More Common than Previously Appreciated.

No top-level findings curated for this source.

PMID:40515634

Medical Biases and Misconceptions Impact Diagnoses in Males With Loss of Function MECP2 Variants.

No top-level findings curated for this source.

PMID:27929079

From Function to Phenotype: Impaired DNA Binding and Clustering Correlates with Clinical Severity in Males with Missense Mutations in MECP2.

No top-level findings curated for this source.

PMID:37537631

An insertion mutation of the MECP2 gene in severe neonatal encephalopathy and ocular and oropharyngeal dyskinesia: a case report.

No top-level findings curated for this source.

PMID:29631775

MECP2 mutation in a boy with severe apnea and sick sinus syndrome.

No top-level findings curated for this source.

PMID:22182064

What does the nature of the MECP2 mutation tell us about parental origin and recurrence risk in Rett syndrome?

No top-level findings curated for this source.

PMID:30405208

Genomic mosaicism in the pathogenesis and inheritance of a Rett syndrome cohort.

No top-level findings curated for this source.

PMID:10508514

Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2.

No top-level findings curated for this source.

PMID:18511691

MeCP2, a key contributor to neurological disease, activates and represses transcription.

No top-level findings curated for this source.

PMID:25232122

Cell-type-specific repression by methyl-CpG-binding protein 2 is biased toward long genes.

No top-level findings curated for this source.

PMID:19234456

Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology.

No top-level findings curated for this source.

PMID:11242117

A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome.

No top-level findings curated for this source.

PMID:11242118

Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice.

No top-level findings curated for this source.

PMID:22412847

MeCP2 mutation results in compartment-specific reductions in dendritic branching and spine density in layer 5 motor cortical neurons of YFP-H mice.

No top-level findings curated for this source.

PMID:20298210

Reversibility of functional deficits in experimental models of Rett syndrome.

No top-level findings curated for this source.

Deep Research

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 19 citations 2026-08-01T11:55:00.306401

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Severe Neonatal-Onset Encephalopathy With Microcephaly
MONDO ID: (if available)
Category: Genetic

Research Objectives

Please provide a comprehensive research report on Severe Neonatal-Onset Encephalopathy With Microcephaly covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Severe Neonatal-Onset Encephalopathy With Microcephaly

Executive summary

Severe neonatal-onset encephalopathy with microcephaly is an ultra-rare, X-linked MECP2 loss-of-function (LoF) disorder, principally recognized in non-mosaic 46,XY infants. It represents the most severe end of the male MECP2-related spectrum: neurological impairment is evident from birth, often with hypotonia, respiratory failure or apnea, seizures, profound developmental impairment, acquired/progressive microcephaly, and death in infancy or early childhood. It must not be conflated with classic Rett syndrome, which usually affects heterozygous females after an initially normal developmental interval, or with MECP2 duplication syndrome, which results from increased rather than reduced MECP2 dosage. Open Targets identifies MECP2 as the sole associated target for this MONDO entity, supported by five evidence records (MONDO:0010397; ENSG00000169057). (OpenTargets Search: severe neonatal-onset encephalopathy with microcephaly-MECP2, pascualalonso2021mecp2relateddisordersin pages 2-4)

The evidence base is exceptionally small. Most disease-specific clinical evidence comes from individual patients, small series, and aggregated reviews of male MECP2 disorders; mechanistic, treatment, and model-organism evidence largely comes from Rett syndrome and Mecp2-null systems. Consequently, disease-specific prevalence, phenotype frequencies, survival curves, formal diagnostic criteria, validated biomarkers, and treatment-response statistics are unavailable.

Knowledge-base field	Best-supported value	Ontology/code suggestion	Evidence scope/caveat
Disease identity	Severe neonatal-onset encephalopathy with microcephaly is an ultra-rare MECP2 loss-of-function neurodevelopmental disorder, usually described in 46,XY males with neonatal encephalopathy and early death; distinct from classic female Rett syndrome and from MECP2 duplication syndrome	MONDO:0010397; gene MECP2; locus Xq28	Direct disease-gene association from Open Targets and male MECP2 reviews; disease-level aggregation rather than large epidemiologic cohorts (OpenTargets Search: severe neonatal-onset encephalopathy with microcephaly-MECP2, pascualalonso2021mecp2relateddisordersin pages 2-4)
Synonyms / related labels	Related labels in the literature include male MECP2 encephalopathy, male RTT encephalopathy, boys with severe neonatal encephalopathy and early death, and severe neonatal encephalopathy due to MECP2 mutation	MONDO:0010397; consider mapping related text synonyms only	Terminology varies across reviews/classifications; not all labels are fully synonymous, but they refer to the same severe male LoF end of the MECP2 spectrum (pascualalonso2021mecp2relateddisordersin pages 2-4, bernardo2024xlinkedepilepsiesa pages 14-17)
Distinguishing from Rett syndrome	Classic RTT usually affects girls after 6–18 months of apparently normal development with regression; in contrast, this disorder shows impairment from birth/neonatal period	Related disease: Rett syndrome; MECP2-related disorder	Much mechanistic/treatment literature is RTT-focused and only partly transferable to neonatal male disease (gold2024rettsyndrome pages 2-3, dominguez2024epigeneticregulationand pages 2-4, percy2024rettsyndromethe pages 1-2)
Distinguishing from MECP2 duplication syndrome	Not MECP2 duplication syndrome: MDS is caused by copy-number gain/duplication including MECP2 (often with IRAK1), whereas severe neonatal encephalopathy is caused by MECP2 sequence loss-of-function variants	MDS OMIM 300260; MECP2 duplication syndrome	Important negative distinction for knowledge-base curation; MDS phenotypes, prognosis, and therapeutic logic differ because of opposite dosage effect (pascualalonso2021mecp2relateddisordersin pages 2-4, pascualalonso2021mecp2relateddisordersin pages 5-7, pascualalonso2021mecp2relateddisordersin pages 7-8)
Causal gene / region	MECP2 (methyl-CpG binding protein 2), X-linked dosage-sensitive gene at Xq28	HGNC: MECP2; Ensembl target ENSG00000169057; cytoband Xq28	Strong direct support; Open Targets shows MECP2 as the sole associated target for MONDO:0010397 (OpenTargets Search: severe neonatal-onset encephalopathy with microcephaly-MECP2, gold2024rettsyndrome pages 2-3, vuu2023mecp2isan pages 4-5)
Molecular function	MeCP2 is a methylated-DNA-binding chromatin regulator that bridges methylated DNA to co-repressor complexes including NCoR/SMRT and HDAC3, regulating neuronal gene expression	GO: methyl-CpG binding, DNA-binding transcription corepressor activity, chromatin organization	Mechanism comes mainly from RTT/MECP2 biology and applies plausibly to the neonatal male LoF disorder because the causal lesion is the same gene with reduced function (dominguez2024epigeneticregulationand pages 2-4, vuu2023mecp2isan pages 4-5, ballas2009non–cellautonomousinfluence pages 1-2)
Inheritance	X-linked dominant/X-linked MECP2-related disorder with severe expression in hemizygous males; many severe cases are de novo, but maternally inherited pathogenic variants from mildly affected/asymptomatic mothers can occur	Inheritance term: X-linked	Male phenotype is modified by mosaicism and 47,XXY/Klinefelter syndrome; mothers may be protected by skewed X-inactivation, so inheritance counseling is essential (pascualalonso2021mecp2relateddisordersin pages 2-4, bernardo2024xlinkedepilepsiesa pages 14-17, pascualalonso2021mecp2relateddisordersin pages 4-5)
Modifier context	Surviving males with classic RTT phenotypes are often somatic mosaics or 47,XXY; non-mosaic 46,XY males with RTT-causing variants tend to show neonatal encephalopathy and early death	HPO conceptually relevant: mosaicism / sex chromosome aneuploidy	This is a major genotype-phenotype modifier and should be captured in interpretation notes (pascualalonso2021mecp2relateddisordersin pages 2-4, percy2024rettsyndromethe pages 1-2)
Representative pathogenic variant	Review literature cites c.806delG as a representative severe variant associated with severe neonatal encephalopathy and premature death	Variant example: MECP2 c.806delG (frameshift, presumed pathogenic/LoF)	Used here as a representative exemplar rather than a complete variant catalog; direct primary-case details are sparse in retrieved context (pascualalonso2021mecp2relateddisordersin pages 2-4)
Variant classes	Reported MECP2 variants in males include single-nucleotide variants, small deletions, small duplications, frameshift, nonsense, missense, and larger intragenic deletions; severe neonatal disease is most strongly associated with RTT-causing LoF variants	ACMG categories: pathogenic / likely pathogenic where established	Variant interpretation should not dismiss inherited variants because maternal skewed X-inactivation can mask phenotype (pascualalonso2021mecp2relateddisordersin pages 4-5, pascualalonso2021mecp2relateddisordersin pages 2-4)
Core phenotype: neonatal encephalopathy	Severe encephalopathy is evident from birth/neonatal period	HPO: Neonatal encephalopathy (HP:0001298)	Direct disease-defining feature from male MECP2 classifications/reviews (pascualalonso2021mecp2relateddisordersin pages 2-4, bernardo2024xlinkedepilepsiesa pages 14-17)
Core phenotype: microcephaly / head growth deceleration	Microcephaly is part of the disease label; deceleration of head growth is a recurrent MECP2-related feature	HPO: Microcephaly (HP:0000252); Progressive microcephaly (HP:0000253); Deceleration of head growth (HP:0000251)	Direct disease name supports microcephaly, but exact frequency in this neonatal subgroup was not available in retrieved evidence; some detailed head-growth data come from broader RTT literature (OpenTargets Search: severe neonatal-onset encephalopathy with microcephaly-MECP2, gold2024rettsyndrome pages 2-3, ballas2009non–cellautonomousinfluence pages 1-2)
Core phenotype: hypotonia	Marked neonatal/early hypotonia is commonly reported in severe male MECP2 disease	HPO: Hypotonia (HP:0001252)	Directly supported in male severe encephalopathy descriptions, though granular prevalence is not available here (bernardo2024xlinkedepilepsiesa pages 14-17)
Core phenotype: seizures / epilepsy	Seizures and often severe epilepsy can occur, including medically refractory epilepsy in male MECP2 disorders	HPO: Seizure (HP:0001250); Epileptic encephalopathy (HP:0200134)	Stronger evidence exists for broader male MECP2 encephalopathy / RTT-related epilepsy than for MONDO:0010397 alone (bernardo2024xlinkedepilepsiesa pages 14-17)
Core phenotype: respiratory dysfunction	Respiratory arrest/distress and ventilatory requirement are reported in severe male MECP2 encephalopathy; cardiorespiratory issues are major mortality drivers across MECP2 disorders	HPO: Abnormality of respiration (HP:0002795); Apnea (HP:0002104)	Directly relevant but much outcome detail is extrapolated from broader male RTT encephalopathy / RTT literature (bernardo2024xlinkedepilepsiesa pages 14-17, pascualalonso2021mecp2relateddisordersin pages 4-5, gold2024rettsyndrome pages 2-3)
Core phenotype: developmental impairment	Severe developmental delay/regression, absent or minimal language, and motor impairment are characteristic	HPO: Global developmental delay (HP:0001263); Severe intellectual disability (HP:0010864); Absent speech (HP:0001344)	Better documented in broader male MECP2 series than in this ultra-rare MONDO subset specifically (pascualalonso2021mecp2relateddisordersin pages 2-4, bernardo2024xlinkedepilepsiesa pages 14-17)
Phenotypic course	Usually congenital/neonatal onset, rapidly progressive, often with infantile death in non-mosaic 46,XY males	HPO: Infantile onset (HP:0003593); Progressive neurologic deterioration (HP:0002344)	Direct disease-spectrum support; exact stage definitions/natural-history curves are lacking (pascualalonso2021mecp2relateddisordersin pages 2-4, bernardo2024xlinkedepilepsiesa pages 14-17)
Primary anatomy affected	Central nervous system, especially brain	UBERON: brain (UBERON:0000955); central nervous system (UBERON:0001017)	Direct from disease phenotype and MeCP2 biology (gold2024rettsyndrome pages 2-3, ballas2009non–cellautonomousinfluence pages 1-2)
Tissue/cell types	Highest MeCP2 expression is in neurons, with expression also in astrocytes and oligodendrocytes; glial dysfunction can secondarily impair neurons	CL: neuron (CL:0000540); astrocyte (CL:0000127); oligodendrocyte (CL:0000128)	Cellular-pathophysiology evidence derives from RTT/MeCP2 experimental studies rather than neonatal male patients directly (gold2024rettsyndrome pages 2-3, vuu2023mecp2isan pages 4-5, ballas2009non–cellautonomousinfluence pages 1-2)
Subcellular/pathway mechanism	Loss of MeCP2 disrupts methylated-DNA reading, chromatin repression, activity-dependent gene regulation, neuronal maturation, dendritic arborization, and possibly mitochondrial/metabolic homeostasis	GO: regulation of transcription by RNA polymerase II, chromatin organization, neuron projection development, mitochondrion organization	Largely extrapolated from RTT, MeCP2-null mice, cellular models, and metabolic reviews; disease-specific neonatal human molecular profiling is lacking (dominguez2024epigeneticregulationand pages 2-4, vuu2023mecp2isan pages 4-5, ballas2009non–cellautonomousinfluence pages 1-2, balicza2024multilevelevidenceof pages 1-2)
Diagnostic approach	In a neonate/infant with severe encephalopathy, microcephaly, hypotonia, seizures, or respiratory crises, prioritize genomic testing including MECP2; NGS panels/WES/WGS improve detection, and high-depth data may help detect mosaicism	Testing terms: MECP2 sequencing, NGS panel, WES, WGS	Direct male MECP2 review support; no disease-specific formal guideline retrieved, so this is evidence-informed practice rather than consensus standard for MONDO:0010397 alone (pascualalonso2021mecp2relateddisordersin pages 4-5, pascualalonso2021mecp2relateddisordersin pages 2-4)
Cytogenetic / copy-number testing	If phenotype suggests MECP2-related disease, distinguish sequence LoF from duplication/triplication using sequencing plus copy-number methods (e.g., array-CGH/MLPA/FISH when indicated)	CMA / MLPA / FISH	Especially important to separate MONDO:0010397 from MDS; copy-number methods are more directly discussed for MDS than for this LoF disorder (pascualalonso2021mecp2relateddisordersin pages 7-8)
Differential diagnosis	Differential includes Rett syndrome in females, male RTT encephalopathy, other developmental/epileptic encephalopathies, mitochondrial disorders, and MECP2 duplication syndrome	Related disease groups: DEE / RTT / MDS	Based on phenotype overlap and diagnostic-testing literature; exact differential algorithms not retrieved (pascualalonso2021mecp2relateddisordersin pages 2-4, pascualalonso2021mecp2relateddisordersin pages 7-8, percy2024rettsyndromethe pages 1-2, balicza2024multilevelevidenceof pages 1-2)
Epidemiology	Ultra-rare; no reliable prevalence or incidence estimates specific to MONDO:0010397 were found in the retrieved sources	MONDO:0010397	Available population statistics concern RTT or MDS, not this neonatal male subtype; avoid imputing RTT prevalence to this disease (gold2024rettsyndrome pages 2-3, dominguez2024epigeneticregulationand pages 2-4)
Prognosis	Prognosis is generally poor in 46,XY severe neonatal cases, with early death/often within the first years of life; survival is better in mosaic or 47,XXY males and in milder male MECP2 phenotypes	Outcome field; HPO: Early death (HP:0003819)	Direct disease-spectrum evidence supports early mortality, but precise survival curves for MONDO:0010397 are unavailable (pascualalonso2021mecp2relateddisordersin pages 2-4, bernardo2024xlinkedepilepsiesa pages 14-17)
Current treatment	No disease-specific curative therapy established; management is supportive and multidisciplinary (respiratory support, seizure control, feeding/nutrition, rehabilitation, surveillance for complications)	NCIT-style intervention terms: supportive care, anticonvulsant therapy, respiratory support, physical therapy	Mostly extrapolated from RTT/male MECP2 disorder management because disease-specific trials/guidelines for neonatal male encephalopathy were not found (gold2024rettsyndrome pages 2-3, percy2024rettsyndromethe pages 13-15, percy2024rettsyndromethe pages 1-2)
Approved targeted therapy relevance	Trofinetide was FDA-approved in 2023 for Rett syndrome, but there is no direct evidence in severe neonatal-onset male encephalopathy with microcephaly	Drug: trofinetide	Important recent development, but applicability here is uncertain and currently extrapolative only (percy2024rettsyndromethe pages 13-15, gold2024rettsyndrome pages 14-14)
Gene therapy / advanced therapeutics	MECP2 gene replacement/editing is under active development for RTT; relevant listed studies include NCT06856759 (AAV-MECP2, active not recruiting, n=8), NCT05740761 (gene editing observational, recruiting, n=40), plus RTT-focused replacement trials discussed in reviews	Trial IDs as above	These are not disease-specific neonatal male trials; age ranges and trial populations usually exclude severely affected neonates/young infants (percy2024rettsyndromethe pages 13-15, jagadeeswaran2025preclinicalmilestonesin pages 2-3)
Related observational studies	MECP2/Rett observational resources include NCT02738281 natural history (completed, n=1044), NCT02705677 biobanking (completed, n=752), NCT05432349 Rett registry (recruiting, n=3000), NCT04502199 dysautonomic phenotype in male patients with MECP2 mutation (unknown status, n=20)	ClinicalTrials.gov IDs	Useful for evidence generation and potential phenotype harmonization; not specific treatment trials for MONDO:0010397 (percy2024rettsyndromethe pages 1-2)
Prevention / counseling	No primary prevention after conception is known; prevention focuses on genetic counseling, family testing, recurrence-risk assessment, and reproductive options, especially because apparently unaffected mothers may carry pathogenic variants with skewed X-inactivation	Genetic counseling intervention	Directly relevant because inherited maternal variants can be overlooked; prenatal/preimplantation options are logical but not directly discussed in retrieved disease-specific sources (pascualalonso2021mecp2relateddisordersin pages 4-5, pascualalonso2021mecp2relateddisordersin pages 2-4)
Model systems	Mecp2-null male mouse (Mecp2-/y) is the principal model for severe MECP2 loss-of-function; additional systems include hiPSC, brain organoids, and glia-neuron coculture models	Model resource terms: mouse knockout, hiPSC, organoid	These models mainly represent RTT/MECP2 loss-of-function biology broadly, but are highly relevant to this severe neonatal male phenotype (pascualalonso2021mecp2relateddisordersin pages 8-10, ballas2009non–cellautonomousinfluence pages 1-2, jagadeeswaran2025preclinicalmilestonesin pages 2-3)
Model findings of note	MeCP2 restoration in mouse models can produce significant improvement; MeCP2-null astrocytes impair neuronal dendritic morphology non-cell-autonomously; hiPSC studies suggest partial rescue with IGF1/KCC2-related approaches	GO/CL relevant: neuron projection development; astrocyte-neuron interaction	Preclinical and not yet disease-specific for MONDO:0010397; nevertheless central to mechanism and therapeutic rationale (pascualalonso2021mecp2relateddisordersin pages 8-10, ballas2009non–cellautonomousinfluence pages 1-2, percy2024rettsyndromethe pages 13-15)

Table: This table summarizes the best-supported knowledge-base fields for severe neonatal-onset encephalopathy with microcephaly (MONDO:0010397), emphasizing what is directly supported for this ultra-rare MECP2 loss-of-function disorder versus what is extrapolated from broader Rett syndrome and MECP2 biology literature.

1. Disease information

Definition and nomenclature

The preferred disease name is severe neonatal-onset encephalopathy with microcephaly. The principal identifier is MONDO:0010397. Literature labels include severe neonatal encephalopathy due to MECP2 mutation, male MECP2 encephalopathy, and, more broadly, male Rett encephalopathy. These labels are not perfectly interchangeable: “male Rett encephalopathy” has also been proposed for males who meet Rett clinical criteria, whereas the present entity is defined by impairment from birth and usually a much more rapidly lethal course. (OpenTargets Search: severe neonatal-onset encephalopathy with microcephaly-MECP2, pascualalonso2021mecp2relateddisordersin pages 4-5, pascualalonso2021mecp2relateddisordersin pages 2-4)

No disease-specific OMIM, Orphanet, MeSH, ICD-10, or ICD-11 code was verified in the retrieved evidence. Related but non-equivalent entries include Rett syndrome, OMIM 312750, and MECP2 duplication syndrome, OMIM 300260. A broad ICD code for neonatal encephalopathy or genetic neurodevelopmental disease may be used operationally, but it should not be represented as a disease-specific identifier. (pascualalonso2021mecp2relateddisordersin pages 5-7, dominguez2024epigeneticregulationand pages 2-4)

The foundational evidence is patient-derived, but modern resources aggregate those cases at disease level. A 2021 review reported 345 males with any MECP2 sequence variant in RettBASE, compared with 3,924 females; only an unspecified minority of those males had this severe neonatal phenotype. Thus, 345 is not a case count for MONDO:0010397. (pascualalonso2021mecp2relateddisordersin pages 2-4)

Critical nosological distinction

MECP2 is dosage-sensitive. Pathogenic sequence variants reducing MeCP2 function cause Rett/MECP2-LoF phenotypes, whereas duplication or triplication causes MECP2 duplication syndrome. Copy-number-gain statistics, infection susceptibility, and antisense strategies developed for duplication syndrome must therefore not be imported into this entity. (pascualalonso2021mecp2relateddisordersin pages 2-4, pascualalonso2021mecp2relateddisordersin pages 5-7, pascualalonso2021mecp2relateddisordersin pages 7-8)

2. Etiology and risk factors

The primary cause is a germline or mosaic pathogenic MECP2 variant that markedly reduces protein function in a hemizygous male. MECP2 lies at Xq28 and encodes methyl-CpG-binding protein 2. Reported classes across affected males include nonsense, frameshift, splice, missense, small insertion/deletion, and larger intragenic deletion variants. A representative severe allele is c.806delG, associated in the reviewed literature with severe neonatal encephalopathy and premature death. (pascualalonso2021mecp2relateddisordersin pages 2-4, gold2024rettsyndrome pages 2-3)

The major genetic modifiers are sex-chromosome complement and mosaicism. Non-mosaic 46,XY males carrying variants that cause Rett syndrome in females typically develop neonatal encephalopathy and die early. Males with somatic mosaicism or 47,XXY Klinefelter syndrome retain a population of cells expressing a normal allele and can instead manifest a more recognizable Rett phenotype. Variant position may also modify severity: one male cohort found higher clinical-severity scores for Rett-causing variants before codon 271 than for later variants. (pascualalonso2021mecp2relateddisordersin pages 4-5, pascualalonso2021mecp2relateddisordersin pages 2-4)

Variants may be de novo or inherited from a clinically normal or mildly affected heterozygous mother. Skewed X-chromosome inactivation can protect a carrier mother; therefore, maternal absence of obvious symptoms is not evidence against pathogenicity. Parental testing and careful evaluation for low-level mosaicism are essential. (bernardo2024xlinkedepilepsiesa pages 14-17, pascualalonso2021mecp2relateddisordersin pages 4-5)

No reproducible environmental, lifestyle, infectious, occupational, or dietary risk or protective factor is known. No validated protective MECP2 allele, modifier gene, founder mutation, or gene–environment interaction has been established for this specific phenotype. Environmental insults may worsen respiratory, nutritional, or seizure complications but are not known primary causes.

3. Phenotypes

The defining course is congenital or neonatal, severe, and generally progressive. The following HPO annotations are appropriate, although disease-specific percentages are unavailable:

Neonatal encephalopathy — HP:0001298: impairment is present from birth rather than after the 6–18-month apparently normal interval typical of classic Rett syndrome.
Microcephaly — HP:0000252, with progressive microcephaly — HP:0000253 or deceleration of head growth — HP:0000251 where longitudinal measurements support them. Exact neonatal-subgroup frequency is unknown.
Hypotonia — HP:0001252: often severe and associated with poor motor acquisition, feeding difficulty, and respiratory compromise.
Seizure — HP:0001250 and developmental and epileptic encephalopathy — HP:0200134: epilepsy can be early, severe, and medically refractory.
Apnea — HP:0002104, respiratory insufficiency — HP:0002093, and abnormal breathing: respiratory arrest and ventilatory dependence are prominent in severe males.
Global developmental delay — HP:0001263, profound intellectual disability — HP:0002187, absent speech — HP:0001344, and severe motor impairment.
Additional plausible MECP2-spectrum annotations include feeding difficulty, dysphagia, growth failure, abnormal muscle tone, stereotypic movements, bruxism, sleep disturbance, diminished pain response, autonomic dysfunction, and scoliosis, but their frequencies in this exact neonatal entity have not been quantified. (bernardo2024xlinkedepilepsiesa pages 14-17, pascualalonso2021mecp2relateddisordersin pages 4-5, gold2024rettsyndrome pages 2-3, ballas2009non–cellautonomousinfluence pages 1-2)

A 2024 epilepsy review summarized the severe presentation as neonatal encephalopathy with respiratory arrest and seizures, with death generally within two years. This is a review-level synthesis rather than a prospective natural-history estimate. (bernardo2024xlinkedepilepsiesa pages 14-17)

Quality-of-life instruments such as EQ-5D, SF-36, or PROMIS have not been validated in this population. Functional burden is nevertheless extreme: affected infants may require continuous caregiving, ventilation, tube feeding, antiseizure therapy, and palliative support. Family and caregiver burden has not been quantified specifically.

4. Genetic and molecular information

Causal gene: MECP2; approved name methyl-CpG binding protein 2; Ensembl ENSG00000169057; cytoband Xq28. The gene has four exons and produces the MeCP2E1 and MeCP2E2 isoforms by alternative exon usage. MeCP2E1 disruption is sufficient to cause Rett-spectrum disease, whereas MeCP2E2 appears less essential for the classic phenotype. (OpenTargets Search: severe neonatal-onset encephalopathy with microcephaly-MECP2, vuu2023mecp2isan pages 4-5)

Pathogenic alleles are constitutional unless demonstrated to be post-zygotic mosaic; this is not a somatic-cancer disorder. Population frequencies should be checked variant by variant in gnomAD. Highly penetrant severe LoF variants are expected to be absent or exceptionally rare among unaffected hemizygous males, but no disease-wide carrier frequency was identified.

ACMG/AMP interpretation should integrate: predicted LoF mechanism; previous occurrence in females with Rett syndrome or males with neonatal encephalopathy; de novo status; segregation; maternal X-inactivation; phenotype specificity; population absence; and functional evidence. An inherited allele should not automatically be downgraded because the mother is asymptomatic. No validated modifier gene or disease-specific epigenetic signature is currently available. (pascualalonso2021mecp2relateddisordersin pages 4-5)

Large Xq28 duplications and triplications are a differential diagnosis, not a cause of this entity. Conversely, intragenic deletions disrupting MECP2 can be causal. Karyotype is relevant for detecting 47,XXY, while chromosomal microarray or dosage analysis distinguishes deletion from duplication.

5. Environmental information

No toxin, radiation exposure, pollution source, maternal behavior, diet, alcohol, tobacco exposure, or infectious agent has been shown to cause this Mendelian disorder. There is no zoonotic or transmissible component. Standard infection prevention, aspiration reduction, nutrition, and respiratory care may reduce secondary morbidity but do not alter the inherited cause.

6. Mechanism and pathophysiology

MeCP2 is an abundant postnatal nuclear protein, particularly in mature neurons. Its methyl-CpG-binding domain recognizes methylated DNA, while its repression region recruits chromatin regulators including NCoR/SMRT and HDAC3. It also interacts with SIN3A, CoREST, and a recently described TCF20–PHF14–HMG20A chromatin complex. Disease variants can disrupt DNA binding, protein stability, nuclear localization, or co-repressor recruitment. (gold2024rettsyndrome pages 2-3, dominguez2024epigeneticregulationand pages 2-4, vuu2023mecp2isan pages 4-5)

A useful causal chain is:

hemizygous MECP2 LoF → deficient reading of methylated DNA and abnormal chromatin/transcriptional regulation → dysregulated activity-dependent and maturation programs in neurons plus abnormal glial support → impaired dendritic arborization, spine/synaptic function and neural-network activity → severe developmental impairment, seizures, autonomic/respiratory instability, and reduced postnatal brain growth.

Neurons are the principal affected population, but pathology is not exclusively cell autonomous. In a landmark mouse/coculture study, MeCP2-null astrocytes and their conditioned medium failed to support normal dendritic morphology in wild-type or mutant hippocampal neurons. The abstract states: “mutant astrocytes from a RTT mouse model, and their conditioned medium, fail to support normal dendritic morphology.” This supports a soluble-factor-mediated astrocyte-to-neuron contribution. (Ballas et al., Nature Neuroscience, published March 2009; DOI: https://doi.org/10.1038/nn.2275; PMID 19234456.) (ballas2009non–cellautonomousinfluence pages 1-2)

Metabolic evidence suggests downstream mitochondrial, glucose, and cholesterol abnormalities. A 2024 analysis described multilevel MECP2-associated mitochondrial dysfunction, but its index male had a broader MECP2 phenotype rather than proven MONDO:0010397. Such findings should be annotated as secondary or spectrum-level evidence, not a diagnostic metabolic signature. (dominguez2024epigeneticregulationand pages 2-4, balicza2024multilevelevidenceof pages 1-2)

Suggested ontology annotations include GO:0006355 regulation of DNA-templated transcription, GO:0006325 chromatin organization, GO:0031175 neuron projection development, and GO:0048666 neuron development. Relevant cells are neuron CL:0000540, astrocyte CL:0000127, oligodendrocyte CL:0000128, and oligodendrocyte precursor cells. No disease-specific single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic, or CRISPR-screen dataset was identified.

7. Anatomical structures affected

The primary organ is the brain and the primary system is the central nervous system: UBERON:0000955 brain and UBERON:0001017 central nervous system. Relevant neural tissues include cerebral cortex and hippocampal circuitry, although no single region explains the multisystem phenotype. Secondary involvement includes respiratory musculature and brainstem autonomic networks, gastrointestinal/feeding systems, musculoskeletal tissues, and growth regulation. (gold2024rettsyndrome pages 2-3, ballas2009non–cellautonomousinfluence pages 1-2)

At subcellular level, the principal compartment is the nucleus, including chromatin and transcriptional co-repressor complexes. Downstream abnormalities involve dendrites, dendritic spines, synapses, and potentially mitochondria. Disease lateralization is not expected; abnormalities are bilateral/systemic.

8. Temporal development

Onset is congenital or neonatal and may be acute in presentation—hypotonia, apnea, feeding failure, or seizures—but reflects an ongoing developmental disorder. Unlike classic Rett syndrome, there is generally no clearly normal early developmental phase. The course is chronic, rapidly progressive, and often fatal in infancy or early childhood. No validated stages, remission pattern, or disease-specific critical intervention window has been defined. (bernardo2024xlinkedepilepsiesa pages 14-17, pascualalonso2021mecp2relateddisordersin pages 2-4)

The neonatal and early postnatal period is biologically important because MeCP2 abundance increases with neuronal maturation. Preclinical rescue studies imply that established dysfunction is not wholly irreversible, but safe human dosage control is crucial because both deficiency and excess are pathogenic. (ballas2009non–cellautonomousinfluence pages 1-2, percy2024rettsyndromethe pages 13-15, jagadeeswaran2025preclinicalmilestonesin pages 2-3)

9. Inheritance and population

Inheritance is X-linked. Severe expression is expected in hemizygous males, while heterozygous females show variable expression because of X-inactivation. A carrier mother has a 50% probability of transmitting the allele in each pregnancy; transmitted pathogenic variants generally place sons at high risk of severe disease and daughters at risk of a Rett-spectrum phenotype, although actual expression depends on the allele and X-inactivation. De novo cases carry a low but non-zero recurrence risk because parental germline mosaicism may occur.

Penetrance is high for established severe LoF alleles in non-mosaic hemizygous males, but expressivity across all MECP2 variants is broad. Anticipation is not recognized. No founder effect, ethnic enrichment, geographic clustering, carrier-frequency estimate, consanguinity association, or reliable sex ratio for this exact entity is available. Its apparent male predominance is mechanistic and ascertainment-related, not an epidemiological male:female ratio from a registry.

No incidence or prevalence per 100,000 has been established. The approximately 1-in-10,000 figure cited for Rett syndrome must not be applied to this neonatal male condition. (dominguez2024epigeneticregulationand pages 2-4)

10. Diagnostics

Diagnosis requires recognition of a severe neonatal neurologic phenotype followed by molecular confirmation. Recommended evaluation includes:

Rapid trio genome or exome sequencing, or a comprehensive neonatal/developmental-epileptic encephalopathy panel that includes MECP2.
High-depth review for post-zygotic mosaicism; Sanger sequencing alone may miss low-level mosaicism.
Copy-number analysis to detect intragenic deletion and exclude MECP2 duplication/triplication.
Parental testing, maternal clinical assessment, and consideration of maternal X-inactivation studies.
Karyotype when 47,XXY is plausible.
Brain MRI, serial head circumference, EEG/video-EEG, swallow and nutrition assessment, cardiorespiratory monitoring, and testing for alternative metabolic/infectious causes according to presentation. (pascualalonso2021mecp2relateddisordersin pages 4-5, pascualalonso2021mecp2relateddisordersin pages 2-4)

WGS is particularly useful when panel/WES findings are negative because it can identify coding, splice, structural, and mosaic variants in one analysis. RNA sequencing may clarify suspected splice variants, but no validated disease-specific transcriptomic assay exists. CMA, FISH, and MLPA are adjuncts for dosage/cytogenetic questions; mitochondrial DNA and repeat-expansion testing are not routine unless the phenotype suggests a separate diagnosis.

Differential diagnoses include hypoxic–ischemic encephalopathy; congenital infection; metabolic/mitochondrial encephalopathy; other neonatal developmental and epileptic encephalopathies; CDKL5, FOXG1, SCN2A, KCNQ2, STXBP1, and PCDH19-related disorders; classic/atypical Rett syndrome; and MECP2 duplication syndrome. There are no universally accepted clinical criteria specific to MONDO:0010397 and no population newborn screen. Molecular cascade testing is appropriate after a familial variant is identified.

11. Outcome and prognosis

The historical prognosis for a non-mosaic 46,XY infant with a severe Rett-causing MECP2 allele is poor. Respiratory arrest, refractory epilepsy, aspiration/feeding complications, and global neurologic deterioration contribute to early mortality; reviews commonly describe death in the first year or by two years. Exact median survival and 5- or 10-year survival are unavailable. Mosaic and 47,XXY males, and males with hypomorphic variants, can survive much longer and should not be pooled with this entity. (pascualalonso2021mecp2relateddisordersin pages 2-4, bernardo2024xlinkedepilepsiesa pages 14-17)

Long-term recovery without molecular therapy is not expected. Disability is profound. No validated prognostic biomarker exists beyond genotype/function, mosaic fraction, sex-chromosome complement, respiratory dependence, and overall neurologic severity. The 2024 Rett primer cautions that life-expectancy estimates for boys with MECP2 variants remain unavailable because the phenotype is still being delineated. (gold2024rettsyndrome pages 2-3)

12. Treatment and current applications

There is no approved disease-modifying treatment specifically for this disorder. Management is individualized and multidisciplinary:

respiratory monitoring, airway clearance, oxygen or ventilation, and aspiration prevention;
standard genotype-agnostic antiseizure treatment, with epilepsy-specialist management for drug resistance;
swallow evaluation, caloric support, reflux/constipation treatment, and nasogastric or gastrostomy feeding when appropriate;
physical, occupational, communication, and positioning therapy;
surveillance for scoliosis, contractures, sleep disturbance, dysautonomia, and bone disease;
early palliative-care involvement and family psychosocial support.

Suggested NCIT intervention concepts are Supportive Care, Anticonvulsant Therapy, Mechanical Ventilation, Gastrostomy, Physical Therapy, Occupational Therapy, and Genetic Counseling.

Trofinetide, a synthetic IGF1-related tripeptide analogue, became the first FDA-approved Rett-specific drug in March 2023. However, its pivotal evidence concerns Rett syndrome—not neonatal male MECP2 encephalopathy—and improvement was incremental rather than curative. There is no evidence supporting routine extrapolation to critically ill neonates. (Percy et al., published September 2024; DOI: https://doi.org/10.1007/s40263-024-01106-y.) (percy2024rettsyndromethe pages 13-15, gold2024rettsyndrome pages 14-14)

MECP2 gene replacement is mechanistically attractive but dosage must be tightly controlled. RTT-focused trials include NGN-401 (NCT05898620) and TSHA-102/REVEAL (NCT06152237). Retrieved trial records also included an AAV-MECP2 study NCT06856759 (early phase 1, active but not recruiting, target n=8) and an observational gene-editing study NCT05740761 (recruiting, n=40). These programs generally enroll older children and do not establish safety or efficacy in neonatal males. Neonatal administration in rodents corresponds developmentally to preterm human infancy, a stage not covered by current trials. (percy2024rettsyndromethe pages 13-15, jagadeeswaran2025preclinicalmilestonesin pages 2-3)

Relevant observational resources include the completed Rett natural-history study NCT02738281 (n=1,044), completed biobank NCT02705677 (n=752), recruiting Rett registry NCT05432349 (planned n=3,000), and male MECP2 dysautonomia study NCT04502199 (planned n=20; status unknown). None is a disease-specific interventional trial for MONDO:0010397.

13. Prevention

There is no vaccine, lifestyle intervention, environmental avoidance strategy, or prophylactic medication that prevents a de novo MECP2 variant. Primary prevention is reproductive: genetic counseling, maternal and family testing, prenatal diagnosis, and—where legally and ethically available—preimplantation genetic testing for a known familial variant. Secondary prevention consists of rapid molecular diagnosis and anticipatory respiratory, seizure, and feeding management. Tertiary prevention targets aspiration, infection, malnutrition, contracture, and caregiver burden. (pascualalonso2021mecp2relateddisordersin pages 4-5)

14. Other species and natural disease

No naturally occurring veterinary counterpart, affected breed, or zoonotic transmission was identified. MECP2 orthologues are evolutionarily conserved across vertebrates, but published animal disease is predominantly engineered rather than naturally occurring. Comparative pathology supports conservation of neuronal maturation, synaptic, respiratory, and motor consequences of MeCP2 deficiency.

15. Model organisms

The principal model is the hemizygous Mecp2-null male mouse (Mecp2−/y), which develops an early severe neurological phenotype and mortality and therefore models the human male LoF state more directly than heterozygous female mice. Conditional deletion in neural progenitors approximates the global-null phenotype; deletion in post-mitotic neurons produces a similar but milder syndrome, demonstrating a major requirement in mature neurons. Genetic reactivation of normal Mecp2 can substantially rescue established abnormalities, establishing biological reversibility. (pascualalonso2021mecp2relateddisordersin pages 8-10, ballas2009non–cellautonomousinfluence pages 1-2, jagadeeswaran2025preclinicalmilestonesin pages 2-3)

Human systems include patient fibroblast-derived iPSCs, differentiated neurons, astrocyte–neuron cocultures, and region-specific brain organoids. Reported experimental rescue strategies include increasing KCC2, IGF1-related treatment, and LIN28 suppression; these remain preclinical and were developed primarily in Rett models. Organoid phenotypes vary by mutation and genetic background, which is useful for studying allelic heterogeneity but limits direct quantitative translation. (pascualalonso2021mecp2relateddisordersin pages 8-10)

Evidence-quality conclusion

The disease–gene relationship is strong, but disease-specific natural-history and therapeutic evidence is weak because the entity is defined from very few severe male cases. The most defensible knowledge-base representation is therefore: high confidence in MECP2 causality, X-linked inheritance, neonatal onset, severe neurologic/respiratory phenotype, microcephaly, and poor prognosis; moderate confidence in detailed phenotype expansion; and explicitly extrapolated evidence for molecular pathways, supportive management, biomarkers, and emerging Rett-directed therapies. Recent 2023–2024 work has materially advanced MECP2 chromatin biology, mitochondrial hypotheses, Rett gene therapy, and therapeutic development, but it has not yet produced a validated intervention for severe neonatal-onset encephalopathy with microcephaly. (dominguez2024epigeneticregulationand pages 2-4, percy2024rettsyndromethe pages 13-15, jagadeeswaran2025preclinicalmilestonesin pages 2-3, balicza2024multilevelevidenceof pages 1-2)

References

(OpenTargets Search: severe neonatal-onset encephalopathy with microcephaly-MECP2): Open Targets Query (severe neonatal-onset encephalopathy with microcephaly-MECP2, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(pascualalonso2021mecp2relateddisordersin pages 2-4): Ainhoa Pascual-Alonso, Antonio F. Martínez-Monseny, Clara Xiol, and Judith Armstrong. Mecp2-related disorders in males. International Journal of Molecular Sciences, 22:9610, Sep 2021. URL: https://doi.org/10.3390/ijms22179610, doi:10.3390/ijms22179610. This article has 57 citations.
(bernardo2024xlinkedepilepsiesa pages 14-17): Pia Bernardo, Claudia Cuccurullo, Marica Rubino, Gabriella De Vita, Gaetano Terrone, Leonilda Bilo, and Antonietta Coppola. X-linked epilepsies: a narrative review. International Journal of Molecular Sciences, 25:4110, Apr 2024. URL: https://doi.org/10.3390/ijms25074110, doi:10.3390/ijms25074110. This article has 14 citations.
(gold2024rettsyndrome pages 2-3): Wendy A. Gold, Alan K. Percy, Jeffrey L. Neul, Stuart R. Cobb, Lucas Pozzo-Miller, Jasmeen K. Issar, Bruria Ben-Zeev, Aglaia Vignoli, and Walter E. Kaufmann. Rett syndrome. Nov 2024. URL: https://doi.org/10.1038/s41572-024-00568-0, doi:10.1038/s41572-024-00568-0. This article has 82 citations.
(dominguez2024epigeneticregulationand pages 2-4): Gaea Dominguez, Yongji Wu, and Jian Zhou. Epigenetic regulation and neurodevelopmental disorders: from mecp2 to the tcf20/phf14 complex. Genes, 15:1653, Dec 2024. URL: https://doi.org/10.3390/genes15121653, doi:10.3390/genes15121653. This article has 7 citations.
(percy2024rettsyndromethe pages 1-2): Alan K. Percy, Amitha Ananth, and Jeffrey L. Neul. Rett syndrome: the emerging landscape of treatment strategies. CNS Drugs, 38:851-867, Sep 2024. URL: https://doi.org/10.1007/s40263-024-01106-y, doi:10.1007/s40263-024-01106-y. This article has 41 citations and is from a peer-reviewed journal.
(pascualalonso2021mecp2relateddisordersin pages 5-7): Ainhoa Pascual-Alonso, Antonio F. Martínez-Monseny, Clara Xiol, and Judith Armstrong. Mecp2-related disorders in males. International Journal of Molecular Sciences, 22:9610, Sep 2021. URL: https://doi.org/10.3390/ijms22179610, doi:10.3390/ijms22179610. This article has 57 citations.
(pascualalonso2021mecp2relateddisordersin pages 7-8): Ainhoa Pascual-Alonso, Antonio F. Martínez-Monseny, Clara Xiol, and Judith Armstrong. Mecp2-related disorders in males. International Journal of Molecular Sciences, 22:9610, Sep 2021. URL: https://doi.org/10.3390/ijms22179610, doi:10.3390/ijms22179610. This article has 57 citations.
(vuu2023mecp2isan pages 4-5): Yen My Vuu, Chris-Tiann Roberts, and Mojgan Rastegar. Mecp2 is an epigenetic factor that links dna methylation with brain metabolism. International Journal of Molecular Sciences, 24:4218, Feb 2023. URL: https://doi.org/10.3390/ijms24044218, doi:10.3390/ijms24044218. This article has 60 citations.
(ballas2009non–cellautonomousinfluence pages 1-2): Nurit Ballas, Daniel T Lioy, Christopher Grunseich, and Gail Mandel. Non–cell autonomous influence of mecp2-deficient glia on neuronal dendritic morphology. Nature Neuroscience, 12:311-317, Mar 2009. URL: https://doi.org/10.1038/nn.2275, doi:10.1038/nn.2275. This article has 574 citations and is from a highest quality peer-reviewed journal.
(pascualalonso2021mecp2relateddisordersin pages 4-5): Ainhoa Pascual-Alonso, Antonio F. Martínez-Monseny, Clara Xiol, and Judith Armstrong. Mecp2-related disorders in males. International Journal of Molecular Sciences, 22:9610, Sep 2021. URL: https://doi.org/10.3390/ijms22179610, doi:10.3390/ijms22179610. This article has 57 citations.
(balicza2024multilevelevidenceof pages 1-2): Peter Balicza, Andras Gezsi, Mariann Fedor, Judit C. Sagi, Aniko Gal, Noemi Agnes Varga, and Maria Judit Molnar. Multilevel evidence of mecp2-associated mitochondrial dysfunction and its therapeutic implications. Frontiers in Psychiatry, Jan 2024. URL: https://doi.org/10.3389/fpsyt.2023.1301272, doi:10.3389/fpsyt.2023.1301272. This article has 3 citations.
(percy2024rettsyndromethe pages 13-15): Alan K. Percy, Amitha Ananth, and Jeffrey L. Neul. Rett syndrome: the emerging landscape of treatment strategies. CNS Drugs, 38:851-867, Sep 2024. URL: https://doi.org/10.1007/s40263-024-01106-y, doi:10.1007/s40263-024-01106-y. This article has 41 citations and is from a peer-reviewed journal.
(gold2024rettsyndrome pages 14-14): Wendy A. Gold, Alan K. Percy, Jeffrey L. Neul, Stuart R. Cobb, Lucas Pozzo-Miller, Jasmeen K. Issar, Bruria Ben-Zeev, Aglaia Vignoli, and Walter E. Kaufmann. Rett syndrome. Nov 2024. URL: https://doi.org/10.1038/s41572-024-00568-0, doi:10.1038/s41572-024-00568-0. This article has 82 citations.
(jagadeeswaran2025preclinicalmilestonesin pages 2-3): Indumathy Jagadeeswaran, Jiyoung Oh, and Sarah E. Sinnett. Preclinical milestones in mecp2 gene transfer for treating rett syndrome. Developmental Neuroscience, 47:147-156, May 2024. URL: https://doi.org/10.1159/000539267, doi:10.1159/000539267. This article has 5 citations and is from a peer-reviewed journal.
(pascualalonso2021mecp2relateddisordersin pages 8-10): Ainhoa Pascual-Alonso, Antonio F. Martínez-Monseny, Clara Xiol, and Judith Armstrong. Mecp2-related disorders in males. International Journal of Molecular Sciences, 22:9610, Sep 2021. URL: https://doi.org/10.3390/ijms22179610, doi:10.3390/ijms22179610. This article has 57 citations.

Artifacts

Edison artifact artifact-00

OpenScientist ▸

1. Disease Information

openscientist-autonomous 37 citations 2026-08-01T12:33:52.903043

1. Disease Information

Overview. Severe neonatal-onset encephalopathy with microcephaly is the male-lethal-equivalent expression of MECP2 loss-of-function. In heterozygous females, one X carries a wild-type MECP2 allele and cellular mosaicism (via X-inactivation) permits survival with classic Rett syndrome. In hemizygous males (46,XY), a single mutant allele leaves every cell devoid of functional MeCP2, producing a much more severe, congenital-onset encephalopathy. Schanen (2001) reframed the earlier "male-lethal" dogma: "mutations in MECP2 that lead to the classical phenotype in females do not appear to result in prenatal lethality of affected hemizygous males. It is likely that sporadic cases are not ascertained because of the relative non-specific congenital onset encephalopathy" (PMID: 11738861).

Key identifiers.

Resource	Identifier
OMIM (phenotype)	#300673 — "Encephalopathy, neonatal severe, due to MECP2 mutations"
OMIM (gene)	*300005 (MECP2)
Orphanet	ORPHA:3095
Mondo	Severe neonatal-onset encephalopathy with microcephaly (MECP2-related)
Gene (HGNC)	HGNC:6990 (MECP2)
UniProt	P51608
NCBI Gene	4204 (human MECP2)
Cytoband	Xq28

Synonyms / alternative names. MECP2-related severe neonatal encephalopathy; severe neonatal encephalopathy due to MECP2 mutations; MECP2 encephalopathy in males; male Rett-equivalent encephalopathy. A C-terminal / exon-1 spectrum also exists (e.g., a rare MECP2_e1 exon-1 mutation reported in a male with severe neonatal encephalopathy, PMID: 27090848).

Information source. Predominantly from aggregated disease-level resources (OMIM, Orphanet) and from small individual case reports/series of affected males (e.g., PMID: 17236109), supplemented by the much larger female Rett cohorts and mouse models used as proxies for the MECP2 CNS phenotype.

2. Etiology

Primary cause — genetic. The disease is caused by germline (or mosaic) loss-of-function mutations in MECP2 at Xq28, inherited X-linked or, far more commonly, arising de novo. Amir et al. (1999) identified MECP2 as the Rett gene and proposed the classic model that "RTT is caused by an X-linked dominant mutation with lethality in hemizygous males" (PMID: 10508514) — a model later refined to recognize that males instead present with severe neonatal encephalopathy.

Genetic risk factors. The causal variants are the same recurrent LoF alleles seen in Rett syndrome: nonsense (R168X, R255X, R270X, R294X), frameshift, splice-site, large deletions (MBD/TRD), and the recurrent missense T158M. These cluster at CpG dinucleotide hotspots as C→T transitions: "All of the nucleotide substitutions involve C-->T transitions at CpG hotspots" (PMID: 10577905). Male sex (hemizygosity) is the principal modifier converting a Rett-causing allele into a lethal neonatal encephalopathy. A supernumerary X (Klinefelter, 47,XXY) can ameliorate the male phenotype toward a Rett-like course by re-introducing mosaicism.

Environmental risk factors. None established as causal. This is a monogenic disorder; there is no evidence for toxic, infectious, or lifestyle contributors to the primary etiology (contrast neonatal encephalopathy of hypoxic-ischemic/inflammatory origin, PMID: 25204207).

Protective factors. No genetic or environmental protective factors are established for the male entity. The only "protective" genetic circumstance is the presence of a second (wild-type) X allele (females, or Klinefelter males), which converts the disorder to the milder, mosaic Rett phenotype.

Gene–environment interactions. Not applicable/none documented for causation. Because the disorder is fully penetrant with complete LoF, phenotype is driven by genotype and zygosity rather than by environmental interaction.

3. Phenotypes

Core phenotype derived from male case series (e.g., T158M brothers and an R294X boy, PMID: 17236109) and the broader MECP2 spectrum. Lundvall (2006): "Two brothers with T158M mutations and normal karyotype had a severe early onset encephalopathy, progressive microcephaly, severe feeding problems, breathing and sleep disturbances. They died at the ages of 1 year and 8 months, and 3 years and 1 month."

Frequency anchors come from a MECP2 (Rett) cohort (PMID: 42213295): "Common features included locomotion difficulties (96%), microcephaly (64%), seizures (60%), and abnormal EEG (64%). Truncating variants (nonsense/frameshift) correlated with severe phenotypes." In hemizygous males the frequency and severity of each feature is typically higher/near-complete because there is no mosaic rescue.

Phenotype	Type	Onset	Severity	Course	Frequency (spectrum)	HPO term
Neonatal encephalopathy	Clinical sign	Neonatal/congenital	Severe	Progressive	Near-universal in males	HP:0007367 / HP:0500217
Acquired/progressive microcephaly	Physical	Postnatal (deceleration from ~6 mo)	Severe	Progressive	~64% (higher in males)	HP:0005484; HP:0000253
Intractable seizures / epileptic encephalopathy	Clinical sign	Neonatal–infantile	Severe	Progressive/refractory	~60% (EEG abn. ~64%)	HP:0011097; HP:0200134
Abnormal breathing (irregular respiration, apnea, central hypoventilation)	Clinical sign	Infantile	Severe	Fluctuating/episodic	Common	HP:0002793; HP:0002104; HP:0002871
Feeding difficulties (often gastrostomy)	Clinical sign	Neonatal	Severe	Progressive	Common	HP:0011968
Abnormal tone (hypotonia → rigidity/spasticity)	Clinical sign	Neonatal	Severe	Progressive	Common	HP:0001252 → HP:0001257
Dystonia	Clinical sign	Infantile	Moderate–severe	Progressive	Common	HP:0001332
Tremor	Clinical sign	Infantile	Variable	Fluctuating	Common	HP:0001337
Myoclonus	Clinical sign	Infantile	Variable	Episodic	Common	HP:0001336
Bruxism	Behavioral/sign	Infantile	Mild–moderate	Stable	Common	HP:0003763
Sleep disturbance	Behavioral	Infantile	Moderate	Fluctuating	Common	HP:0002360
Profound global developmental delay / absent milestones	Clinical sign	Neonatal	Profound	Static/absent acquisition	Near-universal	HP:0012736
Death in infancy/early childhood	Outcome	Infancy–early childhood	—	—	Frequent in males	HP:0001522

Quality-of-life impact. Profound and pervasive: affected boys have total care dependence, no independent mobility or communication, recurrent hospitalizations for seizures/respiratory events, and require gastrostomy feeding. No formal EQ-5D/SF-36/PROMIS data exist for this ultra-rare male entity; QoL is inferred from the profound multisystem burden and early mortality.

4. Genetic / Molecular Information

Causal gene. MECP2 (Xq28; HGNC:6990; OMIM gene *300005; UniProt P51608). Single causal gene; loss of function is the disease mechanism.

Pathogenic variants. - Recurrent hotspot alleles: R106W, R168X, R255X, R270X, R294X, R306C, T158M — plus frameshift/deletion alleles (e.g., 806delG/V288X). Missense variants concentrate in the methyl-binding domain (MBD); nonsense/frameshift in the transcriptional-repression domain (TRD). - Mutational mechanism: C→T transitions at CpG hotspots (PMID: 10577905). - Classification (ACMG/AMP): Pathogenic/Likely Pathogenic — LoF variants invoke PVS1; de novo occurrence PS2; hotspot PM1; missense-constraint PP2. - Population frequency: Essentially absent from gnomAD/1000 Genomes/ExAC — these highly deleterious alleles are not tolerated in the population. - Origin: Germline; overwhelmingly de novo. Somatic/germline mosaicism documented and directly pathogenic in males. - Functional consequence: Loss of function (missense in MBD disrupt methyl-DNA binding; truncating variants remove TRD/downstream domains).

Parental origin & recurrence. Mutations show a strong paternal-origin bias: "The parental origin was paternal in 84/88 [95.5%]… of sporadic Chinese cases" (PMID: 22182064) — reflecting errors during spermatogenesis at CpG sites. Germline and somatic mosaicism are important: "somatic MECP2 mosaicism contributes directly to the pathogenicity of Rett syndrome, especially in male patients", with germline MECP2 mosaicism in 5/21 (23.8%) fathers (PMID: 30405208).

Modifier genes. No classic modifier genes established; the principal severity modifiers are zygosity (hemizygous males most severe), presence of a second X (Klinefelter/mosaic aneuploidy → milder), variant type (truncating > missense; PMID: 42213295), and degree of mosaicism.

Epigenetic information. MeCP2 is itself an epigenetic reader (binds 5mC/5hmC). In discordant monozygotic Rett twins, differential DNA methylation at brain-relevant loci (MKX, CKB, FYN) correlated inversely with expression, illustrating epigenetic modulation of phenotype (PMID: 23805272).

Chromosomal abnormalities. Usually none — most cases carry a point mutation with a normal karyotype. Large exon-level deletions require MLPA/CMA; 47,XXY (Klinefelter) or X-chromosome mosaicism modifies phenotype and should be excluded by karyotype/FISH. (Note: the reciprocal MECP2 duplication syndrome — dosage gain — is a distinct male disorder, PMID: 39696717.)

5. Environmental Information

Environmental factors: None causal for this monogenic disorder. (Experimentally, endocrine disruptors such as triclosan can perturb MeCP2 methylation/function in rodents — PMID: 42172708 — but this is not a cause of the germline LoF disease.)
Lifestyle factors: Not applicable.
Infectious agents: None. Infection/inflammation cause acquired neonatal encephalopathy (PMID: 25204207) and enter the differential, but are not the etiology here.

6. Mechanism / Pathophysiology

Molecular function of MeCP2. MECP2 encodes an abundant nuclear methyl-CpG-binding protein that acts as a transcriptional regulator (both repressor and activator) and an interaction hub for DNA, RNA and transcription factors: "MECP2 is an important epigenetic regulator that plays a pivotal role in neuronal gene regulation, where it has been reported to function as both a repressor and an activator" (PMID: 40360671). It recruits co-repressor complexes (NCoR/SMRT, Sin3A–HDAC).

Long-gene de-repression. A key molecular signature of MeCP2 loss is preferential up-regulation of long genes enriched for neuronal connectivity functions: "genes upregulated following loss of MeCP2 are biased toward longer genes… suggesting MeCP2 may selectively repress long genes" (PMID: 25232122). This disrupts neuronal communication programs.

Failure of neuronal maturation (the core lesion). MeCP2 is required for post-mitotic neuronal maturation. Its loss delays maturation and reduces dendritic complexity and spine density: "delayed transition into a more mature stage, altered expression of presynaptic proteins and reduced dendritic spine density" (PMID: 17532643). In hemizygous mutant male mice, layer-5 cortical neurons show "Spine density… reduced by 47.4% in the apical tuft and 54.5% in secondary apical dendrites" (PMID: 22412847). Neurons are smaller, more densely packed, with reduced neuropil — explaining reduced brain and head size without neurodegeneration.

Systemic proteomic/metabolic dysregulation. "Mecp2- and MECP2-sensitive proteomes were enriched in synaptic and metabolic annotated gene products, the latter encompassing lipid metabolism and mitochondrial pathways" (PMID: 37712894), consistent with mitochondrial/energetic contributions to pathology.

Autonomic / brainstem dysfunction. MeCP2 loss produces autonomic instability driving cardiorespiratory features: "Included in the RTT phenotype are cardiorespiratory disorders involving the autonomic nervous system" (PMID: 21316312) — mediated by bioaminergic and BDNF signaling — underlying irregular breathing/apnea, QT/autonomic instability, and sudden-death risk.

Intrinsic reversibility. Restoration of endogenous Mecp2 rescues symptomatic animals: "reactivation of endogenous Mecp2 in young and adult mice can reverse aspects of RTT-like pathology" (PMID: 20298210; reviewed PMID: 21916843), yielding functionally mature neurons — the disorder is a maturation deficit, not fixed damage.

Causal chain

MECP2 LoF mutation (Xq28, C→T at CpG hotspot; hemizygous → no wild-type MeCP2)
│
▼
Loss of methyl-CpG-binding transcriptional regulation
│  ├─► De-repression of LONG neuronal genes (connectivity programs)
│  └─► Dysregulated synaptic + mitochondrial/lipid proteome
▼
Failure of post-mitotic NEURONAL MATURATION
   (↓ dendritic branching, ↓ spine density, ↓ neuropil; smaller, denser neurons)
│
▼
Globally reduced brain volume  ──►  ACQUIRED / PROGRESSIVE MICROCEPHALY
│
├─► Cortical circuit dysfunction ──► epileptic encephalopathy, profound DD
└─► Brainstem / autonomic dysfunction ──► apnea, irregular breathing,
                                           cardiac instability ──► early death
│
▼
(Intrinsically REVERSIBLE on MeCP2 restoration in models)

Upstream vs downstream. Upstream: MECP2 LoF → transcriptional dysregulation. Downstream: impaired neuronal maturation → structural (microcephaly) and functional (seizure, autonomic) consequences. Cell types: post-mitotic neurons (cortical pyramidal, hippocampal granule; CL:0000540 neuron, CL:0000679 glutamatergic neuron), with contributions from astrocytes/microglia. GO terms: methyl-CpG binding (GO:0008327), chromatin binding (GO:0003682), negative regulation of transcription (GO:0000122), nervous system development (GO:0007399), dendritic spine development (GO:0060996), synapse organization (GO:0050808).

7. Anatomical Structures Affected

Organ level (primary): Brain (UBERON:0000955) — central nervous system (UBERON:0001017). Global, symmetric involvement; cerebral cortex predominant. Brainstem/autonomic centers affected (respiratory/cardiac control).
Secondary organ involvement: Respiratory system (apnea/hypoventilation), heart (autonomic dysrhythmia, QT prolongation), gastrointestinal tract (feeding failure, dysmotility), musculoskeletal (tone abnormalities, contractures/scoliosis in survivors).
Body systems: Nervous (primary), respiratory, cardiovascular (autonomic), digestive.
Tissue/cell level: Nervous tissue; post-mitotic neurons are the principal affected cell population (cortical pyramidal neurons CL:0000598; glutamatergic neurons CL:0000679; hippocampal granule neurons). Glia secondarily involved.
Subcellular level: Nucleus / chromatin (GO:0000785) — site of MeCP2 action; dendritic spine (GO:0043197) and synapse (GO:0045202) — reduced; mitochondrion (GO:0005739) — dysfunctional metabolism/proteostasis.
Localization & lateralization: Diffuse and bilateral/symmetric. Imaging shows global volume reduction with cortical predominance but no focal malformation: "Global and regional volumes were reduced in RTT… Total gray matter was reduced by 19%" (PMID: 40381456); "Significantly smaller volumes were observed in all brain regions" with cortical dominance (PMID: 40147315).

8. Temporal Development

Onset: Congenital / neonatal. Encephalopathy is apparent at or shortly after birth in hemizygous males (unlike females, who typically have a normal early period then regression). Onset pattern is early and rapidly progressive.
Microcephaly timing: Acquired/postnatal — head-growth deceleration (e.g., from ~6 months in an R294X boy), i.e., normal or near-normal OFC at birth followed by progressive microcephaly (PMID: 17236109).
Progression: Rapid and relentless in males; profound impairment with no meaningful developmental gains.
Course pattern: Progressive with superimposed episodic events (seizures, apneic/breathing crises).
Duration: Chronic but short — frequently fatal in infancy/early childhood (documented deaths at 1 y 8 mo and 3 y 1 mo, PMID: 17236109).
Critical periods / intervention windows: Because the disorder is a maturation deficit that is reversible on MeCP2 restoration in models even in adulthood (PMID: 20298210), there is a theoretically broad therapeutic window for gene-directed restoration — a central rationale for gene-replacement development.

9. Inheritance and Population

Epidemiology: Classic Rett affects "approximately 1 in 10,000–15,000 females" (PMID: 41641323). The severe male neonatal encephalopathy is far rarer — only dozens of reported cases worldwide; Orphanet ORPHA:3095 lists prevalence as unknown/<1:1,000,000 — reflecting both the rarity of a male surviving to birth with a null allele and under-ascertainment as "non-specific" neonatal encephalopathy.
Inheritance: X-linked. Predominantly de novo; rare familial cases via carrier mothers. Strong paternal origin of de novo mutations (~95.5%; PMID: 22182064).
Penetrance / expressivity: Complete penetrance in hemizygous males (no mosaic rescue); expressivity uniform-severe. In females, X-inactivation drives variable expressivity.
Genetic anticipation: Not applicable (not a repeat-expansion disorder).
Germline / somatic mosaicism: Common and clinically important — germline mosaicism in ~24% of fathers; somatic mosaicism directly pathogenic in males (PMID: 30405208).
Founder effects / carrier frequency: No founder effect; pathogenic alleles essentially absent from population databases (recurrent de novo generation at CpG hotspots rather than inherited carriage).
Consanguinity: Not relevant (X-linked de novo, not autosomal recessive).
Demographics: No ethnic predilection; recurrent CpG-hotspot mechanism is universal. Sex ratio: this severe neonatal entity is essentially male-specific (the counterpart female disorder is Rett syndrome). Age distribution: neonates/infants/young children.

10. Diagnostics

Diagnostic approach is molecular. - Genetic testing (definitive): Sequencing of MECP2 — single-gene, or via neonatal-encephalopathy/epilepsy/ID NGS panels or WES/WGS — plus MLPA/CMA to detect exon-level deletions/duplications. Karyotype/FISH if Klinefelter (47,XXY) or large rearrangement is suspected. Maternal testing informs recurrence risk. WES/WGS have high yield in neonatal-onset epileptic encephalopathy cohorts; neonatal onset and autistic features associate with positive genetic diagnosis (PMID: 42394473). - Supportive imaging: Brain MRI shows global, symmetric volume reduction without focal malformation (PMID: 40381456; PMID: 40147315) — a useful distinguishing feature from malformative/metabolic mimics. - EEG: Abnormal in ~64% — multifocal epileptiform activity, background disorganization, sometimes burst-suppression/hypsarrhythmia (PMID: 42213295). Neonatal-onset epilepsy with slow background/multifocal discharges predicts drug resistance and severe DD/ID (PMID: 41818656). - Laboratory / metabolic work-up: Routine metabolic screen is normal — helps exclude treatable metabolic mimics. No specific biochemical biomarker exists. - Biopsy/pathology: Not diagnostic; not indicated.

Clinical criteria / differential diagnosis. No formal consensus criteria for the male entity; diagnosis rests on the clinical picture (severe neonatal encephalopathy + progressive microcephaly + intractable seizures + breathing/feeding disturbance) confirmed by MECP2 testing. Key differentials (other neonatal/early-infantile epileptic encephalopathies with microcephaly):

Differential	Gene	Distinguishing features	Reference
CDKL5 deficiency disorder	CDKL5	Early epilepsy, Rett-like; cerebral volume loss	PMID: 41619470
FOXG1 (congenital Rett variant)	FOXG1	Congenital microcephaly, corpus callosum abnormality	—
Molybdenum cofactor / sulfite oxidase deficiency	MOCS1/2, SUOX	HIE-like MRI, ↑sulfite, refractory seizures, early death	PMID: 40134165; PMID: 34957373
Asparagine synthetase deficiency	ASNS	Congenital microcephaly, progressive atrophy	PMID: 31617495
AIMP1 EOEE with burst suppression	AIMP1	Burst-suppression EEG, hypomyelination	PMID: 32531460
STXBP1 / KCNQ2 / ARX encephalopathies	STXBP1, KCNQ2, ARX	Distinct EEG/genetic profiles	—

Screening. Not part of newborn screening. Diagnosis is reactive (symptomatic), followed by cascade/carrier testing of at-risk relatives.

11. Outcome / Prognosis

Survival / mortality: Poor. Hemizygous (null) males frequently die in infancy or early childhood (e.g., 1 y 8 mo and 3 y 1 mo; PMID: 17236109). Causes of death: respiratory failure/apnea, aspiration/pneumonia, intractable seizures, and autonomic-cardiac instability (PMID: 21316312).
Morbidity / function: Survivors have profound intellectual disability, no independent mobility/communication, and total care dependence.
Complications: Recurrent respiratory infections, seizure-related morbidity, feeding failure/aspiration, dysautonomia, scoliosis/contractures.
Recovery potential: None spontaneously; the disorder is intrinsically reversible in models on MeCP2 restoration (PMID: 20298210), but no such therapy is yet available for patients.
Prognostic factors: Variant type (truncating > missense severity; PMID: 42213295); zygosity/degree of mosaicism; presence of a second X (Klinefelter → milder). Neonatal onset + abnormal EEG predict worse outcome (PMID: 41818656).
Prognostic biomarkers: None validated beyond genotype.

12. Treatment

No curative therapy exists; management is supportive/palliative.

Pharmacotherapy (symptomatic): Anticonvulsants for intractable seizures (often drug-resistant); agents for dystonia/movement disorder; treatment of dysautonomia; management of sleep disturbance. Pharmacogenomics: none specific to this disorder.
Disease-modifying (spectrum): Trofinetide (NCIT-relevant: glycine-proline-glutamate / IGF-1 analog) is "the first available treatment for Rett syndrome (RTT) and is approved in the United States in adults and pediatric patients aged ≥2 years" (PMID: 40043705). Important caveat: trials were in females with classic Rett; there is no approved indication for the severe male neonatal encephalopathy. The IGF-1 rationale derives from preclinical rescue of synaptic maturation and brain weight (PMID: 19208815).
Advanced / experimental (preclinical):
AAV MECP2 gene replacement — leading avenue, rationalized by intrinsic reversibility (PMID: 20298210; human-ready mini-MECP2 constructs, PMID: 38254921).
Protein-restoration and repurposing: intranasal NGF improves neurological/metabolic function in Mecp2-null mice (PMID: 39300821); vorinostat (HDAC inhibitor) improved CNS and non-CNS phenotypes in MeCP2-null mice/Xenopus after symptom onset (PMID: 40595330). (RNA-editing/Cas13 strategies target the reciprocal duplication syndrome, PMID: 39668251.)
Surgical/interventional: Gastrostomy for feeding failure; respiratory support; scoliosis management in survivors.
Supportive/rehabilitative: Physical, occupational, and communication therapy; nutritional and respiratory support; palliative care.
Treatment outcomes: Symptomatic only; no therapy alters the underlying trajectory in males to date.

NCIT-relevant terms: Trofinetide; Gene Therapy; Adeno-associated Viral Vector; Supportive Care; Anticonvulsant Agent; Gastrostomy.

13. Prevention

Primary prevention: None for de novo cases (the majority). Genetic counseling is the cornerstone.
Secondary prevention: Not applicable (no presymptomatic window; not in newborn screening).
Tertiary prevention: Aggressive management of seizures, respiratory events, feeding/aspiration, and dysautonomia to reduce complications/mortality.
Genetic counseling: Emphasize de novo/paternal-origin biology and residual recurrence risk from germline mosaicism (~24% of fathers; PMID: 30405208). Recurrence risk in the general population is otherwise low, but not zero for a couple with an affected child.
Reproductive options: Prenatal diagnosis and preimplantation genetic testing (PGT-M) for families with a known MECP2 variant; cascade testing of at-risk female relatives.
Immunization / public health / environmental: Not applicable (monogenic, non-infectious, non-environmental).

14. Other Species / Natural Disease

Taxonomy: Mus musculus (NCBI:txid10090) is the principal model species. Orthologs also in rat, zebrafish, Drosophila, and nonhuman primate.
Ortholog: Mouse Mecp2 (NCBI Gene 17257); zebrafish mecp2; conserved methyl-CpG-binding function across vertebrates.
Natural disease in other species: No well-characterized naturally occurring MECP2 encephalopathy in companion animals/wildlife is established (OMIA); the disorder is studied via engineered models rather than natural animal disease.
Comparative biology: MeCP2 function and the maturation-deficit phenotype are evolutionarily conserved; mouse models faithfully reproduce the reduced-brain-volume, cardiorespiratory, and reversibility phenotypes.
Transmission / zoonosis: Not applicable (genetic, non-transmissible).

15. Model Organisms

Mouse (primary): Male hemizygous Mecp2-null lines (Mecp2^tm1.1Bird, Mecp2^tm1.1Jae) phenocopy the human disorder — a normal early period followed by postnatal onset of hypoactivity, tremor, breathing abnormalities, hindlimb clasping, weight change, and premature death. MRI shows "an overall reduction of the brain volume" and delayed brain growth (PMID: 36931532). Conditional/reactivatable (Lox-Stop) alleles enabled the landmark reversibility experiments (PMID: 20298210).
Genetic model types: Knockout, conditional/reactivatable, knock-in (point mutations), and humanized MECP2 (used chiefly for the duplication syndrome).
Other systems: Rat, zebrafish (mecp2), Drosophila, nonhuman primate (cynomolgus, used for gene-therapy proof-of-concept), and patient iPSC-derived neurons/organoids and Xenopus laevis tadpole models for drug screening (PMID: 40595330).
Phenotype recapitulation: Strong for CNS (reduced spine density, reduced brain volume, cardiorespiratory dysfunction) and reversibility. Limitations: Mouse models reproduce the postnatal-regression Rett-like course better than the extreme congenital male-neonatal severity; timing and lifespan differ; non-CNS/systemic features partially captured.
Applications: Mechanism (long-gene regulation, maturation), preclinical therapy testing (gene replacement, IGF-1/NGF, HDAC inhibitors), biomarker and natural-history studies.
Resources: MGI, IMPC/IMSR (mouse); ZFIN (zebrafish); RGD (rat); Alliance of Genome Resources.

Mechanistic Model / Interpretation

The unifying model is that severe neonatal-onset encephalopathy with microcephaly is what MECP2 loss-of-function looks like when there is no wild-type MeCP2 in any cell. In females, X-inactivation produces a cellular mosaic (roughly half wild-type, half mutant neurons), yielding the classic Rett course with a symptom-free interval and regression. In hemizygous males, every neuron is MeCP2-deficient from the outset, so the maturation program fails uniformly and early — hence congenital/neonatal onset, uniform severity, progressive microcephaly, and early death.

The microcephaly is emphatically not neurodegeneration: neurons are present but arrested in an immature state — smaller somata, sparse dendrites, markedly reduced spine density, and reduced neuropil — producing globally reduced brain volume and thus a small head that becomes progressively smaller as the brain fails to grow normally postnatally. This is corroborated at the cellular level (47–54% spine-density reductions in male-mutant cortical neurons, PMID: 22412847) and the whole-brain level (19% gray-matter reduction, uniform/non-focal, PMID: 40381456). The reversibility of the mouse phenotype on MeCP2 restoration confirms that the lesion is a modifiable maturation deficit, not fixed structural loss — the single most therapeutically important insight, underpinning MECP2 gene-replacement programs.

The cardiorespiratory and sudden-death features trace to brainstem/autonomic dysfunction (bioaminergic + BDNF signaling; PMID: 21316312), while the seizure/encephalopathy features trace to cortical circuit dysfunction from long-gene de-repression (PMID: 25232122) and synaptic immaturity. Systemic proteomic data (PMID: 37712894) add a mitochondrial/metabolic layer that may explain feeding failure, growth issues, and energetic vulnerability.

Evidence Base

PMID	Title (abbrev.)	Supports
11738861	Rethinking the fate of males with MECP2 mutations	Redefines male "lethality" as neonatal encephalopathy — disease identity
17236109	Male Rett phenotypes T158M/R294X	Core clinical description, progressive microcephaly, early death
27090848	MECP2_e1 mutation in male neonatal encephalopathy	Confirms the male entity; exon-1 spectrum
10508514	MECP2 is the Rett gene	Establishes causal X-linked gene, male-lethality model
10577905	Recurrent MECP2 mutations at CpG hotspots	C→T CpG-hotspot mutational mechanism
22182064	Parental origin of MECP2 mutations	~95.5% paternal origin; recurrence-risk implications
30405208	Genomic mosaicism in Rett cohort	Somatic/germline mosaicism; male pathogenicity; counseling
40360671	Complexity of MECP2 function	MeCP2 as neuronal epigenetic regulator (repressor+activator)
25232122	MeCP2 represses long genes	Long-gene de-repression signature
17532643	Mecp2 deficiency → delayed maturation	Neuronal maturation deficit, reduced spines
22412847	Spine/branching reductions in male-mutant cortex	Quantified deficit in hemizygous males
19208815	Partial reversal with IGF-1 peptide	Links maturation deficit to brain weight; IGF-1/trofinetide rationale
37712894	Systemic proteome in Mecp2 mutants	Synaptic + mitochondrial/lipid dysregulation
21316312	Autonomic dysfunction in Rett	Cardiorespiratory/sudden-death mechanism
20298210	Reversibility in Rett models	Intrinsic reversibility → gene-replacement rationale
21916843	MeCP2 reversibility & therapy review	Reversibility; therapeutic avenues
40381456	Globally reduced brain volume in Rett	19% GM reduction; non-focal microcephaly basis
40147315	Diffuse non-homogeneous brain atrophy	Cortical-dominant, correlates with severity
36931532	Longitudinal MRI of Mecp2 mouse	Model recapitulates reduced brain volume
42213295	Iranian MECP2 cohort	Phenotype frequencies; truncating→severe
41641323	Disease-modifying therapies review	Epidemiology anchor; therapy landscape
40043705	DAFFODIL trofinetide trial	Only approved drug (Rett/females), not male entity
38254921	Human-ready mini-MECP2	Gene-therapy construct development
39300821	Intranasal NGF in Mecp2 mice	Preclinical repurposing; metabolic rescue
40595330	Vorinostat for Rett (preclinical)	Multi-organ rescue after symptom onset

Evidence source types: Human clinical (case series/cohorts: 17236109, 27090848, 42213295, 40381456, 40147315); model organism (in vivo mouse/Xenopus/NHP: 17532643, 22412847, 20298210, 36931532, 39300821, 40595330); in vitro/molecular (25232122, 37712894, 40360671); computational/epidemiological (22182064, 30405208).

Limitations and Knowledge Gaps

Sparse male-specific data. The male neonatal-encephalopathy entity is documented in only dozens of case reports; most quantitative phenotype, imaging, and prognosis data derive from female Rett cohorts or mouse models used as proxies. Direct, large-N natural-history data for hemizygous males are lacking.
No formal diagnostic criteria exist for the male entity; diagnosis is molecular by extrapolation from Rett.
No approved therapy for the male disorder; trofinetide's evidence base is entirely female Rett, and gene-replacement remains preclinical/early-clinical.
Quality-of-life instruments (EQ-5D/SF-36/PROMIS) have not been applied to this population.
Frequency percentages (e.g., microcephaly 64%, seizures 60%) come from a mixed MECP2/Rett cohort and likely underestimate severity/penetrance in hemizygous males.
Mechanistic granularity: the precise mapping from specific de-repressed long genes to individual clinical features (which seizure, which autonomic deficit) is incompletely resolved.
Model gap: mouse models better mimic the postnatal-regression Rett course than the extreme congenital male-neonatal presentation.

Proposed Follow-up Experiments / Actions

Assemble an international male-MECP2-encephalopathy registry with standardized deep phenotyping (HPO), longitudinal OFC/MRI, EEG, and survival — to generate the first robust natural-history and genotype–phenotype dataset for hemizygous males.
Genotype-stratified outcome analysis (truncating vs missense; degree of mosaicism; 46,XY vs 47,XXY) to define prognostic modifiers with quantitative effect sizes.
Preclinical gene-replacement optimization in male-null mice, focusing on dosing windows relevant to the congenital-onset phenotype, and on safety (avoiding overexpression → duplication-syndrome phenotype).
Biomarker discovery — CSF/plasma proteomic and metabolomic profiling (leveraging the mitochondrial/lipid signature, PMID: 37712894) to identify tractable pharmacodynamic markers.
Systematic differential-diagnosis pathway — a neonatal-encephalopathy-with-microcephaly gene panel/rapid WGS protocol that includes MECP2 alongside CDKL5, FOXG1, STXBP1, KCNQ2, ARX, and metabolic causes (MOCS1/2, SUOX, ASNS, AIMP1) to shorten time-to-diagnosis.
Repurposing trials informed by preclinical multi-organ rescue (e.g., HDAC-inhibitor class, NGF/IGF-1 axis), with careful attention to whether male-null biology responds like female-mosaic biology.
Genetic-counseling protocol formalizing paternal-germline-mosaicism recurrence-risk estimates (~24%) and PGT-M/prenatal options for affected families.

Report compiled from 9 confirmed findings across 5 investigation iterations and 74 reviewed papers. Evidence spans human clinical case series/cohorts, in vivo model-organism studies, in vitro molecular work, and computational/epidemiological analyses.

Ask OpenScientist

OpenScientist Report

Mappings

Definitions

Inheritance

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Differential Diagnoses

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Severe Neonatal-Onset Encephalopathy With Microcephaly

Executive summary

1. Disease information

Definition and nomenclature

Critical nosological distinction

2. Etiology and risk factors

3. Phenotypes

4. Genetic and molecular information

5. Environmental information

6. Mechanism and pathophysiology

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

11. Outcome and prognosis

12. Treatment and current applications

13. Prevention

14. Other species and natural disease

15. Model organisms

Evidence-quality conclusion

Artifacts

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic / Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

Causal chain

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Mechanistic Model / Interpretation

Evidence Base

Limitations and Knowledge Gaps

Proposed Follow-up Experiments / Actions